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Abstract 
Characterisation and manipulation of Vaccinia virus (VACV) immunomodulators is 
important for engineering recombinant VACV vaccines with enhanced immunogenicity. To 
this end, the goal of this study was to characterise the putative immunomodulator, C16, a 
protein of interest due to proposed similarity to the interleukin 1 receptor antagonist protein.  
 
C16 is a highly conserved, early protein of approximately 37 kDa that actively shuttles 
between the cytoplasm and nucleus in transfected and infected cells. In order to study the 
function of C16, a VACV mutant lacking the C16L gene (v∆C16) and a revertant virus 
wherein the gene was reinserted into the deletion mutant (vC16Rev) were constructed. In cell 
culture, v∆C16 had similar replication kinetics to wild type and revertant control viruses, but 
formed a smaller plaque.  
 
The loss of C16 led to a significantly attenuated phenotype in a murine intranasal model of 
infection that was characterised by reduced weight-loss and signs of illness. While virus titres 
between the virus sets were comparable in the initial days of infection, virus titres of v∆C16 
dropped more rapidly over the course of the infection. In v∆C16-infected mice there was also 
an accelerated recruitment and activation of lymphocytes. In contrast, there was no 
significant difference in the murine intradermal model of infection. Furthermore, the 
omission of C16 did not decrease the efficacy of protective vaccination. The attenuation of 
v∆C16 in vivo may be due to the effect of C16 on IL-6 production which has been 
demonstrated in vitro and in vivo. This is reminiscent of one of the functions of IL-1Ra 
though the precise mechanism of this downregulation of IL-6 by C16 remains to be 
determined. C16 also downregulates ISRE-dependent gene expression, via a mechanism 
independent of STAT1 but which may involve p38 MAPK.  
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vIL-1βR viral IL-1β receptor 
VETF  virus early transcription factors 
VIG  vaccinia immunoglobulin 
v/v  volume/volume 
WHO  World Health Organisation 
WR  Western Reserve 
WT  wildtype 
w/v  weight/volume  
YMTV Yaba monkey tumour virus 
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Chapter 1 
Introduction 
 
1.1  Introduction to poxviruses and vaccinia virus 
Vaccinia virus (VACV) is the prototypal member of the Orthopoxvirus (OPV) genus of the 
Poxviridae, a family of large, complex enveloped viruses with double-stranded (ds)DNA 
genomes, which replicate entirely within the cytoplasm of infected cells (Moss, 2001). The 
classification of poxviruses was initially developed through microscopic and serological 
analysis (Ikuta et al., 1979a; Ikuta et al., 1979b; Woodroofe and Fenner, 1962), but is 
precisely defined by genome sequence analysis (see www.poxvirus.org). The Poxviridae 
comprises 2 sub-families the Chordopoxvirinae and Entomopoxvirinae that infect chordates 
and insects, respectively.  The Entomopoxvirinae is divided into 3 genera, A, B and C and the 
Chordopoxvirinae is divided into 8 genera, as detailed in Table 1.1. 
 
Table 1.1 
Subfamily Genus Examples of member viruses 
Chordopoxvirinae Avipoxvirus Fowlpox virus 
 Capripoxvirus Goatpox virus, Sheeppox virus 
 Leporipoxvirus Myxoma virus 
 Molluscipoxvirus Molluscum contagiosum virus 
 Orthopoxvirus Camelpox virus, Cowpox virus, 
Ectromelia virus, Monkeypox 
virus, VACV, Variola virus 
 Parapoxvirus Orf virus 
 Suipoxvirus Swinepox virus 
 Yatapoxvirus Yaba monkey tumour virus, 
Tanapox virus 
Entomopoxvirinae Entomopoxvirus A Melanoplus sanguinipes 
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entomopoxvirus 
 Entomopoxvirus B Amsacta moorei entomopoxvirus 
 Entomopoxvirus C Chironomus luridus 
entomopoxvirus 
Unclassified poxviruses  Crocodilepox virus, Deerpox virus 
Table 1.1 Orthopoxviridae 
 
The most infamous member of the OPV genus is Variola virus (VARV), the causative agent 
of smallpox, a highly contagious human disease with mortality rate of up to 40 % (Fenner, 
1993; Mack, 1972). The only other human-specific poxvirus is molluscum contagiosum virus 
(MCV) that is spread by direct contact and causes skin lesions (Thompson et al., 1992). 
Humans can also be infected with monkeypox virus (MPXV), orf virus (ORFV), cowpox 
virus (CPXV) and yatapoxviruses as zoononoses. MPXV causes smallpox-like symptoms of 
lesions and febrile myalgia (Arita et al., 1985; Lewis-Jones, 2002). This is a growing concern 
particularly after recent outbreaks in Central Africa (Parker et al., 2007). 
 
VACV was the live vaccine used to eradicate smallpox (Henderson, 1976). The history of 
vaccination began in 1796 with Jenner’s inoculation of a child with CPXV that conferred 
cross-protection against smallpox (reviewed in (Baxby, 1979)) due to the antigenic similarity 
of CPXV and VARV (Macdonald and Downie, 1950). In 1939, comparison of current stocks 
of smallpox vaccines to natural isolates of CPXV (Downie, 1939) revealed that the vaccine 
was not, in fact, CPXV, but a different OPV, which was called VACV, a virus of unknown 
origin. The VACV strains most widely used during the worldwide WHO eradication program 
were EM-63 in Russia, Lister/Elstree in Europe and elsewhere, New York City Board of 
Health (NYCBH)/Dryvax/Wyeth in the United States and Temple of Heaven (Tian Tan) in 
China (Fenner, 1977). The most intensively studied laboratory strain is Western Reserve 
(WR), a derivative of the NYCBH strain adapted to the mouse by serial brain passage. An 
attenuated VACV strain gaining popularity as a vaccine vector is the Modified virus Ankara 
(MVA) strain (Mayr et al., 1978). MVA was derived from chorioallantois virus Ankara 
(CVA) by more than 500 passages in chicken embryo fibroblasts (Meisinger-Henschel et al., 
2007). MVA cannot replicate in most mammalian cell lines (Carroll and Moss, 1997; Drexler 
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et al., 1998 ), and has a highly attenuated phenotype in vivo (Mayr and Danner, 1978; Mayr et 
al., 1978; Moss, 1996) 
 
Though it is now 30 years since the last case of smallpox in 1978 (Baxby, 1996), there are 
compelling reasons to continue to study VACV. It is widely used as a recombinant 
expression vector for laboratory research (Miner and Hruby, 1990; Moss et al., 1983) due to 
the relative ease of constructing VACV recombinants, a capacity for at least 25 kb exogenous 
DNA, the relatively high expression levels obtained and a wide range of cells that can be 
infected (Mackett and Smith, 1986; Moss et al., 1983; Panicali and Paoletti, 1982). These 
attributes, in addition to other useful features of VACV, i.e. stability when freeze-dried, low 
cost, ease of manufacture and administration and the ability to stimulate both antibody and 
cell-mediated immunity, have led to the development of VACV as a potential recombinant 
vaccine for other antigens (Moss et al., 1983; Paoletti, 1990; Perkus et al., 1985). 
Furthermore, VACV expresses an array of immunomodulatory proteins that have increased 
our understanding of host-pathogen interactions and antiviral immunity (Haga and Bowie, 
2005; Smith, 1999). 
 
1.2 The genome structure of OPVs 
The first sequence of a VACV genome was determined for the Copenhagen strain (VACV-
COP) (Goebel et al., 1990). The number of sequenced VACV strains has increased to sixteen 
at the time of writing (www.poxvirus.org). 
 
VACV genomes are between 165 kb (MVA) (Antoine et al., 1998) and 199 kb (Duke) 
(Tulman et al., 2006) of linear dsDNA containing approximately 200 tightly packed open 
reading frames (ORFs). VACV genes do not contain introns and there are no reports of 
splicing, consistent with the cytoplasmic site of replication and transcription of the virus. 
Comparison of poxvirus genomes reveals a set of approximately 90 genes that are conserved 
throughout the Chordopoxvirinae subfamily (vertebrate poxviruses); a subset of 
approximately 50 of these genes is conserved in all sequenced poxviruses (including both 
vertebrate and invertebrate poxviruses) (Gubser et al., 2004; Upton et al., 2003). The VACV 
genome can be split into two distinct regions – a highly conserved central region, and more 
variable terminal regions (Wittek, 1982) as represented diagrammatically in Figure 1.1. In 
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general, ORFs from the central region of the genome are distributed on both DNA strands 
and include structural proteins and enzymes for viral transcription and DNA replication. In 
contrast, genes located in the terminal regions are predominantly transcribed towards the 
adjacent terminus and encode proteins that affect virus virulence, host range and 
immunomodulation. Some of these genes are located in inverted terminal repeat (ITR) 
regions of about 12 kb in VACV WR that are identical but oppositely oriented, so that genes 
within the ITRs are effectively diploid (Garon et al., 1978; Wittek et al., 1980; Wittek et al., 
1978). There are 12 ORFs in the ITR (VACV WR-001 to 012 and VACVWR-207 to 218). 
 
At the genomic termini, the two DNA strands are connected covalently by AT-rich flip-flop 
hairpin loops that are incompletely base-paired and that are important for DNA replication 
(Baroudy et al., 1982; Geshelin and Berns, 1974). Adjacent to the hairpin loops, the ends 
contain a highly conserved sequence that is essential for the resolution of concatemeric DNA 
intermediates formed during DNA replication (DeLange and McFadden, 1987; Merchlinsky 
and Moss, 1989a).  
 
With the publication of the VACV-COP sequence, a genetic nomenclature was adopted in 
which genes were named according to their position relative to the left end of individual 
HindIII restriction fragments of the genome and also according to their transcriptional 
orientation. 
 
Figure 1.1 Simple diagrammatic representation of the OPV 
genome
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1.3  Virion structure 
As the largest of the animal viruses, VACV was the first mammalian virus to be seen by light 
microscopy (reviewed in (Condit et al., 2006)). VACV virions lack any of the symmetrical 
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features common to other viruses such as helical or icosahedral capsids or nucleocapsids. 
Instead, when visualised with an electron microscope, VACV virions appear as smooth 
“brick-shaped” or “ovoid” membrane-bound particles of approximately 360 x 270 x 250 nm 
(Cyrklaff et al., 2005; Hollinshead et al., 1999). Insights into the internal architecture of the 
virion have been gained by the use of thin sections and whole mount preparations, and reveal 
two distinct boundaries, the envelope (surrounding the entire IMV particle) and a core wall 
(surrounding the internal core) (reviewed in (Condit et al., 2006). The core has two central 
bilateral concavities, formed by a separation of the core wall from the membrane, which 
contain amorphous masses referred to as the ‘lateral bodies’ (Dubochet et al., 1994). The core 
contains the virus genome, major structural proteins and a number of proteins involved in 
genome transcription. At least 80 proteins have been identified in VACV WR virions (Resch 
et al., 2007), representing 37 % of the VACV WR proteome. 
 
VACV virions exist in three distinct structural forms: intracellular mature virions (IMV), 
intracellular enveloped virus (IEV), and extracellular virions (including both cell-associated 
enveloped virus (CEV) and extracellular enveloped virus (EEV). These virions have different 
structures, abundance, locations and roles in the virus life-cycle. IMV represents the majority 
of progeny, but remains inside the infected cell until cytolysis (Payne, 1980). IEV is formed 
by wrapping of some IMV with additional intracellular lipid membranes derived from trans-
Golgi cisternae or endosomes (Schmelz et al., 1994) which enables efficient virus transport 
on microtubules to the cell surface. IEV moves to the cell surface where the outer membrane 
fuses with the plasma membrane to form CEV that remains on the cell surface (Blasco and 
Moss, 1992) or EEV that is released from the cell. While EEV is important for dissemination 
of the virus in vivo, IMV is important for long-term stability in the environment and 
transmission between hosts (Payne, 1980). 
 
1.4  The lifecycle of VACV 
The lifecycle of VACV is a sequence of the following steps: virus binding, entry, uncoating, 
gene expression, DNA replication, virion assembly and virion release.   
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1.4.1 Virus binding 
The binding of VACV to permissive cells is the initial step in establishing infection. In a 
recent summary of the known cellular receptors of viruses (Sieczkarski and Whittaker, 2005), 
poxviruses were notable in their omission. VACV can infect many diverse cell types, 
suggesting that either the viral receptor is expressed ubiquitously on cells or that the virus can 
bind to many different receptors (Moss, 2001). Furthermore, the VACV IMV and EEV enter 
cells by different mechanisms (Vanderplasschen et al., 1998a). Several studies have shown 
that cell surface glycosaminoglycans (GAGs) can bind to distinct virus proteins (Hsiao et al., 
1998) however, such interactions are not essential for infectivity (Carter et al., 2005). 
Cholesterol (Chung et al., 2005), laminins (Chiu et al., 2007) and CC chemokine receptor 
(CCR) 5 may (Rahbar et al., 2006) also affect VACV binding and entry.  
 
1.4.2 Virus entry 
The entry of IMV into target cells remains intensively studied. Typically, enveloped viruses 
enter cells by fusing their membrane with either the plasma membrane or the membrane of an 
endocytic vesicle. There is good evidence that both mechanisms are used by VACV. Early 
work identified IMV in vesicles (Dales, 1963) or fusing with the plasma membrane (Chang 
and Metz, 1976). Inhibition studies using cytochalasin B supported an internalisation 
mechanism (Payne and Norrby, 1978). Recent electron microscopy (EM) investigations have 
shown that IMV can enter the cell by a simple membrane fusion event allowing entry of the 
released naked viral core into the cytoplasm (Carter et al., 2005), while there is also evidence 
for a low pH step during virus entry implicating a role for an endosomal entry pathway 
(Townsley and Moss, 2007). A very recent study provided evidence for a macropinocytosis 
entry pathway (Mercer and Helenius, 2008).  
 
As EEV contains an extra lipid envelope surrounding IMV, it raises a topological difficulty 
for EEV entry into cells. Simple membrane fusion of EEV would release an IMV into the cell 
cytoplasm, which would still require removal of a lipid envelope to release the naked viral 
core and enable transcription and replication to proceed. Two models of EEV entry have been 
proposed, the importance of which may vary between different cell types. One model 
proposed that EEV is endocytosed by the host cell, the EEV membrane is disrupted by 
acidification within an endosome exposing the IMV, which is then able to fuse with the 
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membrane of the endosome and release the viral core into the cytoplasm (Ichihashi, 1996; 
Townsley et al., 2006; Vanderplasschen and Smith, 1999). A second model reported that after 
an EEV particle binds to a cell, at the point of contact between the cell and virion the EEV 
membrane ruptures, exposing the IMV to the cell plasma membrane. The IMV proceeds to 
enter the cell by simple membrane fusion. This mechanism allows the double membrane-
bound EEV to enter cells, releasing the required naked viral core into the cytoplasm and was 
termed ligand-dependent non-fusogenic dissolution of a viral membrane (Law et al., 2006).  
 
 1.4.3 Uncoating 
The first stage of uncoating involves the proteolysis of some virion proteins and hydrolysis of 
the virion phospholipid (Zaslavsky, 1985).  Then the disruption of viral cores commences 
(Pedersen et al., 2000). Interestingly, in the absence of the synthesis of VACV early 
messenger RNAs (mRNAs) and/or early proteins, this second uncoating step is blocked, 
suggesting that release of the VACV genome from the core requires the novel synthesis of at 
least one early viral protein (Pedersen et al., 2000; Pedley and Cooper, 1987).  
 
 1.4.4 Gene expression 
After the core is free within the cytosol, the VACV transcription machinery packaged within 
the core is free to transcribe virus genes. VACV genes are transcribed in a strictly controlled 
order that can be defined by four temporal gene classes: immediate early, early, intermediate 
and late (Assarsson et al., 2008). VACV mRNAs, like typical eukaryotic mRNAs, are capped 
and polyadenylated (Kates and Beeson, 1970; Wei and Moss, 1975). 
 
Immediate early genes 
All the components required for the transcription of VACV early genes, including the multi-
subunit virus-encoded DNA-dependent RNA polymerase, various transcription factors and 
capping and polyadenylating enzymes, are packaged within the core of virus particles (Golini 
and Kates, 1985; Kates and McAuslan, 1967; Munyon et al., 1967; Rohrmann and Moss, 
1985). Recently, analysis of mRNA expression of all VACV WR genes, revealed a set of 35 
genes exhibiting immediate early expression profiles (Assarsson et al., 2008). The 
immediate-early class is characterised by expression within 0.5 h.p.i. and reaching a 
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maximum level of transcription at 2 h.p.i. The members of this immediate early gene class 
contain genes involved in virulence and immune evasion, as well as a number of genes 
involved in DNA replication (Assarsson et al., 2008) There is no genetic evidence as yet for 
the subdivision of early and immediate early genes. 
 
  Early genes 
Early genes make up the largest class of ORFs. At least 70 genes are expressed early in 
infection (Assarsson et al., 2008; Broyles, 2003) and this class includes proteins involved in 
transcription, DNA replication and virulence (Assarsson et al., 2008).  Over half the VACV 
virulence factors identified are expressed during this temporal phase (Assarsson et al., 2008). 
VACV early mRNA synthesis is detectable within 1 h of virus entry and reaches maximal 
levels at 2 h.p.i. (Assarsson et al., 2008). The transcription of early genes is regulated by a 
specific A/T-rich promoter sequence located upstream of the RNA start site (Ink and Pickup, 
1989; Weir and Moss, 1987a). A consensus sequence has been identified from -28 and -13 
(relative to the RNA start site) of AAAAAATGAAAAAAA/TA, separated by a T-rich spacer 
sequence from -12 to -2, which is followed by a 7-bp region (-1 to +6) within which initiation 
occurs, usually with a purine (Davison and Moss, 1989a). The 3’-ends of VACV early 
mRNAs are formed 20-50-bp downstream of the sequence TTTTTNT, where N represents 
any nucleotide (Piacente et al., 2008; Rohrmann et al., 1986; Yuen and Moss, 1987). 
 
Intermediate genes 
Following DNA replication, entry into the intermediate and late phases of gene expression 
requires specific promoters and transcription factors (Katsafanas and Moss, 2004; Sanz and 
Moss, 1999). At least 13 proteins are encoded during the intermediate phase of transcription 
(Baldick and Moss, 1993; Broyles, 2003) and these sequences can be expressed from 
plasmids in the absence of VACV DNA replication (Vos and Stunnenberg, 1988). 
Intermediate genes encode proteins including the RNA polymerase, capping enzyme and at 
least one other transcription factor, as well as three transactivators required for late 
transcription (Keck et al., 1990; Zhang et al., 1992). Intermediate mRNAs are detected at 1.5 
h.p.i. levels and reach a peak at 2 h.p.i. before declining rapidly (Baldick et al., 1992). 
Intermediate gene promoters consist of two important regions. These are an A/T-rich 14-bp 
core element separated by 10 or 11 bp from a 4-bp initiator element (TAAA) (Baldick et al., 
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1992; Hirschmann et al., 1990). The core element of intermediate genes cannot tolerate 
substitutions at positions -22, -21, -19 to -17 and -15 to -13 (Hirschmann et al., 1990). 
Intermediate mRNA transcription initiates within the A triplet of the TAAA element, and 
early termination motifs (TTTTTNT) are ignored (Baldick and Moss, 1993).  
 
Late genes 
Late gene transcription begins once the necessary transcription factors (encoded by 
intermediate genes) are available (Zhang et al., 1992). This class includes at least 60 genes 
(Assarsson et al., 2008) that encode structural proteins (including virus core and membrane 
proteins), enzymes and factors required for early transcription that become packaged into 
virions as well as a minority of immunomodulators (Assarsson et al., 2008). Late mRNAs are 
first detected between 2 and 4 h.p.i. and synthesis continues up to 24 h.p.i.  Late gene 
promoters consist of an upstream A/T-rich core region of around 20 nucleotides and a 
conserved TAAAT element within which transcription initiates (Davison and Moss, 1989b; 
Hanggi et al., 1986; Rosel et al., 1986; Weir and Moss, 1987b). The late promoter initiation 
sequence is often followed by G with the resultant ATG acting as the translation start codon 
(Davison and Moss, 1989b).   
 
For intermediate and late viral genes, a 5’ untranslated leader sequence is created in the 
mRNA by slippage of the virus RNA polymerase on the AAA sequence of the transcription 
initiation motif, creating a 5’ poly(A) leader tract of RNA (Schwer et al., 1987). These 
mRNAs are long and heterogeneous in length and do not have defined 3’ ends (Mahr and 
Roberts, 1984) due to a lack of recognition of the early termination motif (TTTTTNT) by the 
late transcription machinery.  
 
 1.4.5 DNA Replication 
To enable virus DNA replication to take place in the cytoplasm, VACV produces enzymes, 
such as DNA polymerase (Earl et al., 1986), DNA helicases (Koonin and Senkevich, 1992), 
DNA ligase (Kerr and Smith, 1989) and type I topoisomerase (Shuman, 1989). VACV also 
encodes enzymes for the synthesis of new nucleoside triphosphates including ribonucleotide 
reductase (Slabaugh et al., 1988), thymidine kinase (Weir et al., 1982), thymidylate kinase 
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(Smith et al., 1989a), or enzymes engaged in proofreading such as the deoxyuridine 
triphosphatase (Broyles, 1993). 
 
A model of VACV DNA replication proposes that replication begins with the introduction of 
a nick into one DNA strand near to a terminal hairpin loop  (Moyer and Graves, 1981) 
exposing a free 3’OH group which serves as a self-primer for VACV-encoded DNA 
polymerase that carries out elongation towards the end of the unfolded terminal hairpin. The 
parent and daughter strands then denature and refold into hairpins allowing replication to 
continue along the rest of the genome. During this replication process, concatemeric 
molecules are formed, which contain a palindromic structure containing a highly conserved 
20-bp concatemeric resolution sequence between the two nascent genomes (Merchlinsky and 
Moss, 1989a; Merchlinsky and Moss, 1989b). Late viral proteins resolve the concatemer into 
individual progeny genomes (Moyer and Graves, 1981).  
 
 1.4.6 Virus morphogenesis, transport and release 
The formation of new virus particles occurs in a series of complex stages, and the details of 
the process have been reviewed (see (Condit et al., 2006)). There was protracted debate as to 
whether new virus particles have one membrane (Hollinshead et al., 1999) or two (Sodeik et 
al., 1993) , and debate as to whether the virion membrane is derived from de novo biogenesis 
(Dales and Mosbach, 1968) or from the diversion of existing intracellular membranes (Sodeik 
et al., 1993). The earliest evidence of virus assembly is the appearance within the factories of 
rigid crescent-shaped structures, 10-15 nm in thickness, which extend to form a complete 
oval-shaped, non-infectious particle termed immature virus (IV). The IV contains the virus 
DNA, core proteins, and transcriptional enzymes required for expression of early genes in the 
next infected cell. The virus genome and associated proteins enters the IV just before it is 
sealed (Cassetti et al., 1998).  
 
The IV to IMV transition involves a rearrangement of the IV to form a distinct core and 
lateral bodies, and in the process, the particle is transformed from an oval / spherical shape to 
a barrel shape. The DNA-nucleoprotein complex condenses and associates with structural 
proteins to become an electron-dense virus core. Proteolysis of some virus core proteins 
occurs  (Moss and Rosenblum, 1973; Yang, 2007) several proteins are incorporated into the 
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IMV surface (da Fonseca et al., 2000; Sodeik et al., 1995) and these steps lead to the 
formation of the characteristic, infectious, brick-shaped IMV particle.   
 
IMV particles leave the virus factories in a process that involves microtubule-based transport 
(Sanderson et al., 2000; Ward and Moss, 2001). These virions are transported to the 
microtubule organising centre (MTOC) where they become wrapped in a double-layer of 
membrane derived from the endosomes (Tooze et al., 1993) or trans-Golgi network (TGN) 
(Schmelz et al., 1994) to form IEV. The IEV then moves to the cell surface on microtubules 
(Hollinshead et al., 2001; Ward and Moss, 2001) where the outer membrane fuses with the 
plasma membrane to form CEV that remains on the cell surface (Blasco and Moss, 1992) or 
is released from the cell as EEV (Smith et al., 2002). CEV induce actin tail formation beneath 
the plasma membrane propelling the virion away from the cell and into surrounding cells or 
the extracellular space.  
 
1.5  The effect of VACV infection on host cells 
VACV infection induces early changes in cell morphology and adhesion properties, shuts off 
host protein synthesis (Parrish and Moss, 2007; Shors et al., 1999), and eventually results in 
death of the infected cells, collectively called the cytopathic effect (CPE). VACV induces cell 
rounding in a reversible and microtubule-dependent manner (Schepis et al., 2006) and 
generates lamellipodia up to 160 µm in length (Sanderson et al., 1998b). VACV infection 
induces changes in the adhesion properties of the infected cells, by imparting a transition 
from Ca2+-dependent to Ca2+-independent cell-matrix adhesion (Sanderson and Smith, 1998). 
Furthermore, VACV induces cell motility in a manner dependent on early gene expression 
(Sanderson et al., 1998b). 
 
1.6 Development and uses of recombinant VACVs 
The use of molecular genetics to clone and express foreign genes from recombinant VACV 
(Mackett et al., 1982; Panicali and Paoletti, 1982) or to delete specific VACV genes, has 
multiple applications in research and medicine (Earl et al., 2001). VACV is being used 
widely as a vaccine vector for the delivery of exogenous antigens to the immune system 
(Gherardi and Esteban, 2005; Sutter and Staib, 2003) or as a gene delivery agent (Guo and 
 39
Bartlett, 2004; Liu et al., 2004), or oncotherapeutic agent (Shen and Nemunaitis, 2005). 
Recombinant VACV lacking specific endogenous gene(s) can be used to investigate VACV 
gene function such as B8R (Symons et al., 2002b), N1L (Bartlett et al., 2002). However, such 
null mutants can only be made for non-essential genes and the study of an essential genes 
requires that the gene is regulated in an inducible manner (Rodriguez and Smith, 1990). 
 
The generation of recombinant VACV virus is accomplished by constructing a plasmid 
containing the gene of interest under the control of a VACV promoter, flanked by VACV 
sequences that determine the site of insertion. Transfection of cells infected by VACV then 
results in homologous recombination between the plasmid and the virus (Mackett and Smith, 
1986; Perkus et al., 1985). Selection markers including colourimetric proteins such as β-
galactosidase (Chakrabarti et al., 1985), fluorescent proteins such as green fluorescent protein 
(GFP) (Dominguez et al., 1998) or drug-selective proteins such as E. coli guanine 
phosphoribosyltransferase (Ecogpt) (Boyle and Coupar, 1988) can be used to generate 
recombinant viruses wherein the transgene of choice is coupled to the selection marker.  
Recombinant vaccinia viruses have also been generated by direct ligation of foreign DNA 
into the virus genome and by recovery of infectious virus using the bacterial artificial 
chromosome (BAC) system (Cottingham et al., 2008; Domi and Moss, 2002).  
 
1.6.1 VACV-based vaccines 
One of the most appealing uses of VACV is to serve as a vaccine vector delivery system for 
heterologous antigens. Concerns about the safety profile of first and second-generation 
VACV strains are being addressed by the development of attenuated vectors. In particular, 
MVA is a popular strain for clinical investigation. MVA has lost the ability to replicate in 
most mammalian cells, is apathogenic even in immunodeficient animals, and was safe in 
humans including many who were considered at risk for the conventional vaccine (Harrer et 
al., 2005; Mayr and Danner, 1978; Sutter and Staib, 2003). 
 
The first recombinant VACV to find widespread use in disease control was a recombinant 
VACV-rabies vaccine for oral vaccination of foxes against rabies. This was launched in field 
conditions in 1987 (Pastoret et al., 1988), proved safe and efficacious, and eradicated rabies 
in areas of Europe where it was used (Brochier et al., 1991). In other animal models, MVA 
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vaccines have been found immunogenic and protective against various infectious agents 
including immunodeficiency viruses (Martinon et al., 2008; Van Rompay et al., 2005), 
influenza virus (Breathnach et al., 2004; Veits et al., 2008), flaviviruses (Men et al., 2000; 
Nam et al., 2002), or plasmodium parasites (Schneider et al., 1998).   
 
Data from human clinical trials confirm that MVA is safe even in immunocompromised 
patients (Harrer et al., 2005; Moorthy et al., 2003). Furthermore, MVA-based vectors, in 
particular when used in a prime-boost strategy, can induce human immunodeficiency virus 
(HIV)-specific (Goonetilleke et al., 2006; Mwau et al., 2004) or tuberculosis (TB)-specific 
(Hawkridge et al., 2008) T cell responses. Some clinical trials have not given such 
encouraging results; for instance, large scale phase 2 trials of MVA based malaria vaccines 
showed no protective response to vaccination (Bejon et al., 2007; Bejon et al., 2006). 
Improvement of the vaccine vector, by removing immunomodulatory proteins (Staib et al., 
2005) or co-expressing of stimulatory molecules (such as IL-12) (Abaitua et al., 2006) as well 
as improving the choice of foreign antigens, are approaches being explored to induce more 
potent immune responses. 
 
1.6.2 VACV in oncotherapy 
The goal of cancer virotherapy is to stimulate immune responses that target and eliminate 
active tumour cells or to mediate direct destruction of the tumour by virus replication. This 
can involve a number of different VACV-based strategies, such as exploiting VACV gene 
expression potential to deliver tumour suppressor genes, or delivering nonspecific or antigen-
based immunotherapy to stimulate anti-tumour immunity or creating oncolytic viruses. 
Recombinant VACV expressing the tumour suppressor p53 gene was created in the Lister 
strain backbone, and in vivo experiments using a glioma tumour model and a bladder cancer 
model showed effective inhibition of tumour growth (Blaszczyk-Thurin et al., 2002; Fodor et 
al., 2005). Cytokines and costimulatory molecules such as IL-2 or IL-12 can be delivered 
intratumourally using recombinant VACV vectors, to modulate the immune milieu and 
activate the immune response at the tumour site (Kaufman et al., 2002; Kudo-Saito et al., 
2007). Alternately, tumour-associated antigen therapy focuses on re-stimulating the immune 
response to cell markers that are overexpressed in tumour cells such as carcinoembryonic 
antigen (CEA) or prostate-specific antigen (PSA). VACV vectors expressing these antigens 
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induce strong humoral and cell-mediated immune responses against tumour cells (DiPaola et 
al., 2006; Greiner et al., 2002; Schmitz et al., 2002). Finally, VACV has been used as an 
oncolytic therapeutic either exploiting its direct CPE (reviewed in (McCart et al., 2001; 
Mullen and Tanabe, 2002)) or by equipping VACV with enhanced cytolytic function (Thorne 
et al., 2005).  
 
1.7  Innate immune responses to VACV infection and VACV immune evasion 
Upon infection, VACV must deal with the onslaught of innate, and subsequently, acquired 
immune mechanisms aimed at elimination and containment of the viral infection. VACV has 
evolved numerous defensive techniques, and VACV immune responses and immune evasion 
mechanisms have become the subject of intense study in the past 20 years.  
 
Typically a poxvirus infection occurs through exposure at the subcutaneous layer or through 
mucus membranes in the airway. At these barriers, innate leukocytes and innate mechanisms 
of host defence recognise non-specific features of microbial invasion and mount the first line 
of defence against invading pathogens. VACV induces (and modulates) innate immune 
mechanisms including the complement system, macrophages, natural killer (NK) cells, γδ T 
cells, and the antiviral state conferred by IFNs.  
 
 1.7.1 Complement 
The complement system is involved in a number of immune functions, including the 
recognition of foreign agents or cells, lysis and opsonisation of infectious agents or cellular 
debris, as well as the communication with and activation of the adaptive immune response. 
Complement is activated through distinct mechanisms known as the classical, lectin and 
alternative pathways (reviewed in (Lambris et al., 2008)). Initiation of the classical pathway 
is brought about by recognition of antigen–antibody complexes by C1q. The lectin pathway 
involves the recognition of microbial carbohydrate ligands by the structurally similar pattern-
recognition receptors, mannose-binding lectin and ficolins. Activation of the alternative 
pathway is initiated by proteolytic activation of native C3 or the presence of foreign surface 
structures. Additional recent findings implicate other processes (such as extrinsic proteases or 
coagulating molecules) in the initiation of complement expanding its role in the innate 
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immune system (Atkinson and Frank, 2006; Markiewski et al., 2007; Spitzer et al., 2007). 
Activation of any of the distinct complement cascades can lead to lysis of virions, the 
neutralisation of virions through opsonisation, membrane lysis of infected cells, increased 
phagocytosis and chemotaxis of neutrophils.  
 
In 1925, Gordon showed that the neutralisation of VACV infectivity was partly dependent on 
a heat-labile complement component in rabbit serum. Activation of the alternative 
complement pathway has been demonstrated in a VACV infection (Hirsch, 1982; Wakamiya 
et al., 1989). IMV is sensitive to complement in the absence of specific Ab whereas EEV is 
relatively resistant to complement mediated neutralisation (Leddy et al., 1977; 
Vanderplasschen et al., 1998b).  
 
VACV modulation of complement – host complement control proteins, VCP 
EEV resistance to complement-induced neutralisation is due to the incorporation of cellular 
regulators of complement cluster of differentiation (CD)55 and CD59 proteins into the EEV 
outer membrane (Vanderplasschen et al., 1998b). Host cells express these regulatory factors 
to downregulate complement activation to prevent destruction of host cells and an 
autoimmune crisis. CD55 inhibits the formation of and accelerates the decay of C3-activating 
enzymes involved in the classical pathway and alternative pathway (C3 convertases); CD59 
prevents the formation of the membrane attack complex.  
 
VACV demonstrates a second distinct mechanism of regulation of complement in the form of 
the C21L gene. This encodes a 28.6-kDa protein with amino acid similarity to a family of the 
host complement regulatory proteins (Kotwal and Moss, 1988). C21 is termed the vaccinia 
complement control protein (VCP) and is secreted from infected cells to prevent antibody-
dependent complement-mediated enhancement of neutralisation. VCP contributes to 
virulence, by binding to both C4b and C3b, (components of the complement cascade), and 
accelerating the decay of both classical and alternative pathway convertase enzymes (Isaacs 
et al., 1992).   
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There have been three other VACV proteins postulated to be involved in modulation of the 
complement defence system. B5 also has amino acid similarity to the family of complement 
control proteins human complement factor H, and two RPXV proteins show significant 
homology to complement components: B20 has significant similarity to the C5 component of 
complement, while M2 shows similarity to C4a and C3, and both contribute to virulence 
(Bloom et al., 1991). 
 
 1.7.2  Neutrophils 
The accumulation of neutrophils on the airway epithelial surface is a key element in host 
defence against infection of the bronchial epithelium (Malech, 2007). Neutrophils are 
recruited rapidly to sites of infection in substantial numbers and thereafter phagocytose and 
eliminate pathogens. Analysis of radiolabelled VACV showed that neutrophils phagocytosed 
VACV in vitro (West et al., 1987), and partially digested intraphagolysosomal virions could 
be seen. Activated neutrophils release a powerful proteolytic enzyme called neutrophil 
elastase (NE) that can induce inflammatory gene expression in bronchial epithelial cells 
(Korkmaz et al., 2008) by activation of IL-1R/Toll-like receptor (TLR)s on the cell surface. 
In particular, NE is capable of inducing IL-8 expression in bronchial epithelial cells, after 
which IL-8 acts as an activator and chemoattractant of neutrophils in a positive feedback 
loop. VACV downregulates the NE signalling cascade (Carroll et al., 2005) by interfering 
with the TLR signalling cascades initiated by NE as discussed below. 
 
 1.7.3  NK cells 
NK cells are large granular lymphocytes that contribute to the early immune responses to 
virus infection (Biron, 1997; Vivier et al., 2008). NK cells act in two ways: by direct lysis of 
infected cells (Chiorean and Miller, 2001), and by release of antiviral cytokines such as IFN-γ 
(Mercer et al., 2005). Several observations suggest that NK cells play a role in defence 
against VACV infection. Depletion of NK cells renders mice more susceptible to VACV 
(Bukowski et al., 1983). VACV infection induces NK cell proliferation, activation and 
accumulation at the site of infection (Jacobs et al., 2006) and provokes an increase in the 
susceptibility of cells to NK cell-directed lysis (Chisholm and Reyburn, 2006). Direct action 
of type I IFN on NK cells, but not on dendritic cells (DCs), is required for NK cell activation 
in response to VACV infection in vitro and in vivo, and this activation of NK cells can lead to 
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efficient VACV clearance (Martinez et al., 2008). In the context of VACV infection in vivo, 
DCs participate in the direct activation of NK cells (Raulet, 2004). As infection progresses 
there is a reduced cytolytic capacity of NK cells, indicating that NK cells are subject to 
infection (Kirwan et al., 2006), although it could be that down-regulation of their activity 
occurs by mechanisms other than direct infection. Some groups have seen sufficient 
downregulation of major histocompatibility complex (MHC)-I molecules on the cell surface 
to prevent killer-cell immunoglobulin-like receptor (KIR)-mediated protection of the target 
cell (Kirwan et al., 2006), and NK cells exhibit increased lysis of VACV-infected targets in 
vitro (Baraz et al., 1999). Deletion of the VACV N1L gene altered the NK cell responses in 
an intranasal (i.n.) model (Jacobs et al., 2008). But VACV encoded proteins that directly 
prevent NK-mediated destruction of target cells, such as those encoded by human 
cytomegalovirus, for instance, have not been reported. This may reflect the fact that VACV 
does not mediate extensive reduction in class I MHC expression unlike the CPXV and some 
herpes viruses.  
 
 1.7.4  Macrophages 
Macrophages represent 95 % of resident phagocytic cells in the respiratory tract and lungs 
(Curtis and Kaltreider, 1989) and act as phagocytic scavengers of infectious agents, and as 
activators of NK and T cells (Fujiwara and Kobayashi, 2005). The importance of 
macrophages is due in part to their role in the cross-presentation of antigen from other 
infected cells to activate T cells (Ramirez and Sigal, 2002). This cross-presentation is 
detectable within 1 h of VACV-infected antigen-donor cell (ADC)-professional antigen-
presenting cell (APC) encounter in vitro and peaks between 2 and 4 h.p.i.(Ramirez and Sigal, 
2002). 
 
The importance of macrophages for the control of VACV infection is illustrated by several 
observations. The depletion of macrophages in a murine i.n. model of VACV infection 
increased the overall severity of the infection, reduced clearance of VACV and resulted in 
more pronounced weight loss (Luker et al., 2005; Rivera et al., 2007). Co-culture of 
macrophages with lung epithelial cells in vitro severely limits VACV replication (Rivera et 
al., 2007). Replication of VACV is inhibited within activated macrophages (Buchmeier et al., 
1979; McLaren et al., 1976; Natuk and Holowczak, 1985). VACV infection induces nitric 
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oxide synthase (NOS) expression in freshly isolated murine peritoneal macrophages, 
(resulting in the production of microbicidal nitric oxide (NO) (Karupiah and Harris, 1995)), 
although these results were contradicted by work in the murine macrophage RAW cell line 
that showed that VACV inhibits NO production (Bellows et al., 2003). VACV infection 
resulted in apoptosis in murine macrophages, via a mechanism independent of NO but reliant 
of VACV early gene expression (Humlova et al., 2002).  
 
 1.7.5  DCs 
DCs are a potent, specialised system of APCs that activate naïve CD4+ and CD8+ T cells to 
initiate the immune response against microbial, tumour and self antigens. Direct visualisation 
of sectioned lymph nodes by confocal microscopy showed virus-specific CD8+ T cell priming 
by infected DCs in vivo (Norbury et al., 2002). DC depletion in mice abrogates the 
production of the effector cytokine IFN-γ by T cells following MVA infection, suggesting 
that DC-mediated Ag presentation is required for the generation of effector T cells in vivo on 
VACV infection (Liu et al., 2008). This depends on the maturation of the DCs: murine bone-
marrow derived DCs (BMDCs) undergo rapid maturation and produce a significant amount 
of IFN-α in response to VACV infection (Liu et al., 2008; Yao et al., 2007). In contrast, 
splenic and immature DCs undergo substantial apoptosis (Liu et al., 2008; Yates and 
Alexander-Miller, 2007) suggesting that on maturation, DCs become somewhat more 
resistant to VACV-induced cell death. VACV infection inhibits the phagocytic activity of 
DCs ex vivo as well as their directional migration without affecting surface expression of 
chemokine receptors or impairing cellular locomotion (Humrich et al., 2007). VACV 
infection of human DCs is abortive, inducing extensive DC apoptosis and blocking DC 
maturation (Drillien et al., 2000; Engelmayer et al., 1999). However, DCs may induce viral 
antigen-specific CTL activity by cross-priming rather than direct antigen presentation 
(Larsson et al., 2001; Liu et al., 2008). 
 
 1.7.6   γδ T cells 
In contrast to αβ T cells, γδ T cells target antigens directly and not via MHC presentation.  
Identification of this innate cell function led to the prediction that γδ cells could play an 
active role in resistance to VACV infection (Welsh et al., 1997) and indeed, mice lacking γδ 
T cells are more susceptible to VACV-induced mortality. This was attributable to enhanced 
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VACV replication early after infection strongly suggesting a role for these cells γδ T cells in 
innate immunity (Selin et al., 2001). As early as day 2 p.i., there was a fourfold increase in 
the total γδ cells present at the site of infection, and 12 % of the γδ T cells in VACV infected 
mice were producing IFN-γ, in contrast to 1 % in uninfected mice (Selin et al., 2001). γδ T 
cells are an abundant cell subset in the skin (Asarnow et al., 1988), and undergo expansion 
and activation in an intradermal (i.d.) infection model (Jacobs et al., 2006). There is also a 
substantial expansion of VACV-specific γδ T cells on VACV-challenge of vaccinated 
patients (Abate et al., 2005; Agrati et al., 2006) indicating a memory γδ T cell response to 
VACV infection.  
 
 1.7.7 Chemokines 
Chemokines are small (8- to 13-kDa) heparin-binding proteins that are grouped according to 
shared structural characteristics including the presence of cysteines in conserved locations 
that are essential to forming their characteristic 3-dimensional “Greek key” shape (as 
reviewed in (Zlotnik and Yoshie, 2000)). Chemokines are classified into C, CC, CXC, or 
CX3C subfamilies (where C represents a cysteine and X represents any amino acid) and are 
responsible for the recruitment of leukocytes to the site of inflammation. The biological 
activities of chemokines are mediated though interactions with seven-transmembrane G-
protein-coupled receptors expressed by different subsets of target cells, and thus the cellular 
distribution of different receptors will determine the leukocyte subset that predominates in the 
inflammatory response. Over 50 chemokines and 16 chemokine receptors have been 
described (reviewed in (Zlotnik and Yoshie, 2000)). In general, CC chemokines attract 
macrophages and T cells populations and CXC chemokines attract neutrophils, while 
lymphotactin (the only C chemokine) attracts T and NK cells. Soluble fractalkine (the only 
CX3C chemokine) attracts monocytes, T cell subsets, and NK cells. Since chemokines 
mediate the migration of immune cells to the sites of infection, they play a critical role in 
immunity.  
 
VACV modulation of chemokines – CCI, A41 
VACV express a secreted protein that binds CC chemokines with high affinity and has been 
termed the viral CC chemokine inhibitor (CCI) or the viral CC chemokine binding protein 
(vCKBP) (Beck et al., 2001; Reading et al., 2003b; Seet et al., 2001). Crosslinking assays 
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using radioiodinated human RANTES (a human CC chemokine), identified a secreted protein 
in the VACV-infected cell supernatant (Alcami et al., 1998).  This protein is expressed as a 
35-kDa protein that also binds the CC chemokine macrophage-inflammatory protein 1α 
(MIP-1α), and blocks the recruitment of inflammatory cells to the lungs of VACV-infected 
mice, by blocking the CC chemokines, CC-motif ligands (CCL) 2, CCL3 and CCL11 
(Reading et al., 2003b).  
 
VACV A41L gene encodes a secreted 30-kDa glycoprotein that shares sequence similarity 
with CCI (Ng et al., 2001) and blocks the binding of some CC chemokines to GAGs (Bahar 
et al., 2008). It has a relatively low affinity for a subset of CC chemokines and consequently 
does not block the interaction of chemokines with their receptors. However, it can still 
function in vivo by blocking the establishment of a chemokine concentration gradient on 
endothelial cells and thereby inhibit chemokine-induced leukocyte chemotaxis. The deletion 
of A41L from VACV reduces virulence, but the deletion mutant induces a stronger CD8+ T 
cell response and confers better protection against subsequent challenge (Clark et al., 2006). 
 
 1.7.8 Pattern recognition receptors (PRRs) 
PRRs trigger the innate immune response and are defined by an ability to recognise 
conserved features of microbes.  These features are called pathogen-associated molecular 
patterns (PAMPs) and include nucleic acid, protein or lipid structures that can be identified as 
non-self. PRRs can either be membrane-bound signalling receptors, predominantly the TLRs 
or soluble receptors such as retinoic-acid-inducible protein I (RIG-I), melanoma-
differentiation-associated gene 5 (MDA5) and protein kinase R (PKR).  
 
TLR involvement in defence against VACV 
The TLR family of PRRs are expressed predominantly on macrophages and DCs, on the 
plasma membrane or endosomal membrane, for review see (Takeda and Akira, 2007). They 
comprise a family of at least twelve proteins in mammals, that are single membrane-spanning 
non-catalytic receptors, and each recognises a unique subset of patterns. On activation of a 
TLR, the cytoplasmic Toll/IL-1 receptor (TIR) homology domain recruits TIR domain-
containing adaptor proteins such as myeloid differentiation factor 88 (MyD88) (for TLR1, 2, 
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4, 5, 6, 7, 8 and 9) and TIR-domain-containing adapter-inducing IFN-β (TRIF) (for TLR3 and 
4). These factors cascade the signal onwards, as detailed in Figure 1.2 to lead to the activation 
of transcription factors such as nuclear factor-κB (NF-κB) and IFN-regulatory factors (IRFs), 
which regulate the expression of genes that encode proinflammatory cytokines and IFNs 
(Figure 1.2). 
  
TLR2 
Infection of TLR2-/- mice with VACV showed that the TLR2/MyD88 pathway is required for 
activation of innate immunity and control of VACV infection in vivo (Zhu et al., 2007). 
TLR2-deficient DCs stimulated with VACV fail to induce the cytokines induced by 
stimulation of wildtype DC, indicating that VACV can induce TLR signalling via the TLR2 
receptor (Zhu et al., 2007). The involvement of the TLR2, a molecule previously shown to 
detect Gram-positive bacteria via lipopeptides in VACV defence, was unexpected.  
 
TLR3 
TLR3 recognises dsRNA, and hence it was expected that this receptor could be a key 
determinant of the host immune response to viruses. DNA viruses as well as RNA viruses can 
produce dsRNA during infection due to hybridization of complementary transcripts. TLR3-/- 
mice were counter-intuitively more resistant than wildtype (WT) mice to i.n. VACV infection 
(Hutchens et al., 2008) and showed less weight loss and reduced morbidity. Mechanistically, 
this was attributed to the involvement of TLR3 in the recruitment of infiltrating cells to the 
site of infection in the i.n. model, and its role in the induction of cytokines including IL-6, 
tumour necrosis factor (TNF)-α (Hutchens et al., 2008).  These factors demonstrate that 
TLR3 plays a role in the immune response to vaccinia virus infection. 
  
TLR9 
TLR9 detects DNA from its localisation in the endosomal compartment. Comparative 
analysis of ultraviolet (UV)-inactivated CVA and MVA indicated that both viruses activated 
DCs. However, infectious CVA inhibits TLR9 recognition, while MVA has lost some of 
those inhibitory mechanisms and is recognised by TLR9 on DCs (Samuelsson et al., 2008). 
Analysis of the importance of TLR9 in DC recognition was advanced by the generation of 
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DCs from WT or TLR9-deficient animals. MVA induced maturation less efficiently in the 
absence of TLR9, indicating that the recognition of MVA employs a TLR9-dependent 
component (Samuelsson et al., 2008).  
 
TLR7 and TLR8 have both been postulated to play a role in VACV innate immune defence 
(Miller et al., 2008), as these receptors detect the presence of non-host nucleic acids within 
the cell, in particular on macrophages and DCs (Bauer et al., 2008) but these responses to 
VACV have not been fully characterised. 
 
VACV modulation of TLR signalling at the receptor level by proteins A46, A52. 
The intracellular VACV proteins A46 and A52 were investigated initially because they 
contained putative TIR homology domains (Bowie et al., 2000). Immunoprecipitation 
analysis showed that A46 associates directly with MyD88 (Stack et al., 2005) in transfected 
and infected cells to directly block MyD88-dependent signalling as indicated in Figure 1.2.  
Consequently A46 blocks the pathway leading to translocation of NF-κB transcription factor 
into the cell nucleus. Given the broad role of MyD88 in transduction of signals from both the 
IL-1R and TLRs 1, 2, 4, 5, 6, 7 and 9, the effect of A46 on MyD88-dependent pathways was 
also analysed and showed that A46 exhibited a pleiotropic downregulatory effect on any 
pathways involving MyD88. A46 also interacts with two other TIR adaptor proteins [MyD88 
adaptor like (MAL) and Trif Related Adaptor Molecule (TRAM)], and this interaction 
antagonizes TRIF-dependent pathways that induce IRF3 activation leading to IFN-β 
expression (Stack et al., 2005).  
 
A52 inhibits NF-κB activation by TLRs 1, 2, 3, 4, 5 and 6 (Harte et al., 2003). 
Immunoprecipitation analysis showed that A52 associates with both IL-1 receptor-associated 
kinase 2 (IRAK2) and TNF receptor associated factor 6 (TRAF6) (Harte et al., 2003). This 
disrupts the signalling complexes containing these proteins by displacing TNF-associated 
kinase (TAK)-1 binding protein (TAB1) from the TRAF6 complex, and MAL from the 
IRAK-2 signalling complex.   
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VACV modulation of intracellular TLR signalling by proteins B14, M2, and K1 and K7.  
NF-κB is a transcription factor, stimulated by multiple signalling pathways including the 
TLRs and cytokines such as IL-1 and TNF-α. NF-κB modulates the expression of genes 
critical for the innate and adaptive immune response to infection, for review see (Bonizzi and 
Karin, 2004). In most cell types, NF-κB is sequestered in the cytoplasm through an 
interaction with the IκB proteins. When IκB-α is phosphorylated by the IκB kinase (IKK), 
IκB-α is ubiquitinated and degraded, the complex disassociates and NF-κB translocates to the 
nucleus. Here it increases transcription of genes encoding chemokines, cytokines and 
adhesion molecules to produce secondary inflammatory mediators and inhibitors of apoptosis 
(Ghosh et al., 1998).  
 
B14 is an intracellular VACV protein, which contributes to virulence in the i.d. model (Chen 
et al., 2006). B14 associates with the IKK complex via IKK-β to inhibit the activity of the 
IKK complex, and thereby prevent NF-κB activation from multiple signalling pathways 
(Chen et al., 2008).  
 
The M2 protein was identified as a modulator of NF-κB activity, in a screen designed to 
identify the signal transduction pathways modulated in human embryonic kidney 293T 
(HEK) cells in response to MVA infection (Gedey et al., 2006).  The M2 protein inhibits the 
phosphorylation of extracellular-signal regulated kinase (ERK2), and alternative upstream 
activator of the NF-κB signalling cascade. Like other modulators of the NF-κB pathway 
(A46, A52, B14, K7), M2 is expressed early in infection and downregulates NF-κB 
activation, however in contrast to these other NF-κB regulating proteins, M2 is localised 
exclusively to the ER and this localisation is necessary for its function (Hinthong et al., 
2008). Hence it is possible that M2 is inhibiting the recently-identified ER-localised protein, 
STING, which is involved in NF-κB and IFN induction (Barber, 2008), though this 
hypothesis remains to be investigated.  
 
VACV protein K1 inhibits IκB-α degradation though its exact mechanism of action remains 
ill-defined. K1 prevents complex disassociation and nuclear translocation of NF-κB in 
transfected cells (Shisler and Jin, 2004). This protein also acts as a host restriction factor, 
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permitting replication in rabbit cell lines, though the significance of its NF-κB-regulatory 
activity in this host restriction function is ill-defined (Bradley and Terajima, 2005).  
 
VACV protein K7 inhibits PRR-induced IFN-β induction by preventing TRAF-associated 
NF-κB activator (TANK)-binding kinase (TBK1) and inducible IκB kinase (IKKε)-mediated 
from activating IRF3 transcription factor activity as indicated in Figure 1.2. K7 interacts with 
Asp-Glu-Ala-Asp (DEAD) box protein 3 (DDX3) RNA helicase protein that stimulates IFN-
β induction through TBK1/IKKε (Schroder et al., 2008).  
B14
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Figure 1.2. Representation of key components of TLR signalling, and the points of 
action of VACV immune evasion proteins A46, A52, K7, B14, K1 and M2. Adapted from 
(Takeda and Akira, 2005) 
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Soluble PRRs 
Cytosolic or soluble PRRs can also sense foreign RNA or DNA.  
 
DNA–sensing 
The presence of DNA in the cell cytoplasm indicates cell dysfunction or a microbial invasion. 
Recently, a soluble sensor of DNA was identified – the DNA-dependent activator of IFN-
regulatory factors (DAI) protein that binds to cytosolic DNA and activates the innate immune 
response (Takaoka et al., 2007). DAI contains two binding domains: the first binds Z-form 
DNA, and on binding DNA, the protein undergoes homodimerisation and phosphorylation. 
Thereafter DAI recruits TBK1, and IRF3 transcription factor by its second domain and 
induces expression of type I IFN as above (Wang et al., 2008). Recent data indicate the 
presence of an additional cytosolic DNA-sensing molecule(s), which remain unidentified, but 
may also contribute to activating the innate immune response in a similar mechanism to DAI 
in a cell-dependent manner (Wang et al., 2008). 
   
VACV modulation of DAI – E3 
The VACV protein E3 contains a domain with amino acid and structural similarity to the Z-
DNA binding domain of DAI (Kim et al., 2003). The N-terminal domain of E3 binds Z-DNA 
and contributes to viral virulence in a murine intracranial model (Brandt et al., 2005). This Z-
DNA binding domain can inhibit apoptosis, as well as gene transactivation (Kwon and Rich, 
2005) and was implicated in modulation of the DAI pathway (Wang et al., 2008). However a 
direct involvement in the DAI pathway remains to be confirmed. Downregulation of this 
proinflammatory pathway would explain the effect of RNA-independent effect of E3 on IRF3 
and IRF7 phosphorylation in virus-infected cells (Smith et al., 2001). 
 
RNA-sensing: RIG-1, MDA5, PKR, OAS 
RNA produced during viral replication is an important trigger to activate innate immunity 
and is mediated by the RNA helicase enzymes RIG-I and MDA5, for review see (Asahina et 
al., 2008). Both proteins contain two N-terminal caspase-recruitment domains (CARDs) 
followed by a DExD/H-box RNA helicase domain (Yoneyama et al., 2005), which interacts 
with RNA thereby inducing an ATP-dependent catalytic activity (Vitour and Meurs, 2007). 
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The proteins have distinct signalling contributions in the context of virus infections (Loo et 
al., 2008) and while RIG-I senses single-strand (ss)RNA with a 5’ triphosphate, MDA5 
senses dsRNA. RIG-I and MDA5 both associate with an adaptor protein, IFN-β promoter 
stimulator 1 (IPS-1) (also known as MAVS, VISA or CARDIF), which also contains a 
CARD (Kawai et al., 2005; Meylan et al., 2005). IPS-1 then associates with TRAF3 which 
recruits and activates two kinases TBK1 and IKKε, which phosphorylate IRF-3 and IRF-7 
leading to type I IFN production (Kawai et al., 2005).  
 
The dsRNA-dependent PKR is an enzyme with multiple roles in the cell and plays a critical 
role in the antiviral innate response. PKR contains two dsRNA binding domains and a serine-
threonine kinase domain that phosphorylates eukaryotic initiation factor (eIF) 2 , thereby 
resulting in translational arrest of both cellular and virus mRNAs (Dey et al., 2005; Garcia et 
al., 2007; Sadler and Williams, 2007). PKR is also engaged as an intermediary during TLR3 
signalling and is recruited by TAK1 to further amplify that signal (Williams, 2001). PKR 
integrates and transmits these signals to eIF2, but also to the Signal Transducers and 
Activators of Transcription (STAT) protein family, IRF1, c-Jun N-terminal kinases (JNKs), 
and p38 mitogen activated protein kinase (MAPK), as well as engaging the NF-κB pathway 
(Bottrel et al., 1999; Deb et al., 2001; Goh et al., 2000; Takada et al., 2007). PKR has also 
been implicated in induction of apoptosis pathways (Lee and Esteban, 1994) and the 
modulation of cell growth pathways (Meurs et al., 1993) 
 
The 2’5’-oligoadenylate synthetase (2’5’-OAS) is dsRNA-dependent enzyme that converts 
adenosine triphosphate (ATP) to 2’,5’-linked oligoadenylates with the unusual 2’-5’ instead 
of 3’-5’ phosphodiesterase bond (Hovanessian, 1991; Hovanessian and Justesen, 2007). 
These molecules activate RNase L, an endoribonuclease that catalyses the cleavage of single-
stranded, thereby leading to inhibition of protein synthesis (Silverman, 2007). Activation of 
the 2-5 synthetase/RNAseL system results in substantial (>90 %) inhibition of VACV 
replication (Diaz-Guerra et al., 1997). EM further identified maturation steps of the VACV 
lifecycle that were inhibited by 2-5 synthetase (Esteban and Patino, 2000). 
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VACV modulation of PKR and OAS by E3 and K3 
E3 was first identified as a potential immunomodulator from the purification of VACV-
infected cells which showed a factor that could bind dsRNA and prevent PKR activation 
(Rice and Kerr, 1984). This was confirmed to be the E3 protein through the discovery of a 
region of significant homology between E3 and PKR (Chang and Jacobs, 1993; Chang et al., 
1992). E3 inhibits the activation of PKR (Chang et al., 1992) and OAS (Rivas et al., 1998) 
via the C-terminal domain that binds and sequesters dsRNA (Beattie et al., 1995; Chang and 
Jacobs, 1993).  This is partly responsible for the IFN-resistant phenotype of VACV but its 
dsRNA-binding activity is also involved in host range restriction as viruses lacking this 
domain cannot replicate effectively in human cell lines and undergo apoptosis (Shors et al., 
1997).  
 
The VACV K3L gene product exerts immunomodulatory roles that overlap with E3. Initially, 
it was shown that K3 potentiates translation by inhibiting PKR (Davies et al., 1992). 
However, this inhibition is accomplished by a different mechanism (Davies et al., 1993). 
Instead of binding dsRNA, K3 downregulates translation by acting as a psuedosubstrate for 
PKR (Beattie et al., 1991) and prevents phosphorylation of eIF2 to which it is a 
pseudosubstrate (Kawagishi-Kobayashi et al., 1997). K3 also affects host range and enables 
VACV replication in BHK cells (in contrast to E3 that allows replication in HeLa cells) 
(Langland and Jacobs, 2002). 
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Figure 1.3 Representation of soluble PRRs involved in VACV innate immunity and the 
points of action of the immune evasion proteins E3 and K3. 
 
 1.7.9  IFNs 
IFNs are very important for defence against viruses and consequently there are a myriad of 
viral immune evasion strategies that target the production or action of IFNs. In 1957, Isaacs 
and Lindemann published a seminal paper in which they demonstrated the existence of a 
substance that interfered with viral infection, which they called IFN (Isaacs and Lindenmann, 
1957). The IFNs now refer to a family of structurally-related cytokines that are involved in 
numerous immune interactions as inducers, regulators and effectors of both innate and 
adaptive antiviral mechanisms (Muller et al., 1994; Pestka et al., 2004). There are 3 types of 
IFNs (I, II and III) as well as IFN-like cytokines. In general, IFNs are produced rapidly after 
virus infection and restrict viral replication and spread (Muller et al., 1994). Type I IFNs 
include the many different IFN-αs and IFN-β and others (see below), but the α and β IFNs 
are best characterised. These are induced by the PRRs and downstream signalling cascades 
and are among the earliest host molecules upregulated upon viral infection, with initial IFN-β 
induction leading to a positive feedback upregulation of IFN-α. Type I IFNs induce a shut-
down of protein synthesis, the induction of more pro-inflammatory cytokines, and a positive 
feedback loop that results in induction of an anti-viral state in neighbouring cells as well as 
 56
within the infected cell. Type II IFN (IFN-γ) is associated with adaptive immune responses 
because it is secreted by T cells and enhances Th1 adaptive responses.  However, it is also 
secreted by macrophages and NK cells and leads to the activation of further inflammatory 
cells. Type III IFNs (IFN-λs) are a more recently described set of IFNs (Kotenko et al., 2003) 
that can induce similar outcomes to type I IFNs, but have a different cellular distribution and 
are abundant in dermal tissues and less widely expressed than type I IFNs. 
 
  IFN subfamilies 
Type I IFNs (Roberts et al., 1998) comprise IFN-α, β, ω or ε (Langer, 2007; Pestka et al., 
2004) and κ (LaFleur et al., 2001), τ (Roberts et al., 1999), δ (Lefevre et al., 1998), and ξ 
(limitin) (Oritani et al., 2000), and are united by their affinity for a receptor complex 
composed of two subunits, IFNAR1 and IFNAR2 (Abramovich et al., 1994b). Ultimately, 
these IFNs lead to degradation of viral RNA, protein synthesis shutdown and an upregulation 
of MHC I molecules (Muller et al., 1994). IFN-α and IFN-β both bind the IFNAR1/2 
complex, though the signals induced are distinct. IFNAR2 is phosphorylated after binding 
either IFN-α or IFN-β, though the association of IFNAR2 and IFNAR1 can only be detected 
on IFN-β stimulation (Abramovich et al., 1994a; Abramovich et al., 1994c). Furthermore, 
while Tyrosine kinase (Tyk)-2-deficient cells are unresponsive to IFN-α, they retain 
sensitivity to IFN-β stimulation, suggesting that different conformational changes induced by 
different type I IFNs result in activation of distinct downstream signalling pathways 
(Velazquez et al., 1992). The type I IFN genes are all clustered on the human chromosome 9 
and the murine chromosome 14 and a gene disruption study (Sato et al., 2000) revealed that 
IRF-3 and IRF-7 are essential transcriptional factors for virus-induced expression of IFN-α/β. 
Each subtype is encoded by its own gene and controlled by individual promoter sequences.  
 
Exposure of cells to viruses or dsRNA generally induces the production of IFN-α, IFN-β and 
IFN-ω, by the activation of PRRs including the TLRs (Takeda and Akira, 2005), cysotolic 
dsRNA sensors including RIG-I and MDA5 (Yoneyama et al., 2005) and cytosolic DNA 
sensors such as DAI (Takaoka and Taniguchi, 2008). 
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Type II IFN family comprises solely IFN-γ. Like type I IFN, IFN-γ has direct antiviral 
activity but also is a potent cytokine promoting the Th1 immune response. IFN-γ is produced 
strongly by activated T cells or NK cells but not by virus-infected cells. The production of 
IFN-γ contributes to the promotion of the development of CD4+ and CD8+ T cells (Ikeda et 
al., 2002).  The IFN-γ signals through a dimeric receptor comprising, IFNGR-1 and IFNGR-
2, that is distinct from the type I IFNAR. 
 
More recently, IFN-λs or IL-28/29, were recognised. The receptors for IFN-λ are distinct 
from the type I and II IFN receptors (Onoguchi et al., 2007) although the downstream 
signalling molecules overlap. Type III IFNs are induced upon viral infection, and mediate 
antiviral activity by inducing IFN-stimulated genes (ISGs) such as those encoding OAS, PKR 
and MxA, to lead to the subsequent formation of the IFN-stimulated gene factor (ISGF) 3. 
The type III IFNs exhibit potent antiviral activity in vivo in a poxvirus infection model 
(Bartlett et al., 2005).  
 
  Action of type I and type II IFNs 
The intracellular domains of the IFN receptors (IFNAR1, IFNAR2, IFNGR1, IFNGR2) are 
associated with Janus protein tyrosine kinases (JAK PTKs): Tyk2, JAK1, JAK1 and JAK2 
respectively (Darnell et al., 1994). The binding of both types of IFNs to IFNAR or IFNGR 
results in the cross activation of these JAK PTKs, which then phosphorylate two members of 
the family of signal transducers and activators of transcription (STATs), namely, STAT1 and 
STAT2  (Darnell et al., 1994; Ihle and Kerr, 1995; Schindler and Darnell, 1995). Tyrosine 
phosphorylation of the STATs leads to the formation of two transcriptional activator 
complexes, IFN-α-activated factor (AAF) (also known as ISGF3) and IFN-γ-activated factor 
(GAF) (Darnell et al., 1994; Ihle and Kerr, 1995; Schindler and Darnell, 1995). ISGF3 is a 
heterotrimeric complex of tyrosine-phosphorylated STAT1, STAT2 and another transcription 
factor, IRF9 (or p48) whereas GAF is a homodimer of phosphorylated STAT1 as illustrated 
in Figure 1.3 (Bluyssen et al., 1995). These complexes translocate into the nucleus, where 
GAF and ISGF3 bind to specific DNA sequences namely the IFN-γ-activated sequence 
(GAS; (Decker et al., 1991; Lew et al., 1991) and the IFN-stimulated regulatory element 
(ISRE; (Kessler et al., 1990) respectively. The stimulation of the promoters containing ISRE 
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and GAS results in the transcriptional induction of a large number of target ISGs to evoke 
versatile biological activities. 
 
Constitutive production of IFN-α/β is critical for eliciting strong responses to IFN-γ and IL-6 
(Mitani et al., 2001; Takaoka et al., 2000). Additionally, low levels of IFN-α/β aid efficient T 
cell activation and the regulation of adaptive immune responses. T cells lacking IFNAR-1 
cannot respond efficiently to antigen stimulation (Buller et al., 1987; Ogasawara et al., 2002).  
 
IFNs play an important role in controlling VACV infection. It was suggested that the 
presence of IFNs in the smallpox scabs used for variolation contributed to the reduced fatality 
observed compared to naturally acquired VARV (Wheelock, 1964).  When administered the 
day before inoculation, IFN from rabbit cells protected rabbits from an intradermal VACV 
infection (Isaacs and Burke, 1959). More recent investigations have analysed the various 
roles and contributions of different types of IFNs. IFN-λ also provides significant antiviral 
activity in mice (Bartlett et al., 2005). Rapid upregulation of genes involved in the IFN (α, β 
and γ) response was also observed in macaques following VARV infection (Rubins et al., 
2004). 
 
VACV modulation of IFN signalling: proteins B18, B8, H1 
The VACV strain WR B18 protein is a type I IFN receptor, secreted by the virus to bind 
soluble IFN-α and IFN-β (Colamonici et al., 1995; Symons et al., 1995). B18 binds to human 
and rabbit IFN-α with high affinity, while its affinity for bovine and rat IFN-α was reduced, 
and its affinity for murine IFN-β was low but still in the nanomolar (nM) range. Despite this 
low affinity for murine type I IFNs, the phenotype of the v∆B18R viruses was attenuated in 
vivo in the murine intranasal model (Symons et al., 1995).  
 
The B8R gene of VACV WR encodes a secreted 43-kDa glycoprotein with a sequence 
similarity to the binding domain of cellular IFN-γ receptors (IFN-γRs) (Alcami and Smith, 
1995), which is synthesized and secreted early in infection. It binds to and inhibits the 
activity of IFN-γ by preventing its interaction with cellular receptors (Alcami and Smith, 
1995). B8 has broad cross-species specificity for IFN-γ and can inhibit the biological 
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activities of human, bovine, equine, ovine and rat IFN-γ (Alcami and Smith, 1995; Mossman 
et al., 1995; Symons et al., 2002b) but not murine IFN-γ (Symons et al., 2002b). 
 
VACV inhibits phosphorylation of STAT1 and STAT2 in response to either type I or type II 
IFNs (Mann et al., 2008; Najarro et al., 2001). This blocks IFN-γ-mediated stimulation of 
antigen presentation in VACV-infected cells, and is accomplished in part by the H1 or VH1 
phosphatase protein bringing about the dephosphorylation of the STATs (Najarro et al., 
2001). Furthermore, VACV can block IFN-induced gene expression in a STAT1-independent 
pathway, suggesting that other VACV proteins interact with multiple downstream effectors of 
the IFN pathway (Mann et al., 2008).  
H1 H1
B8B18
 
Figure 1.4 Representation of the IFN signalling pathways and the points of action of the 
immune evasion proteins B8, B18 and H1.  Adapted from (Goodbourn et al., 2000).  
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  Alternative induction pathways of the ISREs  
Although JAKs and STATs are the primary signalling components involved in IFN-induced 
signal transduction, some other signalling molecules are vital for the biological effects of the 
IFNs (Katsoulidis et al., 2005; Kaur et al., 2005). These additional signal transducers support 
IFN signalling in a diverse array of ways, and both in STAT-dependent and STAT-
independent manners. For example, ERK2 is required for the STAT-mediated effects of IFN-
β (David et al., 1995), and SHP-2 (Src homology (SH)2-containing phosphatase-2) becomes 
tyrosine-phosphorylated upon IFN-α/β stimulation, and expression of a dominant-negative 
form can suppress reporter activity driven by ISGF-3. Cytosolic phospholipase A2 (PLA2) 
activity is also required for signal transduction leading to the formation of ISGF3 (Flati et al., 
1996; Hannigan and Williams, 1991).because PLA2 mediates IFN-stimulated activation of 
the p38 MAPK (Goh et al., 1999). Several stimuli can induce activation of the p38 MAPK 
serine/threonine phosphorylation activity, such as stress stimuli and pro-inflammatory 
cytokines, such as IL-1, TNFα, transforming growth factor β (TGF-β) and the CD40 ligand 
(CD40L). Thus it participates in diverse signalling cascades. 
 
  Involvement of p38 MAPK in IFN signalling 
The involvement of the p38 MAPK pathway in type I IFN-signalling in a variety of cell types 
strongly suggests that the pathway may play a significant role in the induction of type I IFN-
dependent biological responses (Goh et al., 1999; Uddin et al., 2000; Uddin et al., 1999). p38 
MAPK is activated in response to IFN-α or IFN-β (Uddin et al., 1999) and can phosphorylate 
activating transcription factor (ATF)-2 as an exogenous substrate in in vitro kinase assays 
(Goh et al., 1999; Uddin et al., 1999). In addition, ISRE and GAS activity in luciferase 
promoter assays were reduced by the pharmacological inhibition of p38 MAPK (Uddin et al., 
1999). ISRE-dependent or GAS-dependent gene transcription is also reduced in MAPK 
kinase (MKK)3 or MKK6 knockout mouse embryonic fibroblast (MEF) cells (Li et al., 
2005). Elucidation of the upstream effectors of p38 MAPK in the IFN pathways has not been 
as straightforward. There is evidence that the small G-protein Rac1 is activated during 
treatment of cells with IFN-α or IFN-β and that a dominant negative form of Rac1 inhibits 
IFN-dependent activation of p38 MAPK, indicating that Rac1 may function as an upstream 
effector of p38 MAPK in the IFN system (Uddin et al., 2000). Pan-tyrosine kinase inhibitors 
have indicated that the activation of Rac1 by type I IFN, is reliant on an upstream tyrosine 
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kinase (Uddin et al., 2000) thus it is possible that JAKs or other tyrosine kinases downstream 
of the JAKs regulate phosphorylation of Rac1 via phosphorylation and activation of a protein 
that functions as a guanine exchange factor (GEF) for Rac1. This protein may be Vav, an 
oncoprotein which is expressed in cells of hematopoietic origin, contains SH2 and SH3 
domains and is tyrosine phosphorylated in an IFN-α dependent manner (Crespo et al., 1997). 
More importantly, there is evidence that in other systems, Vav may function as a GEF for 
Rac1 (catalysing guanosine diphosphate (GDP)/guanosine triphosphate (GTP) exchange 
(Crespo et al., 1997; Gringhuis et al., 1998; Salojin et al., 1999). 
 
 1.7.10  Apoptosis 
To limit viral replication and spread, infected cells may undergo apoptosis (Roulston et al., 
1999). Programmed cell death is a strictly regulated process that is involved in cell 
homeostasis and the immune system, and acts to eliminate cells that are no longer useful, or 
cells that have are aberrant as a result of DNA damage/physiological stresses, or as a result of 
infection. Apoptosis can be induced by extracellular stimuli such as TNF or Fas-binding, or 
by intracellular stimuli that cause DNA damage and mitochondrial dysfunction or signal 
microbial invasion. Two protein families involved in the induction of apoptosis are the 
cysteine-aspartic acid proteases (caspase) and B-cell leukaemia/lymphoma 2 (Bcl-2) proteins. 
The caspase family comprises aspartic proteases, which are present as inactive pro-enzymes 
that are activated in a proteolytic cascade (Thornberry, 1999). Caspases can be activated by 
extracellular stimulation such as by Fas ligand protein. Fas receptors contain so-called death-
domain motifs, and a consequential series of interactions of death-domain-containing proteins 
is initiated. This leads to the recruitment of a caspase initiator protein via their CARDS which 
can bring about the cleavage of a caspase protein. This initiating step induces a cascade of 
proteolytic caspase cleavages that result in the eventual disassembly of cellular structures and 
deregulation of homeostatic cellular activities. An alternative pathway of caspase activation 
begins at the mitochondrion where apoptotic signals can converge, resulting in the loss of 
membrane potential, which leads to the release of proapoptotic proteins including second 
mitochondria-derived activator of caspases (SMAC), apoptosis inducing factor, endonuclease 
G, and cytochrome c. Mitochondrial-released cytochrome c initiates caspase activation 
through an interaction with the adapter molecule apoptotic protease activating factor 1 
(APAF-1) and the subsequent recruitment and activation of caspase 9 (for review see 
(Budihardjo et al., 1999)) . 
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 The Bcl-2 family of proteins regulate the release of apoptotic molecules from the 
mitochondrion and includes both pro- and anti-apoptotic members (reviewed in (Adams and 
Cory, 1998)). These proteins are characterised by up to four sequences termed Bcl-2 
homology (BH) (1-4) domains, and can function as homo- or heterodimers to regulate 
apoptosis. The balance between apoptosis and cell survival is dependent on the relative levels 
of pro- and anti-apoptotic members. Anti-apoptotic Bcl-2 family members, such as Bcl-2, 
block APAF-1-mediated pro-caspase activation, while pro-apoptotic members, like Bik 
release this inhibition.  
 
VACV modulation of caspases: B13 and B22 
VACV encodes two proteins, B13 and B22 that inhibit the caspase cascades by inhibiting 
proteolytic activity. Cell death, measured via release of intracellular chromium or the 
fragmentation of DNA was inhibited by VACV infection, but this inhibitory affect was 
abrogated in the absence of B13 (Dobbelstein and Shenk, 1996; Kettle et al., 1997). Further 
analysis of B13 in an intraperitoneal model showed that the lack of B13 led to stronger T-
helper responses and more potent cytotoxic T-cell responses (Legrand et al., 2004). B22 is a 
second VACV protease inhibitor (Kettle et al., 1995) that modulates apoptotic cascades by 
acting as pseudosubstrates for target proteinases. B22 is an intracellular protein, which is 
expressed early during infection and highly conserved across VACV strains (Kettle et al., 
1995). Further analysis showed that deletion of the B22R gene in VACV strain rabbitpox 
restricted host range and in cells that became non-permissive, the host restriction was due to 
the induction of apoptosis  (Brooks et al., 1995) due to formation of a complex with cathepsin 
G via the serine protease inhibitor (serpin) motifs (Moon et al., 1999).  
 
VACV modulation of Bcl-2 proteins: N1 and F1 
VACV also encodes at least two proteins that inhibit the activity of pro-apoptotic Bcl-2 
activity in infected cells, N1 and F1. N1 is a virulence factor in the i.d., i.n. and intracranial 
(i.c.) mouse infection models (Abrahams et al., 2005; Bartlett et al., 2002). The structure of 
N1 has been solved and showed that N1 is a Bcl-2 protein and interacts with the pro-
apoptotic Bcl-2 family proteins (Aoyagi et al., 2007; Cooray et al., 2007). Functional 
analyses demonstrated cells expressing N1 were resistant to staurosporine (ST)-induced 
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apoptosis (Cooray et al., 2007). The VACV strain COP F1 protein localises to mitochondria 
where it regulates the initiation of the apoptotic cascade by inhibiting release of cytochrome c 
(Cuconati and White, 2002; Wasilenko et al., 2003). F1 contains a single transmembrane 
domain that is sufficient for localisation to the mitochondrion (Stewart et al., 2005). Deletion 
of the gene results in an increase in apoptosis and biosensor analysis indicates a direct 
interacting with the BH3 domains of Bcl-2 proteins to directly inhibit activation of apoptosis 
(Fischer et al., 2006).  
 
Table 1.2 
Protein Function 
 Complement modulation 
C21/VCP Binds to C3 and C4b; inhibits the classic and alternative pathways of 
complement activation (Isaacs et al., 1992) 
 Chemokine modulation 
vCKBP/ 
CCI 
Binds to CC chemokines to inhibit chemotaxis (Beck et al., 2001; Seet et al., 
2001) 
A41 Chemokines binding protein (Bahar et al., 2008; Clark et al., 2006) 
 Extracellular PRR signal induction 
A46 Targets IRAK2 and TRAF6 (Bowie et al., 2000; Stack et al., 2005) 
A52 Targets TIR adaptors (Bowie et al., 2000; Harte et al., 2003) 
K7 Interacts with TBK1 and IKKε (Schroder et al., 2008) 
K1 Host range gene; NF-κB inhibitor by suppressing IκB-α degradation  (Bradley 
and Terajima, 2005; Shisler and Jin, 2004) 
M2 NF-κB inhibitor (Hinthong et al., 2008) 
B14 NF-κB inhibitor; targets IKK-β to downregulate IKK activity (Chen et al., 2008) 
 Intracellular PRR signal induction 
E3 Binds to dsRNA, preventing PKR and OAS activation and inhibition of protein 
synthesis and apoptosis (Kwon and Rich, 2005; Langland and Jacobs, 2002) 
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K3 Mimics eIF2 as a pseudo substrate for PKR (Davies et al., 1992) 
 IFN 
B18 Binds to and inhibits IFN-α/β (in solution and on the cell surface) (Colamonici 
et al., 1995; Symons et al., 1995) 
B8 Binds to and inhibits IFN-γ (Symons et al., 2002b) 
H1 IFN signalling inhibitor; dephosphorylates STAT1 (Mann et al., 2008; Najarro 
et al., 2001) 
 Apoptosis 
B13 Serpin; inhibits the action of caspase 1 and thereby i) the maturation of IL-1β 
and IL-18 from their precursors and ii) TNF- or Fas-induced apoptosis (Blake et 
al., 1995; Dobbelstein and Shenk, 1996; Kettle et al., 1997) 
B22 Serpin (Blake et al., 1995) 
F1 Interferes with cytochrome c release from mitochondria and apoptosis (Boya et 
al., 2004; Wasilenko et al., 2003) 
N1 Inhibits apoptosis (Aoyagi et al., 2007; Cooray et al., 2007) 
 Cytokines 
B15 Binds to and inhibits IL-1β to inhibit febrile response during systemic infection 
(Alcami and Smith, 1992; Smith and Chan, 1991; Spriggs et al., 1992a) 
C12 Binds to IL-18; inhibits IL-18-induced IFN-γ production (Reading and Smith, 
2003; Symons et al., 2002a) 
CrmE Binds to and inhibits activity of TNF-α (Reading et al., 2002) 
 Other 
A44 3-β-hydroxysteroid dehydrogenase; synthesizes steroid hormones that inhibit 
inflammatory response (Moore and Smith, 1992; Reading et al., 2003a) 
C2 Kelch-like protein; affects VACV-induced inflammation in a murine i.d. model 
(Pires de Miranda et al., 2003) 
F3 Kelch-like protein; affects VACV-induced inflammation in a murine i.d. model 
(Froggatt et al., 2007) 
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A55 Kelch-like protein; affects VACV-induced inflammation in a murine i.d. model 
(Beard et al., 2006) 
A39 Semaphorin glycoprotein that affects the outcome of infection in a murine i.d. 
model (Gardner et al., 2001) 
A40 Type II membrane glycoprotein that affects the murine i.d. (Tscharke and Smith, 
1999; Wilcock et al., 1999) 
 Table 1.2 Summary of VACV innate immune evasion proteins 
 
1.8 Adaptive immune responses to VACV infection 
 1.8.1 Humoral responses 
Ab can directly bind to virus particles, causing aggregation and obstructing viral binding to 
and internalisation into cells. Alternatively, Ab-binding to the virion, can lead to 
complement-mediated lysis or opsonisation, Ab can also bind to the infected host cell, 
leading to Ab-dependent cell-mediated cytotoxicity.  
 
Comparative analysis of the contribution of humoral and cellular immunity to VACV 
infection in mice shows that B-cell deficient mice and CD4+ T cell depleted mice show an 
inability to clear VACV, whereas depletion of CD8+ T cells by mAb or gene knockout had 
little effect on the course of primary infection (Xu et al., 2004). The Ab response is CD4+ T 
cell-dependent (Xu et al., 2004) and Abs are predominantly of an IgG2a isotype (Fogg et al., 
2004). IgM appear by 7 days p.i. and IgG are present by day 14 (Spriggs et al., 1992b). Ab 
levels peaked at around 6 weeks p.i. (Meseda et al., 2005; Wyatt et al., 2004) and were 
maintained for more than 3 months (Coulibaly et al., 2005; Meseda et al., 2005). 
 
In human vaccination studies, strong Ab responses are elicited after primary vaccination. Abs 
are not detected before day 10 p.i. (McClain et al., 1997) but are apparent by day 13/14 
(Greenberg et al., 2005), and continue to rise until a peak at approximately day 28 (Frey et 
al., 2003; Greenberg et al., 2005). The Abs were long lived and were present up to 50 years 
post-vaccination (Putz et al., 2005). VACV-specific memory B cells are also generated after 
smallpox vaccination (Crotty et al., 2003) in humans. At 4 weeks to 6 months p.i., 1 % of 
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circulating IgG+ memory B cells was VACV-specific. A moderate correlation could be seen 
between memory B cells and serum Abs, indicating that multiple factors may be involved in 
Ab maintenance (Crotty et al., 2003; Slifka and Ahmed, 1998). 
 
  Antibody epitopes 
In animals and humans, a selection of about 10 immunodominant antibody targets had been 
identified by immunoblotting (Cheliapov et al., 1988; Demkowicz et al., 1992; Jones-Trower 
et al., 2005; Wilton et al., 1986) and more so by proteome arrays (Davies et al., 2005). While 
there is some variation between species, in general, the predominant Ab targets are core 
proteins such as A4, E3 and A10, IMV surface antigens such as H3, D8, and A27, and EEV-
specific antigens such as A56, B5, A33 and F13. The targets for neutralising Ab activity are 
the IMV and EEV surface antigens. H3, D8 and A27 are targets of IMV neutralising Abs, as 
well as L1, A17 and F9. B5 is the only EEV target for neutralising Abs (Putz et al., 2006).  
 
B5-specific Ab can be detected after immunisation of mice with VACV strain Wyeth (Fogg 
et al., 2004) and macaques with Dryvax (Earl et al., 2004). A33 is important for Ab-resistant 
direct cell-to-cell spread (Law et al., 2002) and A33-specific Abs were detected after VACV 
immunisation of mice (Fogg et al., 2004), macaques (Earl et al., 2004) and humans 
(Galmiche et al., 1999; Putz et al., 2006) but showed no neutralising activity in the absence of 
complement. A56 is the viral haemaglutinin (HA) protein (Shida, 1986), but A56-specific 
Abs do not neutralise EEV (Law and Smith, 2001; Putz et al., 2006). 
 
For the IMV antigens, there is more than one target of neutralising antibodies. Sera from 
mice immunised with an A27 DNA vaccine neutralised IMV (Hooper et al., 2003). H3 is a 
highly immunogenic antigen in mice, macaques and humans (Chertov et al., 1991; Davies et 
al., 2005; Demkowicz et al., 1992) and is a target of IMV-neutralising Abs (Davies et al., 
2005). D8 is a target of IMV-neutralising Abs in mice (Sakhatskyy et al., 2006) and induces 
cellular proliferative responses in VACV-immunized mice (Demkowicz et al., 1992). 
Moderate L1-specific responses were detected in mice after immunisation with the Wyeth 
vaccine (Fogg et al., 2004; Wyatt et al., 2004) while poor responses were detected in 
macaques (Hooper et al., 2003) following DNA vaccination and no antibody response to L1 
was detected in human serum analysis (Putz et al., 2006). 
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1.8.2 Cellular responses 
Immunisation with VACV induces cellular immune responses that persist for >35 years 
(Demkowicz et al., 1992; Hammarlund et al., 2003). Kinetic analysis of infection shows that 
VACV induces a potent primary CD8+ T cell response as well as long-term memory in vivo 
(Harrington et al., 2002). An IFN-γ positive, CD8+ T cell response in mice was detected as 
early as day 6 p.i. and peaked at day 7, with 30 % of CD8+ T cells in the spleen being VACV-
specific (Ahmed and Gray, 1996; Harrington et al., 2002). Despite the large CD8+ response, 
in CD8+-depleted or CD8+ null mice, virus was cleared at similar rates to control, suggesting 
that the activated CD8+ T cells are not essential for virus clearance following acute infection 
(Xu et al., 2004). Furthermore, β2m-/- mice that are deficient in CD8+ T cells survived sub-
cutaneous (s.c.) infection with similar lesion development as control mice (Spriggs et al., 
1992b). However, in the absence of a humoral or CD4+ based response, a partial protective 
function of CD8+ T cells can be demonstrated (Xu et al., 2004).  
 
In mice, the CD4+ T cell response exhibited similar kinetics to that of CD8+ T cells but at 
lower frequencies (Harrington et al., 2002). The peak response was detected 1 week p.i., with 
3 % of the CD4+ T cells in the spleen being VACV-specific.  Compared to the CD8+ T cells, 
a higher percentage of CD4+ T cells produced IL-2, demonstrating an increased proliferative 
response compared to the CD8+ T cell compartment (Harrington et al., 2002).  This is 
consistent with the role of CD4+ T cells as T helper cells.  By day 30, the response had 
declined by approximately 90 % but was then maintained at that level for over 300 days 
(Harrington et al., 2002).  In humans, CD4+ T-cell responses were detected after 2 weeks 
(0.14 to 1.1 %) but were 2- to 4-fold lower than CD8+ responses (Amara et al., 2004). 
However, unlike CD8+ T-cell responses, VACV-specific CD4+ T cells are long lived and 
detected in the majority (82-100 %) of individuals vaccinated up to 75 years previously 
(Amara et al., 2004; Hammarlund et al., 2003) even when CD8+ T-cell responses were low 
(Amara et al., 2004).   
 
T cell epitopes 
Approximately 50 murine MHC-I-restricted (Mathew et al., 2005; Moutaftsi et al., 2006; 
Tscharke et al., 2005; Tscharke et al., 2006) and human leukocyte antigen (HLA)-A/B-
restricted VACV epitopes (Drexler et al., 2003; Oseroff et al., 2005; Pasquetto et al., 2005; 
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Snyder et al., 2004; Terajima et al., 2003) have been identified. The HLA-restricted human 
epitopes come from 35 different proteins, spanning almost 20 % of predicted ORFs, and are 
recognised by PBMCs from vaccinated humans. Overall, the proteins involved are usually 
greater than 100 aas in size, are approximately 50 % early and 50 % late and there is no 
obvious bias towards either a particular localisation pattern or function of the epitope 
proteins.  
 
In mice, analysis of MHC-II-restricted epitopes showed that the pattern of antigens 
recognised by CD4+ T cells differs substantially from the pattern of antigens recognised by 
CD8+ T cells (Moutaftsi et al., 2007). A recent study analysing the human MHC-II epitopes 
(Jing et al., 2008) identified 122 VACV proteins that stimulated CD4+ responses. In this 
analysis, the proteins most frequently recognized by CD4+ T cells were virion structural 
proteins and tended to have high molecular weights and to be expressed with late during 
infection. 
  
 1.8.3 Vaccination 
Primary vaccination by i.d. inoculation with replication-competent VACV strains results in 
local viral replication followed by complete virus elimination. Vaccination is achieved 
through scarification of the epidermal layers covering the upper deltoid region of the arm.  
Following primary vaccination, VACV replicates in the basal layer of the skin where a 
papule appears at the primary site within 3-5 days and develops into a pustular vesicle that 
reaches a maximum size within 8-10 days (Fenner, 1989).  A scab then forms, which 
separates after 17-21 days, leaving a vaccination scar. Aside from the primary site lesion, 
most vaccinees experienced a mild fever and localised discomfort. Local responses included 
erythema, pain and swelling (Fenner, 1989; Frey et al., 2002; Greenberg et al., 2005; Orr et 
al., 2004). Systemic responses included fever, fatigue, malaise, headaches, nausea, diarrhoea 
and vomiting (Frey et al., 2002; Orr et al., 2004). 
 
On rare occasions, severe complications were observed after vaccination. These were 
commonly associated with virus escape from the site of vaccination and included accidental 
infection of the eye, eczema vaccinatum, generalised vaccinia, postvaccinial encephalitis, 
progressive vaccinia and myopericarditis (Bray, 2003; Kempe, 1960; Lane et al., 1969; Neff 
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et al., 1967a; Neff et al., 1967b). Accidental infection of secondary sites such as the eye or 
genitalia were more common in children, occurring at a rate of 25-529 cases per million 
(Talbot et al., 2004).  Eczema vaccinatum was observed in 10-40 cases per million, in people 
with skin disorders, such as eczema or atopic dermatitis, as a result of mechanical and blood 
borne viral dissemination (Babic, 2007). The outcome ranged from benign to fatal (Kempe, 
1960). Generalised vaccinia describes the formation of additional lesions at secondary sites 
after vaccination following blood-borne dissemination that could be treated with VACV 
immunoglobulin (VIG) (Vellozzi et al., 2005). Postvaccinial encephalopathy was more 
severe and often fatal, but had a lower incidence rate, occurring in 3-12 vaccinees per million 
(Kempe, 1960). The most severe complication of vaccination was progressive vaccinia, 
which occurred at a rate of 1 per million (Bray and Wright, 2003). It results from a complete 
lack of ability to control virus replication due to T cell deficiency. Myopericarditis was also 
recognised as a complication of vaccination (Chen and Lane, 2003). 
 
Protection induced by vaccination is shared between Ab and cellular immunity (Belyakov et 
al., 2003). When B cell-deficient mice (JH knock out) were immunised with either Wyeth 
vaccine (VACV strain NYCBH) or MVA, and challenged with VACV WR 28 days later, 
they were protected (Wyatt et al., 2004; Xu et al., 2004), indicating that Abs were not 
essential for VACV immunity.  However, Ab are also sufficient for protection, as shown by 
passive transfer of sera from immunised animals (Boulter et al., 1961; Law et al., 2005). 
Equally, T cells are not strictly necessary for protection. In mice, depletion of CD8+ T cells 
prior to challenge with VACV WR (Belyakov et al., 2003) had no effect compared to control 
animals, nor did challenge of β2m-/- mice (Wyatt et al., 2004). In contrast, CD4+-deficient 
(MHC II-/-) mice were not protected from challenge (Wyatt et al., 2004). Following adoptive 
transfer of CD4+ and/or CD8+ T cells from MVA-immunised mice, naïve mice were not 
protected against challenge with VACV WR (Wyatt et al., 2004), though in a separate study, 
adoptive transfer of WR-activated memory CD8+ T cells resulted in a 2-fold log reduction of 
virus in the ovaries (Xu et al., 2004).   
 
The precise duration of protection afforded by vaccination is unclear. For example, in Europe 
between 1950 and 1971, only 2 %, 6 % and 7 % fatality rates were observed in those 
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vaccinated 0-10, 11-20 and >20 years previously, respectively, while naïve individuals were 
highly susceptible with a 40 % fatality rate (Mack, 1972).    
 
1.9 IL-1 Pathway 
IL-1 is a 31-kDa pro-protein or 17-kDa secreted protein existing in two distinct isoforms, IL-
1α and IL-1β that are produced by phagocytes and DCs during the initial phase of infection 
and have a broad range of stimulatory effects on immunological cell types (Dinarello, 1996a; 
Dinarello, 1997). Activation of the IL-1 pathway also induces the febrile response (Dinarello, 
1996b; Dinarello, 1999). The IL-1 pathway comprises the two natural ligands (IL-1α and IL-
1β), two receptors (IL-1R types 1 and 2), an IL-1R accessory protein (IL-1RAcP) and four 
isoforms of an IL-1 receptor antagonist (IL-1Ra). Despite a relatively low sequence similarity 
(27 % aa identity), IL-1α and IL-1β bind to the same receptor  (Arend et al., 1994). However, 
IL-1α is mostly cell-associated and is primarily a regular of local effects, whereas IL-1β is 
released and has a systemic role. Both IL-1α and IL-1β are produced by caspase-1-mediated 
proteolytic cleavage of larger precursors, known as pro-IL-1α and pro-IL-1β (Black et al., 
1988). IL-1RI is biologically active but IL-1RII is a decoy receptor which binds IL-1β and 
does not initiate a signalling cascade (Colotta et al., 1993).   
 
 1.9.1 IL-1 receptor signalling 
IL-1RI is an 80-kDa transmembrane protein, with a cytoplasmic tail of 213 aa, which 
contains the TIR domains for signal transduction (Dinarello, 1994). In contrast, IL-1RII is a 
smaller protein, of approximately 67 kDa, with a shorter cytoplasmic domain of 29 amino 
acids long and acts as a decoy receptor (Colotta et al., 1993). Both receptors belong to the 
immunoglobulin superfamily and are expressed on many cell types. After binding of IL-1α or 
IL-1β to IL-1RI, the IL-1RAcP is recruited and this causes activation of the TIR domain of 
IL-1RI (Korherr et al., 1997). Signalling by IL-1 leads to the activation of four protein kinase 
cascades, including the NF-κB, p38 MAPK, ERK and JNK pathways. MyD88 is one of the 
first cytoplasmic proteins to interact with the TIR domains. MyD88 recruits IRAK (Muzio et 
al., 1997) that autophosphorylates and then dissociates from the complex to interact TRAF6 
(Cao et al., 1996). Like TLR signalling, this results in activation of IKK, leading to 
phosphorylation of IκB, releasing NF-κB and allowing its translocation to the nucleus (Karin 
and Ben-Neriah, 2000).  
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 VACV modulation of extracellular IL-1 by protein B15 
Several VACV strains express a soluble IL-1 receptor (vIL-1βR) that bind IL-1β but not IL-
1α (Alcami and Smith, 1992; Smith and Chan, 1991). Viruses containing the vIL-1βR 
prevent activation of the febrile response in mice infected i.n., whereas strains lacking vIL-
1βR cannot do so. Curiously, inactivation of the B15R gene from VACV WR decreases virus 
virulence in mice after i.c. infection (Spriggs et al., 1992a) but enhances virus virulence when 
administered i.n. with doses that induce a systemic infection (Alcami and Smith, 1992). This 
may be reflective of the properties of IL-1β having beneficial affects in moderation but 
detrimental effects in excess in certain organs (Dinarello, 1994). vIL-1βR binds human or 
mouse IL-1β with high affinity (Alcami and Smith, 1995), but neither human nor mouse IL-
1α can bind vIL-1βR and so is more reminiscent of the IL-1RII decoy receptor (Alcami and 
Smith, 1992).  
 
 1.9.2 IL-1α and IL-1β 
IL-1α and IL-1β are synthesised in response to many stimuli including microbial products, 
cytokines [TNF, IFN-γ, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-2] 
and immune complexes such as T cell/APC interactions. These proteins have low sequence 
identity (20-30 % in mammals) but high three-dimensional similarity. The promoters for both 
genes contain binding sites for NF-κB, while the IL-1β promoter also has binding sites for 
activator protein (AP)-1, the cyclic AMP (cAMP) response element binding protein (CREB) 
and a novel nuclear factor NF-βA (Shirakawa et al., 1993).  
 
Both IL-1α and IL-1β are synthesized as cytosolic precursors of 31-kDa which are cleaved to 
generate mature proteins (17 kDa). Pro-IL-1β is cleaved by the cysteine proteinase IL-1β 
converting enzyme (ICE) while pro-IL-1α is processed by calpain-like proteases to generate 
C-terminal mature 17-kDa IL-1α and an N-terminal 16-kDa pro-peptide (reviewed in 
(Dinarello, 1997)). Originally, both IL-1α and β were considered as secreted cytokines, 
induced by inflammatory insult or stress, and acting in an endocrine manner to stimulate the 
inflammatory response resulting in pryogenesis, upregulation of acute phase proteins and 
cytokines, and the recruitment and expansion of lymphocytes. While in their recombinant 
form the two IL-1 agonists bind to the same receptors and exert the same biological activities, 
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their divergence in cellulo is notable. IL-1β is not present in homeostatic conditions, and its 
expression and secretion are tightly controlled at the levels of transcription, mRNA stability, 
translation, processing and secretion. In contrast, IL-1α is present in the cytosol and 
associated with the membrane of cells in homeostatic states, but is upregulated in 
inflammation. Beyond that, IL-1α is only rarely secreted by living cells or detected in body 
fluids (Arend et al., 1994). Pro-IL-1α and IL-1α both have enzymatic activity and the amino-
terminal pro- region is subject to several post-translation modifications, inducing 
phosphorylation (Beuscher et al., 1988) and myristyl acylation (Stevenson et al., 1993) 
whereas only the cleaved form of IL-1β has biological activity. 
 
VACV modulation of IL-1α and IL-1β production: protein B13 
B13 shows aa similarity to the serpin family (Smith et al., 1989b) and is synthesized early 
during infection. Early investigations on the CPXV orthologue showed that crmA inhibits 
both ICE and caspase 1 (Ray et al., 1992) and granzyme B, a serine protease (Quan et al., 
1995). Through the inhibition of ICE, B13 prevents the production of mature IL-1β (Howard 
et al., 1995). B13 did not affect VACV WR virulence in the i.n. model (Kettle et al., 1997) 
and did not affect the febrile response to infection that was controlled by the B15 protein. 
 
 1.9.3 Functions of IL-1 
Together with TNF-α, the IL-1 cytokines are defined as the alarm cytokines that are secreted 
by macrophages to initiate inflammatory responses (reviewed in (Dinarello, 1994)). They 
induce expression of pro-inflammatory genes including cyclooxygenase type 2 (COX-2), 
iNOS, chemokines such as IL-8, cytokines such as IL-6, and matrix metalloproteinases 
(MMPs) that exert many functions including the degradation of collagen. IL-1 stimulates the 
expression of high-affinity adhesion molecules on endothelial cells and by this mechanism 
promotes infiltration of inflammatory cells from the blood into tissues. These roles have been 
more tightly associated with IL-1β, which is easily detected in body fluids.  
 
Intracellular functions of the N-terminal propiece and full-length IL-1α protein have 
emerged. The discovery that 16-kDa N-terminal moiety of pro-IL-1α contains a nuclear 
localisation sequence (NLS) and that nuclear translocation of pro-IL-1α or of the N-terminal 
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propeptide is required for some of these intracellular effects (Wessendorf et al., 1993) made a 
significant intracellular role for pro-IL-1α more probable. In transfected cells, pro-IL-1α 
localises to the nucleus, whereas mature IL-1α remains in the cytosol (Beasley and Cooper, 
1999; Maier et al., 1994; Wolf et al., 2001). This nuclear localisation is essential for some 
pro-IL-1α functions (Burysek and Houstek, 1996). It also seems noteworthy that the propiece 
of IL-1α is more highly conserved through evolution than the C-terminal mature IL-1α, 
indicating that domains with the IL-1 propiece may be instrumental in some of the functions 
attributed to IL-1 activity. 
 
The roles of pro-IL-1α within the cell are beginning to be defined. pro-IL-1α is involved in 
the modulation of cell proliferation and senescence (Maier et al., 1990), apoptosis (Pollock et 
al., 2003; Stevenson et al., 1993), migration (McMahon et al., 1997) and cytokine production 
(Garat and Arend, 2003; Werman et al., 2004). There is still confusion over whether internal 
IL-1α acts to regulate the same pathways induced by IL-1RI receptor binding, or whether its 
functions within the cell are distinct if overlapping. 
 
Apoptosis and cell proliferation 
Stably transfected cells expressing intracellular IL-1α show resistance to Fas-induced 
apoptosis (Tatsuta et al., 1996). However, the overexpression of pro-IL-1α in HEK cells 
resulted in a substantial upregulation of apoptosis (Wolf et al., 2001), and a series of 
sequential deletions of portions of the proteins indicated that a pro-section of IL-1α was 
necessary and sufficient for this apoptotic activity. Overexpression of pro-IL-1α results in 
transformation and morphological dysregulation of rat mesangial cells (MCs) resulting in a 
spindle cell-type tumour phenotype (Stevenson et al., 1993). In combination with studies 
linking IL-1α to autocrine growth stimulation in several malignant cell types, including 
gastric carcinoma cells, B-lineage lymphoblasts and acute myeolgenous leukemia cells, these 
indicate that IL-1α can regulate cellular functions key to oncogenesis (Estrov et al., 1992; Ito 
et al., 1993).  
 
Cellular senescence in vitro is marked by the failure of the cells to respond to exogenous 
growth factors and stimuli. Senescent human endothelial cells contain high amounts of pro-
IL-1α, and senescence could be reversed by treating the cells with siRNA against pro-IL-1α 
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(Maier et al., 1990). This function was confirmed in slower proliferation rates and the 
mechanism was shown to rely on the nuclear localisation of pro-IL-1α (Maier et al., 1994). 
Pro-IL-1α stimulates human umbilical vein endothelial cell line ECV304 cell motility, this 
stimulatory effect is mediated by the N-terminal propiece of the pro-IL-1α protein, and this 
effect is antagonised by IL-1Ra (Merhi-Soussi et al., 2005).  
 
Cytokine production 
Some of the cytokine and chemokine responses attributed to the IL-1 proteins are 
independent of IL-1RI signalling, implying a role for the biologically active pro-IL-1α. 
Expression of pro-IL-1α and its localisation to the nucleus is stimulated by inflammatory 
signals, and activates NF-κB and AP-1 in a surface IL-1R-independent manner (Werman et 
al., 2004). Pro-IL-1α induces IL-6 and IL-8 production and the activation and secretion of 
these inflammatory cytokines (Palmer et al., 2005; Werman et al., 2004). By blockading the 
extracellular signal induction with sIL-1Ra, the effect of pro-IL-1α on internal factors could 
be analysed: the NF-κB-regulated cytokines, IL-6 and IL-8 can be activated in the presence 
of pro-IL-1α intracellularly without additional stimuli. Expression of pro-IL-1α augmented 
the response of cells to IFN-γ or TNF-α and upregulated its own synthesis in an autocrine 
positive-feedback loop (Werman et al., 2004). Both mature IL-1α and pro-IL-1α directly 
contribute to IL-8 production during microbial infection. Analysis of IL-8 production in IL-
1RI-/- cells shows that pro-IL-1α expression correlates with IL-6 and IL-8 production (Cheng 
et al., 2008).  
 
 1.9.4 Mechanisms of action 
One binding partner identified for pro-IL-1α through a yeast two hybrid screen was the 
nuclear protein necdin (Hu et al., 2003), an interaction confirmed by co-immunoprecipitation, 
and the proteins co-localised in the nucleus of transfected mammalian cells. While Necdin 
has a growth inhibitory effect on human osteosarcoma (SAOS)-2 cells, of the interactions 
with pro-IL-1α counteracted this effect (Hu et al., 2003). 
 
pro-IL-1α also modulates the histone acetyltransferase (HAT) complexes (Buryskova et al., 
2004). Initiation of transcription in eukaryotes is brought about by the recruitment of various 
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multiprotein complexes to the promoter sequence. These complexes include the RNA 
polymerase II complex, general and sequence-specific transcription factors and regulators, 
and HAT. The HAT complexes are necessary to remodel the chromatin structure prior to 
gene targeting (Nakatani, 2001). Pro-IL-1α can act as an activator of transcription in yeast 
and mammalian cells, through a physical interaction with mammalian HATs (Buryskova et 
al., 2004). 
 
There has been one report of pro-IL-1α binding to HS1-associated protein (HAX)-1 (Yin et 
al., 2001). Initially, HAX-1 was described as an interacting protein HS1, a haematopoietic 
cell-specific molecule that is rapidly tyrosine phosphorylated upon stimulation of 
lymphocytes (Suzuki et al., 1997). Intriguingly, the Epstein Barr virus (EBV) transcription 
protein, EBV nuclear antigen (EBNA)2, interacts with HAX-1 (Kawaguchi et al., 
2000).EBNA- leader protein exists in the nucleus as a component of nuclear entities called 
promyelocytic leukaemia-associated-protein containing bodies (PMLs) and EBNA2 prevents 
the recruitment of HAX-1 to these complexes (Kawaguchi et al., 2000). 
 
 1.9.5 IL-1Ra 
The IL-1Ra family of molecules originated with the discovery of a molecule secreted from 
monocytes and macrophages that competitively inhibited the binding of IL-1 to cell surface 
receptors (Hirsch et al., 1996) The family of molecules expanded to include that one secreted 
isoform (sIL-1Ra) as well as three intracellular isoforms (icIL-1Ra1,2, and3) (Malyak et al., 
1998a; Malyak et al., 1998b). The potential intracellular roles of the icIL-1Ra remain unclear, 
though icIL-1Ra may function to regulate the intracellular activities of IL-1α or may have 
entirely IL-1-independent functions (Arend et al., 1994; Banda et al., 2005; Watson et al., 
1995). 
 
In many cells, IL-1Ra production immediately follows after that of IL-1, though IL-1Ra is 
regulated as an acute phase protein (Gabay et al., 1997b) and is induced by a wide range of 
cytokines including GM-CSF, IL-1, IL-2, IL-3, IL-4, IL-6, IL-10, TGF-β, IFN-α and IFN-γ as 
well as exogenous stimuli such as lipopolysaccharide (LPS) and viral proteins 
(Apostolopoulos et al., 1996).This indicates that IL-1Ra is induced in vivo in numerous 
chronic inflammatory and infectious disease states. Polymorphisms in the IL-1Ra gene are 
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associated with increased prevalence of inflammatory disorders such as ulcerative colitis 
(Tountas et al., 1999), systemic lupus erythematous skin lesions (Blakemore et al., 1994), 
alopecia areata (Tarlow et al., 1994) and rheumatoid arthritis (Cantagrel et al., 1999). Most of 
these diseases are found in epithelial cells, also one of the primary targets of VACV 
infection, and a tissue where icIL-1Ra rather than sIL-1Ra predominates (Apostolopoulos et 
al., 1996). 
 
  sIL-1Ra 
The sIL-1Ra isoform of IL-1Ra is secreted as a glycosylated species of 22-25 kDa from 
monocytes, macrophages, neutrophils, hepatocytes, microglial cells and other cells (Hannum 
et al., 1990). sIL-1Ra binds to both the type I and II IL-1 receptor (IL-1RI and IL-1RII) with 
an avidity equivalent to the two receptor agonist substrates, IL-1α and IL-1β, yet fails to 
induce receptor activation or intracellular responses (Dripps et al., 1991).  Circulating levels 
of IL-1Ra in a variety of human inflammatory diseases, as well as in tissues, have been 
examined (Arend et al., 1998). sIL-1Ra is produced by hepatocytes as an acute phase protein, 
and higher levels of IL-1Ra have been detected in the circulation of patients with a variety of 
inflammatory diseases (Gabay et al., 1997a).  
 
Multiple investigations over the past two decades have indicated that the major function of 
sIL-1Ra is to modulate the pleiotropic effects of IL-1 by competitively inhibiting its binding 
to its cell surface receptors (Arend and Gabay, 2000). Thus the balance between sIL-1Ra and 
IL-1 is a key to the regulation of inflammation. The ablation of sIL-1Ra function, either by 
the administration of neutralising Abs, or in transgenic knockout animal models, results in an 
earlier onset and a substantially more severe course of inflammation in multiple animal 
models of disease (Fujioka et al., 1995).   
 
High doses of recombinant IL-1Ra reduce inflammation in experimental arthritis and 
improve survival during endotoxemic shock. Maintenance of an appropriate balance between 
IL-1Ra and IL-1 may also have an important role in preventing diseases characterised by 
excessive inflammation, such as arthritis and colitis. IL-1Ra deficient mice can spontaneously 
develop inflammatory arthritis resembling rheumatoid arthritis in humans (Horai et al., 2000) 
or an inflammatory arterial disease similar to polyarteritis in humans (Nicklin et al., 2000). 
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These observations indicate that adequate levels of IL-1Ra counter the potential injurious 
effects of excessive IL-1. Endogenously produced IL-1Ra impairs the host response to 
bacterial infection, but improves the host response to septic shock (Hirsch et al., 1996; 
Mancilla et al., 1993). In some animal models of disease, in particular rheumatoid arthritis 
and colitis, treatment with soluble IL-1Ra can lead to partial prevention or lessening of the 
disease symptoms, for review see (Arend, 1993). Clinical trials with recombinant human sIL-
1Ra in patients with sepsis did not lead to substantial benefit (Fisher et al., 1994). In contrast, 
recombinant sIL-1Ra showed efficacy in patients with rheumatoid arthritis (Campion et al., 
1996). 
 
  icIL-1Ra  
The icIL-1Ra proteins are created by alternative transcriptional splicing of the same gene 
responsible for the production of sIL-1Ra (Malyak et al., 1998b). The first intracellular 
isoform (icIL-1Ra1) described is created by the splicing of an upstream exon into the amino 
terminus of sIL-1Ra that removes the signal peptide and creates a protein of 18 kDa (Malyak 
et al., 1998a). icIL-1Ra1 is a major protein in keratinocytes and other epithelial cells (Bigler 
et al., 1992; Haskill et al., 1991) and is also produced in monocytes and macrophages (Arend 
and Guthridge, 2000). icIL-1Ra2 contains a 63-bp insert between the first and second exons 
for icIL-1Ra1. The complementary DNA (cDNA) is present in fibroblasts, keratinocytes and 
myelomonocytic cells, although the protein product has not been seen as a natural product in 
any cell type to date (Muzio et al., 1995). The third intracellular form, icIL-1Ra3 is a 16-kDa 
protein, which is similar to the sIL-1Ra mRNA, but uses an alternative translational initiation 
site, which removes the signal peptide. This form is the major protein in hepatocytes and 
neutrophils (Malyak et al., 1998a), and is also seen in small amounts in monocytes, 
macrophages, and keratinocytes (Arend and Gabay, 2000). While icIL-1Ra can be released 
by activation of the P2X7 receptor (Wilson et al., 2004), most studies detailed here have 
shown extracellular levels of icIL-1Ra to be negligible. 
 
icIL-1Ra1, icIL-1Ra2 and sIL-1Ra bind equally well to IL-1RI and can inhibit the 
stimulatory effects of IL-1. This is in contrast to icIL-1Ra3, which predominates in 
neutrophils and hepatocytes, and is a weak inhibitor of receptor binding of IL-1 (Malyak et 
al., 1998a). The intracellular localisation of icIL-1Ra seems to vary in a cell-specific, 
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stimulus-specific manner. While icIL-1Ra is predominantly cytoplasmic, some icIL-1Ra is 
seen in the nucleus (Merhi-Soussi et al., 2005). The presence and localisation of icIL-1Ra is 
not altered by co-transfection with pro-IL-1α. Neither is the localisation of pro-IL-1α altered 
by co-transfection with icIL-1Ra (Merhi-Soussi et al., 2005).  
 
icIL-1Ra1 activity is independent of the IL-1/IL-1RI signalling cascade system (Evans et al., 
2006) but downregulated pro-IL-1α functions including the overexpression of IL-6 and CXC 
chemokine ligand (CXCL)8 (or IL-8). The production of CXCL1 [Growth related oncogene 
(GRO)] and IL-8 might be affected in post-transcriptional manner (Watson et al., 1995) 
through regulation of mRNA stability. In particular, analysis of icIL-1Ra activity in cells 
stimulated with IL-1β showed that increased expression of icIL-1Ra resulted in the reduced 
expression of IL-6 and IL-8 in the cell supernatants in an intracellular fashion, as supernatant 
levels of ic or sIL-1Ra remained minimal (Garat and Arend, 2003). icIL-1Ra could not 
abrogate production of these molecules brought about by overexpression of the various 
intermediate signalling molecules such as MyD88, IRAK1 and TRAF6 indicating that its 
activity is independent of IL-1R signalling. icIL-1Ra does not affect the growth inhibitory 
effect of pro-IL-1α (Palmer et al., 2005). However, this group also showed that while 
transfection of pro-IL-1α strongly induced IL-6 production, cotransfection with icIL-1Ra 
inhibited this induction. High levels of icIL-1Ra also reduce expression of collagenase 
(MMP-1) without affecting expression of analogous proteins such as TIMP (Kanangat et al., 
2006). MMP-1 is the major enzyme involved in the degradation of native collagen in the 
skin, and as such plays a key role in inflammation in the skin. Its expression is stimulated by 
p38 MAPK, JNK and ERK as well as AP-1. Hence it is possible that icIL-1Ra decreases the 
activity of one or more of those intracellular pathways as discussed below with the result of 
downregulating MMP-1 expression (Kanangat et al., 2006). 
 
Pro-IL-1α activates four protein kinase cascades, including the NF-κB, p38 MAPK, ERK and 
JNK pathways. Many of the biological effects of IL-1 are mediated by NF-κB signal 
transduction, and icIL-1Ra can inhibit this pro-IL-1α induced p65 NF-κB translocation into 
the nucleus, and in so doing, icIL-1Ra downregulates NF-κB induced gene expression (Garat 
and Arend, 2003). Pharmacological inhibition suggested that the MAPK pathways were 
involved in the icIL-1Ra-mediated downregulation of pro-IL-1α induced IL-6 and IL-8 
 79
production, in particular. Pro-IL-1α-induced phosphorylation of p38 MAPK was specifically 
inhibited by IL-1Ra (Garat and Arend, 2003), while total levels of p38 MAPK were 
unaltered. There was no difference observed in ERK or JNK phosphorylation levels. Once 
phosphorylated, p38 MAPK generally translocates to the nucleus where it regulates various 
transcription factors, to modulate their transactivation and induction capacity.  
 
A novel interaction partner for icIL-1Ra was identified through a yeast two hybrid screen or 
HeLa cell library for proteins (Banda et al., 2005). This was the third component of the COP9 
signalosome complex 3 (CSN3), and the interaction was confirmed by co-
immunoprecipitation. CSN3 acts as an interface between signal transduction pathways and 
ubiquitin-dependent proteolysis (Bech-Otschir et al., 2001) and phosphorylates many proteins 
involved in signal transduction including IκB-α, p105, c-Jun and p53 (Bech-Otschir et al., 
2001). icIL-1Ra inhibits the activity of these CSN-associated kinases. Again, this group also 
observed that icIL-1Ra1 inhibits pro-IL-1α-induced IL-6 and IL-8 production in keratinocyte 
cell lines through binding to CSN3 with inhibition of phosphorylation of p38 MAPK (Banda 
et al., 2005).  
 
1.10  C16 
The C16L ORF is located in the ITRs of the VACV WR genome (www.poxvirus.org). It is 
predicted to encode a protein of 331 amino acids with a molecular mass of approximately 
38.5 kDa. The VACV COP strain orthologue of C16, C10, possesses a short peptide sequence 
in its carboxy-terminal domain that is very similar to a peptide identified in IL-1Ra and that 
competes with IL-1α for IL-1R-binding (Kluczyk et al., 2004; Kluczyk et al., 2002). This 
peptide showed the immunosuppressive qualities of IL-1Ra when added to cells in the 
extracellular medium (Kluczyk et al., 2002). In addition Kluczyk et al. demonstrated that the 
carboxy-terminal 154 aas of C10 could be readily fitted to the known crystal structure of IL-
1Ra, although no experimental structure of C10 has been obtained. It has therefore been 
postulated that this viral protein may represent a further immunomodulatory mechanism, by 
mimicking endogenous IL-1Ra, and downregulating IL-1 mediated anti-viral immune 
responses. 
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The only previous analysis of C16 showed by yeast two-hybrid studies that it interacts with 
the VACV K1 protein (McCraith et al., 2000). K1 affects host range (Bradley and Terajima, 
2005) and, as detailed above, is involved in the inhibition of NF-κB activity by suppressing 
IκB-α degradation. So, should C16 have an immunomodulatory mechanism, it may be 
involved in this downstream effect (Shisler and Jin, 2004). Currently, C16 and C10 are 
uncharacterised, notwithstanding the intriguing data indicating its potential IL-1Ra mimicry.  
 
1.11 Project Aims  
This study aims to characterise C16 from VACV WR strain, and investigate its role in VACV 
infection. Characterisation of C16 will start from first principles as we aim to delineate its 
conservation through the OPV genus, its size, expression profile, localisation and post-
translational modifications within the context of a viral infection. Further, the role of C16 in 
virus replication within cell culture is analysed, as well as any potential role C16 may play in 
virus virulence and immunomodulation in vivo. Additionally, by combining these in vivo 
studies with in vitro functional assays, we seek to determine an understanding of the function 
and mechanism of action of C16 within infected cells.  
 
The results are divided as follows: 
1) Basic characterisation of the C16L ORF and its protein product 
2) Characterisation of C16 in cell culture 
3) In vivo characterisation of C16 
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Chapter 2  
Materials and Methods 
 
2.1 Preparation, analysis and cloning of DNA 
2.1.1 Restriction enzyme digestion of DNA 
DNA was digested with restriction enzymes in 20–50 µl reaction mixtures containing a 
minimum of 1 U of restriction enzyme per 1 µg of DNA. Enzymes and buffers were supplied 
by New England Biolabs. The total glycerol content of the reaction was minimised by 
including no more than 10 % (v/v) restriction enzyme solution. DNA was digested for 2 h at 
37 ˚C. Where appropriate, DNA was purified from restriction digestion reactions by agarose 
gel electrophoresis and extraction from agarose gels. 
 
2.1.2 Resolution of DNA by agarose gel electrophoresis 
DNA was resolved on 0.6–1 % agarose gels in Tris Acetate ethylene diamine tetraacetic acid 
(EDTA) (TAE) [40 mM Trisma, 40 mM Sodium (Na) Acetate, 1 M EDTA pH 8.0]) buffer. 
Gels were run at 25–100 V for an appropriate time in TAE containing 10 µg/ml ethidium 
bromide (EtBr3). Samples were mixed with 20 % (v/v) DNA loading buffer (Bioline). DNA 
was visualised using a transilluminator and was photographed using the Chemi Doc gel 
documentation systems (Bio-Rad) with Quantity One software (Bio-Rad). 
 
2.1.3 Isolation of DNA from agarose gels 
The DNA band of interest was visualised under UV transillumination and excised from 
agarose gels with a clean scalpel. DNA was purified using the QIAquick gel extraction kit 
(QIAGEN) according to manufacturer’s instructions. Briefly, the gel slice was added to 3 x 
(w/v) the amount of buffer QG and heated gently until the gel dissolved. The pH of buffer 
QG is optimised (< 7.5) to allow DNA to bind to a spin column that contains a filter coated 
with a silica-gel membrane. DNA binds to this membrane in the presence of high 
concentrations of salt, provided by buffer QG. Centrifugation of the column allows impurities 
to pass through into waste, whilst DNA remains bound to the column, is washed and then 
eluted with 30–50 µl of deionised distilled H2O (ddH2O). 
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2.1.4 Ligation of DNA fragments 
Blunt ligations were carried out using the Zero Blunt TOPO Cloning Kit (Invitrogen) where 
the plasmid vector (pCR4Blunt-TOPO) is supplied linearised with vaccinia virus 
topoisomerase I covalently bound to the 3’ ends. The topoisomerase binds to duplex DNA at 
specific sites and ligates the vector and the insert. The vector and the fresh polymerase chain 
reaction (PCR) product insert were mixed gently in a solution containing salt as supplied by 
the manufacturer for 5 min at room temperature (RT). The reaction mix was then placed on 
ice and transformed into chemically competent NovaBlue E. coli (Novagen). 
 
Sticky-end ligations were carried out in a 10–20 µl volume containing 200 ng vector DNA, 
600 ng insert DNA (1:3 ratio) and 1 U of T4 DNA ligase (Roche) in 1 x T4 DNA ligase 
buffer (Roche). Reactions were placed at 16 ˚C for 2 h or 4 ˚C for 16 h.  
 
2.1.5 Transformation of competent bacteria with plasmid DNA 
Aliquots of 20 µl of chemically competent NovaBlue E. coli (Novagen) were thawed on ice 
and 1 µl of miniprep or ligation reaction DNA was added as per the manufacturer’s 
instructions. Cells and DNA were incubated together on ice for 5 min before a heat-shock at 
42 ˚C for 30 sec in a water-bath, followed by 2 min on ice. After adding 80 µl of Super 
Optimal Catabolite (SOC) medium, the cells were plated onto agar plates containing the 
relevant antibiotic. Plates were incubated at 37 ˚C overnight and examined for colonies the 
following morning.  
 
2.1.6 Screening of colonies  
The incorporation of the correct insert was verified by PCR and/or restriction enzyme digest 
analysis of single colonies. The single colony was isolated by a toothpick and dipped in the 
PCR tube, before being used to inoculate 3 ml of Luria Bertani broth (LB). The inoculate was 
incubated at 37 ˚C overnight, with shaking at 200 rotations per minute (rpm), and plasmid 
DNA was extracted from a miniprep (as described in section 2.1.8) and digested with 
restriction enzymes. The presence of an insert was confirmed by agarose gel electrophoresis.  
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2.1.7 Preparation of glycerol stocks 
A single bacterial colony on an agar plate was used to inoculate 5 ml of LB, which was 
incubated at 37 ˚C overnight with shaking. An aliquot of the culture was taken and an equal 
volume of 30 % (v/v) sterile glycerol solution was added and the bacteria were stored frozen 
at -70 ˚C. When required, the frozen glycerol stock was scraped using a sterile 20 µl pipette 
tip and used to inoculate 3 ml of LB with shaking overnight, followed by 1:1000 dilution in 
LB for a larger scale inoculation. 
 
2.1.8 Small scale preparation of plasmid DNA (miniprep) 
Plasmid DNA was purified by the QIAGEN miniprep method, which involved inoculating 3 
ml LB containing the appropriate antibiotics with a single bacterial colony and growing 
overnight at 37 ˚C with shaking. Cultures were centrifuged at 2000 x g in a microcentrifuge 
for 10 min and the manufacturer’s instructions were followed. The procedure consists of 
three steps: firstly, bacteria are lysed by the modified alkaline lysis method (Birnboim and 
Doly, 1979). The alkaline lysate is neutralised and the salt concentration is increased to allow 
binding of DNA to a silica-gel membrane. The supernatant is applied to the silica-gel 
membrane and after washing, the DNA is eluted with a low-salt solution, such as ddH2O and 
is collected by centrifugation. 
 
2.1.9  Large scale preparation of plasmid DNA (maxiprep) 
To prepare highly pure and concentrated plasmid DNA, a maxiprep kit (Qiagen) was used 
according to the manufacturer’s instructions. A single colony of bacteria was used to 
inoculate 3 ml of LB, which was supplemented with appropriate antibiotics and incubated at 
37 ˚C with shaking at 200 rpm overnight. One ml of the starter culture was used to inoculate 
250 ml of LB, which was incubated overnight with shaking at 200 rpm. The bacteria were 
collected by centrifugation at 3000 x g (Beckmann JA-10 rotor) for 10 min in a 250 ml 
centrifugation bottle and were resuspended in 10 ml P1 buffer. The cells were lysed by the 
modified alkaline lysis method (Birnboim and Doly, 1979), whereby the lysate was 
neutralised (and its salt concentration increased) and cleared by centrifugation at 10000 x g 
(Beckman J2-HS centrifuge (JA-17 rotor), 4 ˚C for 30 min. The supernatant was loaded onto 
a DNA purification column pre-equilibrated with 10 ml of QBT buffer. The column was 
washed twice with 30 ml QC buffer and the DNA was eluted with 15 ml of QF buffer. 
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Plasmid DNA in the eluant was precipitated with 0.7 volumes of isopropanol, collected by 
centrifugation, washed with 5 ml of 70 % ethanol, and dissolved in 0.5 ml ddH2O. 
 
2.1.10 Crude DNA extraction from virus cores   
175 cm2 flasks of thymidine kinase-deficient cell line strain 143 (TK-143) cells were infected 
with VACV as detailed below and incubated until obvious CPE was observed. The infected 
cells were scraped from the flask into the medium and collected by centrifugation for 5 min at 
2000 x g. The cell pellet was washed in ice-cold phosphate-buffered saline (PBS), before 
being washed once in 10 ml ice-cold isotonic buffer (10 mM Tris-HCl, 1 mM EDTA, 150 
mM NaCl, pH 8.0), resuspended in 10 ml ice-cold hypotonic buffer (10 mM Tris-HCl, 1 mM 
EDTA, 10 mM NaCl, pH 8.0) and incubated on ice for 15 min to swell. The cells were lysed 
by adding 1 ml of 10 % (v/v) Triton-X-100 with 25 µl of 14 M β-mercaptoethanol (β-ME) 
and incubating for 10 min on ice. Cell nuclei and debris were removed by centrifugation at 
2000 x g for 5 min at 4 ˚C and the virus cores in the supernatant were collected by 
centrifugation at 15000 x g for 1 h at 4 ˚C in a Beckman J2-HS centrifuge (JA-17 rotor). The 
virus cores were resuspended in 800 µl of TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 
8.0). The viral DNA was released from the virus cores by adding 15 µl β-ME, 50 µl 
proteinase K (10 mg/ml), 200 µl 30 % (w/v) sarcosyl and 1.4 ml of 54 % (w/v) sucrose, 
mixing gently and incubating for 2 h at 55 ˚C. The DNA was then deproteinised by 
phenol/chloroform extraction as detailed below. 
 
2.1.11 Phenol/chloroform extraction of DNA 
Proteins were removed from aqueous solutions of genomic DNA by the addition of an equal 
volume of 25:24:1 phenol:chloroform:isoamyl alcohol mixture. Tubes were inverted gently 
several times to mix the solutions without shearing the DNA and centrifuged at 2000 x g for 
15 min. The upper, aqueous phase was removed, taking care not to disturb the lower organic 
phase or the interface between the two phases. An equal volume of the phenol mixture was 
again added to the aqueous solution, mixed and centrifuged as before. The aqueous phase was 
removed and an equal volume of a 24:1 part mixture (chloroform:isoamyl alcohol) was 
added, the tube was inverted to mix the solutions and was centrifuged to separate the layers. 
The aqueous phase was removed and DNA was recovered by ethanol precipitation.  
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2.1.12 Ethanol precipitation of DNA 
DNA was extracted from aqueous solutions by the addition of NaAcetate (pH 5.2) to a final 
concentration of 0.3 M, followed by the addition of 2.5 volumes of absolute ethanol. Tubes 
were inverted gently several times to mix and were incubated at -20 ˚C for at least 2 h, or 
overnight. DNA was recovered by centrifugation (2000 x g, 15 min) and was washed twice 
with 95 % ethanol, and once with 70 % ethanol, centrifuging the tubes (2000 x g, 15 min) 
between each addition of alcohol. The DNA pellets were dried by exposure to the atmosphere 
until no moisture was visible inside the tube and were dissolved overnight in 100 µl sterile 
ddH2O. 
 
2.1.13 Proteinase K extraction of virus DNA for PCR analysis 
Confluent african green monkey basal stem cells (BSC-1) cells were infected with 50 µl of a 
plaque isolate (Section 2.5.3) in 200 µl Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with 2.5 % foetal bovine serum (FBS) for 48 h in a 96-well plate at which 
point the supernatants were removed. The cells were washed twice with PBS, and 50 µl of 
proteinase K reaction solution was added (6 µg proteinase K [Invitrogen], 5 µl 10 x 
magnesium (Mg2+)-free buffer [Promega], 45 µl ddH2O) and the cells were freeze-thawed 
twice. The surface of each well was scraped using a blunt-ended 200 µl micropipette tip to 
dislodge cells adhered to the plastic, and the contents were transferred to 0.2 ml PCR tubes 
(Axygen). A thermocycler was used to heat the tubes at 56 ˚C for 20 min and then at 85 ˚C 
for 10 min. 
 
2.1.14 Oligonucleotides 
Oligonucleotide primers were produced by Invitrogen, UK. Lyophilised primers were 
dissolved in ddH2O to yield a master stock with a concentration of 100 µM as designated by 
the manufacturer. Concentrations were verified by spectrophotometry, using the formula one 
unit of optical density (OD) at 260 nm equals 33 µg/ml of ssDNA. Working stocks were 
made by diluting master stocks to a concentration of 10 µM in ddH2O.  
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Table 2.1  
AF1  Construction of Ecogpt/ enhanced GFP (EGFP) plasmid 
AGTCGAATTCATAGCGAAAAATACATCGTCACCTGGGAC 
AF2   Construction of Ecogpt/EGFP plasmid 
GCGCTAGCGGATCTGAGCGACCGGAGATTGGCGGG 
AF3   Construction of Ecogpt/EGFP plasmid 
CGCCAATCTCCGGTCGCTCAGATCCGCTAGCGCTACCG 
AF4   Construction of Ecogpt/EGFP plasmid 
AGTCCCCGGGATAAAAATTTACTTGTACAGCTCGTCCATGCCGAG 
AF5   Amplification of flanks of C16L ORF 
GACGGTATGTATTGTAGATGCTCTCATGG 
AF6   Amplification of flanks of C16L ORF 
CGTCAAACAATCATTCCCGGGTATAATATCTAGAGGTAGAGG 
AF7   Amplification of flanks of C16L ORF 
CCTCTAGATATTATACCCGGGAATGATTGTTTGACGAATCACG 
AF8   Amplification of flanks of C16L ORF 
GGAGATCATACTACCACAACTTATTATTATGC 
AF9    Construction of pET28a C16L-CHis 
AGATCCATGGGTGATATTTACGACGATAAAGGTCTACAG 
AF10   Construction of pET28a C16L-CHis   
AGATGAATTCCCGCTGCCGCGCGGCACCAGTTTCGGCATATTAAAGTAAAA
TC 
AF11  Analysis of C16L ORF in recombinant VACV 
CCAGAGGGAGATGGATATTGTTTACACG  
AF12 Analysis of C16L ORF in recombinant VACV 
GATTCCAAAAATACTGAATACAAAGTCC 
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AF13 Analysis of C16L ORF in recombinant VACV 
CGAATTGGGCCCGACGTCGCATGC 
AF14 Analysis of C16L ORF in recombinant VACV 
CGTTGGGAGCTCTCCCATATGG 
AF15 Analysis of 5’ [Unique sequence (US) / ITR] boundary 
CACCCATATG TTAATGCCGACG 
AF16  Analysis of 5’ US/ITR boundary 
CAATGAACTCGGATGTCCTCC 
AF17  Analysis of ITR boundaries 
CGTATCGCCGGAAGGGACTATATG 
AF18 Analysis of 3’ US/ITR boundary 
GACTGGACTATCGGCGTACTATCC 
AF19  Analysis of 3’ US/ITR boundary 
GGGAATTGGTCACGACGACAGAAAGC 
AF20   pCI-C16 
AGACGAATTCGCCACCATGGATATTTAGGACGATAAAGGT 
AF21   pCI-C16 
AGATGCGGCCGCTTATTTCGGCATATTAAACTAAAATCTA 
AF22   pCI-IL-1Ra 
CGTAGAATTCATGGCTTCAGAGGCAGCCTGCCCGCCCTTCTCGG 
AF23   pCI-IL-1Ra 
GCTAGCGGCCGCTTACTATTGGTCTTCCTGGAAGTAGAAC 
AF24   pCI-pro-IL-1α 
CGTAGAATTCCATGGCCAAAGTTCCTGACTTGTTTG 
AF25   pCI-pro-IL-1α 
 88
GCTAGCGGCCGCTTATGATATCTGGAAGTCTGTCATAGAGGG 
Table 2.1 Primers used in this study. Restriction enzyme sites are indicated in italics. 
 
2.1.15 PCR 
Unless specified, each 20 µl PCR contained 100 ng of template DNA or 2 µl of virus DNA 
prepared by Proteinase K extraction (Section 2.1.13), 1 x thermophilic DNA polymerase 
buffer (Promega), 37.5 µM MgCl2, 250 µM deoxyribonucleotide triphosphate (dNTP) mix 
(Invitrogen) and 1 U Taq DNA polymerase (Promega). Reactions were performed in a 
programmable thermocycler. The template DNA was denatured at 95 ˚C for 2 min, followed 
by 5 cycles of denaturing at 95 ˚C (30 sec), annealing at 45 ˚C (5 ˚C lower than the lowest 
melting temperature of the primers used, calculated using the Sigma-Aldrich genosys DNA 
calculator:https://www.sigma-genosys.com/order_DNACalcasp) for 30 sec and extension at 
72 ˚C (for a length of time equal to 1 min per kb of desired extension product). A further 25 
cycles were performed as above but with annealing temperatures equalling the lowest melting 
temperature of the primers used. A final extension at 72 ˚C for 10 min followed. For 
amplifications requiring high fidelity, such as when the PCR product was to be cloned, 
Platinum HiFi Taq (Promega), which has a proofreading capacity, was used in the place of 
Taq, the extension temperature was reduced to 68 ˚C and the number of cycles was reduced 
to 20. 
 
2.1.16 Purification of PCR products 
For purification of PCR products that were not immediately electrophoresed on agarose gels, 
the QIAGEN PCR purification kit was used following the manufacturer’s instructions. The 
addition of PB, a high-salt solution, allows the DNA to bind to a silica-gel membrane in a 
spin column. Centrifugation of the spin column enables the removal of impurities including 
oligonucleotides up to 50 nucleotides in length. The DNA is then eluted by the addition of a 
low-salt solution such as ddH2O, followed by centrifugation.  
 
 
 
 89
2.1.17 Quantification of DNA 
The concentration of the DNA solutions was determined by spectrophotometry measuring 
UV absorbance at 260 nm (1 OD260 = 50 µg/ml dsDNA) using a NanoDrop ND-1000 
spectrophotometer. The purity of the nucleic acids was assessed by the OD 260/280 ratio. Pure 
DNA has a value between 1.8 and 2.0. 
 
2.1.18 Automated sequencing of DNA 
Sequencing was performed by the Advanced Biotechnology Centre (part of Imperial College 
London). 
 
2.2  Protein Analysis 
2.2.1  Resolution of proteins by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Protein gels were assembled in vertical Mini-PROTEAN II apparatus (Bio-Rad) as directed 
by the manufacturer and consisted of a 0.8 ml stacking gel sitting directly upon a 4 ml 
separating gel. Stacking gels were composed of 12 % acrylamide solution (Protogel, National 
Diagnostics), 125 mM Tris-HCl (pH 6.8) and 0.1 % SDS polymerised with 0.15 % 
ammonium persulphate (APS) and 0.001 % N,N,N,N-tetramethylethylenediamine (TEMED) 
(both Sigma-Aldrich). Separating gels consisted of 8–12.5 % acrylamide solution, 375 mM 
Tris-HCl (pH 8.8) and 0.1 % SDS polymerised with 0.15 % APS and 0.001 % TEMED. 
Protein samples were mixed with an appropriate volume of 6 x Laemmli sample buffer (300 
mM Tris-HCl [pH 6.8], 12 % SDS, 60 % glycerol and 0.6 % bromophenol blue with 10 % β-
ME except when samples were run under non-reducing conditions), heated at 85 ˚C for 3 min 
and left to cool for 5 min at RT. The samples were electrophoresed alongside pre-stained 
molecular mass markers (Life Technologies and Bio-Rad) in a Tris/Glycine buffer (25 mM 
Tris-HCl, 250 mM Glycine, 0.1 % SDS). Samples were electrophoresed at 80 V through the 
stacking gel and then at 200 V through the separating gel. After electrophoresis, the gels were 
processed for Coomassie staining or immunoblotting. 
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 2.2.2 Resolution of proteins by native gel electrophoresis 
Protein gels were assembled in vertical Mini-PROTEAN II apparatus (Bio-Rad) as directed 
by the manufacturer and consisted of a 0.8 ml stacking gel sitting directly upon a 4 ml 
separating gel. Separating gels were composed of 10 % acrylamide solution (Protogel, 
National Diagnostics), 480 mM Tris-HCl (pH 8.9) and polymerised with 0.15 % APS and 
0.001 % TEMED. Stacking gels were composed of 125 mM Tris-HCl (pH 6.8), 3 % 
acrylamide solution (Protogel, National Diagnostics), 0.15 % APS and 0.001 % TEMED. 
Protein samples were mixed with an appropriate volume of native loading buffer, which 
contained 50 % glycerol, and 125 mM Tris-HCl (pH 6.8) with 0.6 % bromophenol blue. The 
samples were electrophoresed in a Tris/Glycine buffer containing 50 mM Trizma and 380 
mM glycine. Samples were electrophoresed at 80 V through the stacking gel and then at 200 
V through the separating gel. After electrophoresis, the gels were processed for Coomassie 
staining or immunoblotting. 
 
 2.2.3  Detection of proteins by Coomassie staining 
Acrylamide gels were stained for 1 h in Coomassie blue stain (0.25 % [w/v] Coomassie 
brilliant blue R-250 [BDH], 10 % [v/v] acetic acid, 45 % [v/v] methanol), then destained in 
destain buffer (20 % [v/v] methanol / 10 % [v/v] acetic acid). The destain buffer was replaced 
with ddH2O when the protein bands were visible clearly with minimal background. The gels 
were dried between 2 sheets of ddH2O-soaked cellophane (Bio-Rad) using a Bio-Rad gel 
drier (model 583) for 2 h at 80 ˚C. 
 
2.2.4  Detection of proteins by immunoblotting  
Proteins that had been resolved by PAGE were transferred to nitrocellulose membranes 
(Hybond ECL, Amersham) by electro-transfer in protein transfer buffer (25 mM Tris-HCl, 
190 mM Glycine, 0.037 % [w/v] SDS and 20 % [v/v] methanol) at 300 mA for 20 min using 
a Mini-Electrophoretic Trans-Blot apparatus (Bio-Rad) according to the manufacturer’s 
instructions.  
 
Prior to detection with antibody (Ab), membranes were blocked with blocking buffer (5 % 
[w/v] nonfat dried milk powder, 0.1 % [v/v] Tween-20 in PBS) either for 1 h at RT or at 4 ˚C 
 91
overnight with gentle rocking. For phospho-Abs, a blocking buffer of (5 % [w/v] BSA, 0.1 % 
[v/v] Tween-20 in Tris-buffered saline [TBS]) was used. Membranes were then incubated at 
RT with gentle rocking for 1 h with primary Ab diluted in a minimal volume of blocking 
buffer. After primary Ab incubation, membranes were rinsed twice with wash buffer (0.1 % 
[w/v] Tween-20 in PBS) before being washed three times for 10 min each with gentle 
agitation. For phospho-Abs, the wash buffer was 0.1 % (w/v) Tween-20 in TBS. Bound 
primary Ab was detected by rocking membranes for 1 h at RT with a mouse anti-rabbit or 
goat anti-mouse horseradish peroxidase (HRP)-conjugated secondary Ab (both Sigma-
Aldrich) diluted 1:2000 in blocking buffer. Membranes were rinsed and washed as before, 
and detected using enhanced chemiluminescence (ECL) reagents (Amersham) according to 
the manufacturer’s instructions. Finally, membranes were wrapped in Saran wrap and 
exposed to film (X-OMAT/LS, Kodak) for variable lengths of time (normally 30 sec to 10 
min). Details of all primary Abs used for immunoblotting are given in Table 2.2. 
 
Table 2.2  
Antibody 
Name Source Species 
Western blot 
dilution factor 
Immunofluorescence 
dilution factor 
C16 Harlan Rabbit 2000 500 
D8 Harlan Mouse 2000  
A56 Harlan Rabbit 1000  
B5 Harlan Mouse  200 
A41 Harlan Rabbit 500  
Anti-rabbit 
IgG-HRP-
conjugated  
Sigma-
Aldrich Mouse 2000  
Anti-mouse 
IgG-HRP-
conjugated  
Sigma-
Aldrich Goat 2000  
Lamin AbCam Mouse 100  
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Tubulin Upstate Mouse 1000  
CSN1 Biomol Rabbit 3000  
CSN3 Biomol Rabbit 3000  
CSN8 Biomol Rabbit 3000  
p65 
Santa 
Cruz 
Biotech Mouse 1000  
IκBα 
Cell 
Signaling Rabbit 500  
Cleaved Poly 
(ADP-ribose) 
polymerase 
(PARP) 
New 
England 
Biolabs Mouse 1000  
STAT1 
Santa 
Cruz 
Biotech Rabbit 400  
Phosphor-
STAT1 Zymed Mouse 400  
MAPK 
Cell 
Signaling Rabbit 1000  
Phosphor-
MAPK 
Cell 
Signaling Rabbit 1000  
icIL-1Ra 
R&D 
Systems Rabbit 100  
Pro-IL-1α 
R&D 
Systems Rabbit 100  
Tetramethylrh
odamine 
isothiocyanate 
Jackson 
Immuno 
Research Donkey   2000 
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conjugated 
(TritC) anti-
rabbit IgG 
Fluorescein 
isothiocyanate
-conjugated 
(FITC) anti-
mouse IgG 
Stratech 
Scientific Goat  
2000 
Table 2.2. Antibodies used in this study. This table shows the Abs used in this study as well 
as their species and their dilution factor in the relevant applications. 
 
To reprobe immunoblots with different Abs, membranes were stripped twice for 30 min each 
in 25 ml 2 % (w/v) SDS, 100 mM β-ME at 60 ˚C in a rotating oven. Membranes were washed 
twice for 30 min in 0.1 % (w/v) Tween-20 in PBS at RT with gentle rocking before blocking 
and detecting as normal. 
 
 2.2.5  Measurement of protein content 
Samples were diluted with ddH2O 1:50 or 1:80 and were mixed with an acidic dye from the 
Bio-Rad protein assay (Bio-Rad) according to the manufacturer’s instructions. After adding 
the dye, absorbance at 595 nm was measured for each sample and compared to a standard 
curve using BSA solution using a NanoDrop ND-1000 spectrophotometer. 
 
 2.2.6  Immunofluorescent staining 
Cells used for fluorescent and confocal microscopy were grown on 22-mm sterilised glass 
coverslips (borosilicate glass, BDH) in 6-well plates. After 24 h cells were infected with 10 
plaque-forming units (p.f.u.)/cell. At various time points, the medium was removed and the 
cells were chilled on ice for 1 min. The cells were washed three times in ice-cold PBS, before 
being fixed with 4 % paraformaldehyde (PFA) for 30 min. Cells were washed three times (in 
ice-cold PBS), before being quenched for 5 min with 150 mM NH4Cl. After another three 
washes (in ice-cold PBS), cells were permeabilised in 0.1 % (w/v) Triton X-100 (Sigma-
Aldrich) for 10 min in PBS. The cells were then blocked for 1 h at RT with PBS, 10 % FBS 
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and incubated for 30 min with primary Ab diluted in the same blocking mixture. The sample 
was then stained with TritC-conjugated secondary Ab (Jackson Immunoresearch) or a FITC-
conjugated secondary Ab (Stratatech Scientific) at RT for 30 min. The plates were washed 
three times in PBS/FBS as above, followed by one wash in PBS, and one wash in ddH2O. 
Then they were mounted in Mowiol-4’,6-diamidino-2-phenylindole (DAPI) mounting 
medium. Samples were examined with a Zeiss LSM5 Pascal confocal microscope using Zeiss 
LSM software and images were reconstructed and processed using Confocal Assistant and 
Adobe Photoshop software. 
 
For nuclear translocation analysis, cell medium was removed 6 h.p.i. and cells were 
incubated with 1 ng/ml leptomycin B (LMB) (Sigma-Aldrich) for 2–4 h prior to cell fixing. 
 
2.2.7  Immunoprecipitation analysis 
175 cm2 flasks were infected with 10 p.f.u./cell of vC16, v∆C16 or mock-infected for 6 h. 
Cells were lysed in radio immunoprecipitation assay (RIPA) buffer [150 mM NaCl, 50 mM 
Tris-Acetate (pH 8.0), 1 mM EDTA, 1 % Nonidet P-40 (NP-40), 0.1 % SDS] for 30 min at 4 
ºC and centrifuged at 10000 x g for 15 min. Lysates were pre-cleared against 30 µl Protein-G 
Sepharose beads for 2 h. In parallel 30 µl Protein-G Sepharose beads per sample were 
incubated with a dilution of 1:1000 anti-C16 polyclonal Ab or an anti-Cop9 signalosome 
complex (CSN)3 monoclonal (m)Ab (Biomol) for 2 h at 4 ºC. The cell lysates:beads mix was 
centrifuged at 10000 x g and the supernatants of the cell lysates were harvested as pre-cleared 
cell lysates. The Ab:beads mix was centrifuged at 10000 x g and the pellet (Ab-conjugated 
beads) was resuspended with the cell lysates. The Ab:bead:cell lysate mix was incubated for 
2 h at 4 ºC, and then harvested by centrifuging at 10000 x g for 15 min. The preparation was 
resuspended in RIPA buffer to wash, and centrifuged at 10000 x g for 2 min 5 times. The 
beads were then resuspended in 2 x Laemmli buffer, centrifuged briefly and heated to 100 ºC 
for 3 min. The beads were then centrifuged and the supernatants analysed by SDS-PAGE and 
immunoblotting. 
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 2.2.8 Cell fractionation 
Cells were harvested into fresh medium as detailed in 2.4.1, having removed the supernatant, 
and washed twice with PBS. Cells were centrifuged at 3000 x g for 5 min at 4 ˚C, before 
being washed in PBS and centrifuged again as before. Cells were resuspended in 10 mM 
Tris-HCl (pH 9.0) with protease inhibitors, and incubated on ice for 15 min to swell the cells. 
The cell suspension was then transferred to a sterile dounce homogeniser to disrupt the cell 
membranes. This mix was then transferred to a fresh 10 ml tube and centrifuged at 300 x g to 
collect the cell nuclei. The supernatant fraction contained the cytoplasmic proteins and was 
placed at 4 ˚C before further analysis. The pellet was washed twice by re-suspending in 10 
mM Tris-HCl (pH 9.0) and re-centrifuged. The pellet was then resuspended in RIPA buffer 
(150 mM NaCl, 1 % [v/v] NP-40, 0.5 % [w/v] Deoxycholic acid, 0.1 % [w/v] SDS, 50 mM 
Tris-HCl [pH 8.0]) with protease inhibitors, and incubated on ice for 15 min. This was 
centrifuged at 10000 x g in a microcentrifuge for 10 min. The supernatant fraction contains 
nuclear proteins, while the pellet constituted the insoluble fraction. The insoluble fraction was 
washed and resuspended in 1 % SDS. Both fractions were stored at 4 ˚C until further 
analysis. One hundred µl of each fraction was mixed 1:1 with Laemmli buffer, heated to 85 
˚C for 3 min, and then stored at -20 ˚C for future SDS-PAGE analysis 
 
 2.2.9  Gel filtration 
Five 10-cm2 dishes of sub-confluent HeLa cells were infected with VACV with 5 p.f.u./cell. 
At 4 h.p.i., the infected cells were washed once with ice-cold PBS and lysed with 600 µl (120 
µl per dish) of CE buffer (10 mM 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid 
[HEPES], 10 mM KCl, 0.1 mM EDTA [pH 8.0], 0.1 mM ethylene glycol tetraacetic acid 
(EGTA), 1 mM dithiothreitol (DTT), 0.05 % NP-40, 20 mM B-glycerophosphate, 1 mM 
Na3VO4, 1 x protease inhibitor cocktail II [CalBio]) for 30 min at 4 ˚C. The extract was 
centrifuged at 10000 x g for 30 min at 4 ˚C. A 500 µl aliquot of the supernatant was loaded 
onto a Superose6 gel filtration column (Amersham) that had been equilibrated in gel filtration 
buffer (25 mM Tris-HCl [pH 7.6], 150 mM NaCl, 0.2 % NP-40, 5 % [v/v] Glycerol). The 
flow rate of the column was maintained at 0.2 ml/min and fractions of 500 µl each were 
collected by fast protein liquid chromatography (FPLC). A 50 µl sample of each fraction was 
analysed by SDS-PAGE followed by immunoblotting with the indicated Ab. The column was 
calibrated using protein standards: thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 
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kDa), γ-globulin (158 kDa), bovine serum albumin (BSA) (96.7 kDa) and ribonuclease A (13 
kDa) (standards kit from Amersham). 
 
 2.2.10  Yeast two hybrid analysis 
The C16L and icIL-1Ra genes were sub-cloned in frame with the GAL4-DNA binding 
domain into pGBKT7 vector (Clontech) to perform a two-hybrid interaction screen. These 
genes were also subcloned in frame with the GAL4-DNA activation domain in the pGADT7 
vector (Clontech). The resultant plasmids were co-transformed into AH109 strain of S. 
cerevesiae according to the manufacturer’s instructions (Clontech Matchmaker system) and 
the transformants were inoculated onto Synthetic Defined (SD) medium dropout plates 
(lacking tryptophan and leucine). The transformants were also inoculated onto plates lacking 
tryptophan, leucine and histidine, and finally onto plates lacking all tryptophan, leucine and 
histidine but containing 100 mM 3-amino-triazol (3-AT)) to detect any interaction. 
 
2.3  Production and purification of recombinant C16 protein and production of anti-
C16 serum 
 2.3.1 Construction of prokaryotic expression vectors 
The C16 ORF was amplified by PCR using primers AF9 (5’-
AGATCCATGGGTGATATTTACGACGATAAAGGTCTACAG-3’) and AF10 (5’-
AGATGAATTCCCGCTGCCGCGCGGCACCAGTTTCGGCATATTAAAGTAAAATC-3’) 
and VACV WR DNA as template. The product was digested with NcoI and EcoRI (indicated 
in primers in italics) and cloned into NcoI- and EcoRI-digested pET28a (Novagen) and the 
resultant plasmid, pET28a-C16L-CHis, was termed pAFE and the fidelity of the C16L ORF 
was verified by DNA sequencing. 
 
 2.3.2 Expression of C16 using an inducible system 
The pET28-based recombinant plasmid, pET28a-C16-CHis, was transformed into 
BL21(DE3) cells. A single bacterial colony was picked and used to inoculate 5 ml of LB 
containing kanamycin (Kan; 30 µg/ml). The 5 ml culture was expanded into 500 ml of LB 
containing Kan (30 µg/ml) and were incubated with shaking at 200 rpm at 37 ºC until 
reaching an OD600 of 0.4. The incubation temperature was reduced to 30 ºC until an OD600 of 
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0.6 was reached. IPTG was added to a final concentration of 0.5 mM and the incubation was 
continued for 5 h at 30 ºC. The cells were harvested by centrifugation at 2000 x g for 20 min 
at 4 ºC and the cell pellet was frozen and thawed once. The cells were resuspended in 10 ml 
of lysis buffer (50 mM Tris-HCl pH 8.0, 0.5 M NaCl and 2 % [v/v] Triton X-100). The 
mixture was cooled on ice and sonicated until the cells were lysed completely. The cell lysate 
was centrifuged at 15000 x g for 30 min and the pellet was discarded. 
 
 2.3.3 Affinity purification of C16 
The soluble recombinant His-tag fusion protein was purified by Ni2+-chelate column 
chromatography using a His Trap HP 5 ml column (GE Healthcare, Amersham Biosciences). 
The column was equilibrated with binding buffer [30 mM imidazole, 0.5 M NaCl, 20 mM 
Tris-HCl (pH 7.9)]. The soluble proteins in binding buffer were loaded onto the column, 
washed with 25 ml of binding buffer and 15 ml of washing buffer [30 mM imidazole, 0.5 M 
NaCl, 20 mM Tris-HCl (pH 7.9)]. The proteins were eluted with an increasing imidazole 
gradient (30 mM up to 500 mM) using eluting buffer [1 M imidazole, 0.5 M NaCl, 20 mM 
Tris-HCl, (pH 7.9)] and fractionated by FPLC.  
 
 2.3.4 Gel filtration purification 
Samples from fractions of affinity-column purification of C16 were separated by SDS-PAGE 
and immunoblotted. Fractions containing C16-CHis were concentrated using a YM-10 
Centricon concentrating filter (Millipore) as per the manufacturer’s instructions. The 
concentrated sample (0.5 ml) was then loaded on a Superdex 200 column that had been 
equilibrated in gel filtration buffer [25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.2 % (v/v) 
NP-40, 5 % (v/v) glycerol]. The flow rate of the column was maintained at 0.2 ml/min and 
fractions of 500 µl each were collected by FPLC. From each fraction, 50 µl was analysed by 
native and SDS-PAGE and immunoblotting. 
 
 2.3.5 Production of rabbit anti-C16 polyclonal serum 
Affinity-purified recombinant C16 protein was sent to Harlan Sera-Lab (Leicestershire, 
England) to generate a polyclonal rabbit serum. Pre-bleed serum samples were taken from 
two rabbits prior to immunisation and their serum was tested for reactivity against VACV-
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infected cell lysates. Purified protein (100–200 µg with an estimated purity of 90 %) was 
injected into New Zealand White rabbits with Fruend’s complete adjuvant full adjuvant to 
produce anti-C16 serum. Boosters of protein with Freund’s incomplete adjuvant were injected 
at 14, 28, 42, 56 and 70 days after the primary immunisation. Test-bleeds were taken in 10 ml 
aliquots at 35, 49 and 63 days after the primary immunisation, and the terminal bleeds were 
taken 77 days after the initial immunisation. 
 
2.4  Tissue Culture 
2.4.1  Maintenance of cell stocks 
Mammalian cell lines used included African green monkey kidney fibroblasts (BSC-1 and 
CV-1 cells), human lung osteosarcoma fibroblasts (TK-143B cells, ATCC CRL-8303), 
human cervical carcinoma cells (HeLa cells, ECACC CCL-2), and a subclone of HeLa cells 
(D98OR cells, ATCC CCL18.3), a human embryo kidney cell line (HEK293T, CRL-1573) 
and rabbit kidney (RK)13 cells. RK-13, BSC-1, CV-1, HEK293T and D98OR cells were 
cultured in DMEM supplemented with 10 % heat-treated (56 °C, 1 h) FBS. TK-143B cells 
and HeLa cells were cultured in Minimum Essential Medium (MEM, Gibco BRL) 
supplemented with 10 % FBS, 2 mM L-Glutamine (Gibco BRL) and 1 x non-essential amino 
acid solution (Sigma-Aldrich). All cells were grown at 37 ˚C in a humidified incubator 
(Heraeus) in the presence of air containing 5 % (v/v) CO2. 
 
2.4.2  Subculture of cell lines 
Growth medium was discarded from cell monolayers, which were then washed twice in PBS. 
Cells were detached by addition of a small volume of 0.125 % trypsin / 500 µM EDTA 
(Sigma-Aldrich) and 5 min incubation at 37 ˚C. Detached cells were collected by 
centrifugation at 2000 x g for 5 min before cell pellets were resuspended thoroughly and 
diluted into the appropriate medium and used to seed dishes or flasks. 
 
 2.4.3  Transfection 
FuGene HD Transfection Reagent (Roche) was used for transfection according to the 
manufacturer’s instructions. Briefly, cells were seeded at 30–50 % confluency. After 16 h, 
the culture medium was replaced by pre-warmed complete medium (1 ml per well for a 6-
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well plate). A ratio of 1:3 DNA (µg) to liposome (µl) was calculated. The plasmid DNA was 
added to serum-free OptiMem, and then the liposome was added directly into the DNA 
mixture. The reagents were mixed gently, incubated for 20 min at RT and added drop-wise to 
the cells. 
 
Polyethylinimine (PEI) transfection reagent (Sigma-Aldrich) was also used for transfection. 
Briefly, cells were seeded at 80-90 % confluency. After 16 h, the culture medium was 
replaced by pre-warmed DMEM containing 2 % FBS. A 1:1.5 ratio of µg DNA : µg PEI was 
used. The plasmid DNA was added to serum-free OptiMem and then PEI was added directly 
into the DNA mixture. The reagents were vortexed briefly and incubated for 10 min at RT 
and added dropwise to the cells. 
 
2.5. Construction of mammalian expression vectors.  
To express the C16 protein in transfected cells, DNA fragments were generated by PCR 
using VACV WR as a template. A DNA fragment containing the C16L gene was produced 
by PCR with oligonucleotides AF20 (5’- 
AGACGAATTCGCCACCATGGATATTTAGGACGATAAAGGT-3’) containing an EcoRI 
site as indicated and AF21 (5’- 
AGATGCGGCCGCTTATTTCGGCATATTAAACTAAAATCTA-3’) containing a NotI site 
as indicated.  
 
To express the icIL-1Ra protein, DNA fragments were generated by PCR using mouse RAW 
cell cDNA as a template. A DNA fragment containing the icIL-1RaI gene was produced by 
PCR with oligonucleotides AF22 (5’-
CGTAGAATTCATGGCTTCAGAGGCAGCCTGCCCGCCCTTCTCGG-3’) containing an 
EcoRI site as indicated and AF23 (5’- 
GCTAGCGGCCGCTTACTATTGGTCTTCCTGGAAGTAGAAC- 3’) containing a NotI 
site as indicated. 
 
To overexpress the pro-IL-1α protein, DNA fragments were generated by PCR using mouse 
RAW cell cDNA as a template. A DNA fragment containing the pro-IL-1α gene was 
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produced by PCR with oligonucleotides AF24 (5’- 
CGTAGAATTCCATGGCCAAAGTTCCTGACTTGTTTG-3’) containing an EcoRI site as 
indicated and AF25 (5’- 
GCTAGCGGCCGCTTATGATATCTGGAAGTCTGTCATAGAGGG- 3’) containing a NotI 
site as indicated. 
 
Following gel purification, the products were ligated into pGEMT (Promega) and sequenced. 
The resultant plasmids were then digested with EcoRI and NotI, as was pCI vector (Promega) 
and the individual constructs were ligated into pCI as detailed above.  
 
2.6  Growth and Purification of VACV 
 2.6.1  Infection of mammalian cells with VACV 
Virus stocks (either crude cell lysates or purified stock) were sonicated for 30 sec at 20 % 
power output (cup sonicator W-385, Heat Systems Ultrasonics) to disrupt virus aggregates. 
Virus was then diluted as required into a minimal volume of either DMEM or MEM 
(depending on the cell type involved) containing 2.5 % FBS, before being added to the cells 
and incubated at 37 ˚C for 1.5-2 h with gentle rocking every 15 min to distribute the virus 
evenly. The inoculum was aspirated and cells were washed twice in PBS before being 
incubated in the appropriate medium at 37 ˚C for the desired time. “Mock” infection refers to 
treatment of cells in an identical manner but without the addition of virus. 
 
 2.6.2  Preparation of crude stocks of VACV 
Flasks of BSC-1 or RK-13 cells were infected with VACV at approximately 0.1 p.f.u./cell 
and incubated at 37 ˚C in suitable medium supplemented with 2.5 % FBS until a complete 
CPE was observed. Cells were scraped into the medium, centrifuged at 2000 x g (GH3.7 
rotor, Beckmann GPR centrifuge) for 5 min at 4 ˚C and resuspended in a small volume of 
DMEM supplemented with 2.5 % FBS. Infected cells were subjected to 3 freeze-thaw cycles, 
then aliquoted and stored at -70 ˚C. Prior to use, stocks were titrated by plaque assay on BSC-
1 cells to determine virus infectivity (section 2.4.3). 
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 2.6.3 Plaque assays 
The infectivity of the virus was determined by plaque assay. Sonicated virus stocks were 
diluted 10 or 100-fold through a dilution series in DMEM containing 2.5 % FBS in triplicate. 
One ml of the appropriate dilutions was used to infect 6-well plates of confluent BSC-1 cells 
(or CV-1 or RK-13 cells). The plates were incubated at 37 ˚C and rocked gently every 15 min 
for 1.5 h. The inocula were aspirated and the cells were overlayed with 2 ml DMEM (2.5 % 
FBS) containing 1.5 % carboxymethylcellulose (CMC). After 48 or 72 h, the overlays were 
aspirated, and the cells were washed with PBS and stained with 0.01 % (w/v) crystal violet in 
15 % (v/v) ethanol, which was left for 2 h and washed off by submersion in ddH2O. 
Individual foci of infection (plaques) were counted, and the titre of virus calculated and 
expressed as p.f.u./ml. 
 
2.6.4  Purification of VACV through a sucrose cushion 
Flasks of TK-143 cells were infected with 0.1 p.f.u./cell for 48 h or until complete CPE 
occurred. The cells were dislodged by agitation or scraped into the medium, centrifuged at 
2000 x g for 5 min at 4 ˚C (Beckman GPR centrifuge, GH-3.7 rotor), resuspended in PBS to 
wash, collected by centrifugation and then resuspended in 10 mM Tris-HCl (pH 9.0) and 
allowed to swell on ice for 15 min. The cells were broken by 25 strokes of a dounce 
homogeniser keeping the virus on ice throughout. The nuclei were then centrifuged at 500 x g 
for 5 min at 4 ˚C (Beckman GPR centrifuge, GH-3.7 rotor) and the supernatant retained and 
sonicated for 30 sec. This was then layered onto an equal volume of 36 % (w/v) sucrose in 10 
mM Tris-HCl (pH 9.0) (sucrose cushion) and centrifuged through the cushion at 15000 x g 
for 80 min at 4 ˚C (Beckman L8-M ultracentrifuge, SW28 rotor). The virus pellet was 
resuspended in 1 ml of 1 mM Tris-HCl (pH 9.0), sonicated for 20 sec, aliquoted and stored at 
-70˚C.  
 
2.6.5  Purification of VACV through a sucrose density gradient 
The crude viruses purified by sedimentation through a sucrose cushion were further purified 
by sedimentation through a continuous 15–40 % (w/v) sucrose gradient (prepared in 10 mM 
Tris-HCl [pH 9.0]) at 19000 x g for 50 min at 4 ˚C. Virus present in distinct bands in the 
gradient was collected, diluted three-fold with 10 mM Tris-HCl (pH 9.0) and recovered by 
centrifugation at 24000 x g for 80 min at 4 ˚C. The pellet was resuspended in 1 ml of 10 mM 
 102
Tris-HCl (pH 9.0), sonicated, aliquoted and stored at -70 ˚C. The yield of virus was 
calculated by spectrophotometry (1 unit OD260 = 64 µg of virus = 1.3 x 1010 particles). The 
virus infectivity was also determined by plaque assay as above. 
 
2.7  Construction of recombinant VACV 
A C16L substitution virus was generated by replacement of gene C16L in the VACV WR 
genome by a selectable marker. A deletion virus was then constructed by removing this 
selectable marker, and a revertant virus constructed wherein C16 was restored.  
 
2.7.1  Plasmid construction 
A cassette containing the Ecogpt gene fused inframe with the EGFP gene and downstream of 
synthetic early/late VACV promoter was assembled as follows. The Ecogpt gene was 
amplified by PCR with primers AF1 (5’-
AGTCGAATTCATAGCGAAAAATACATCGTCACCTGGGAC-3’) and AF2 (5’-
GCGCTAGCGGATCTGAGCGACCGGAGATTGGCGGG-3’) and pGpt07/14 as template 
(Boyle and Coupar, 1988). The EGFP gene was amplified by PCR using primers AF3 (5’-
CGCCAATCTCCGGTCGCTCAGATCCGCTAGCGCTACCG-3’) and AF4 (5-
AGTCCCCGGGATAAAAATTTACTTGTACAGCTCGTCCATGCCGAG-3’) and 
pEGFPC2 (BD Biosciences) as template. These PCR products were joined together by splice 
overlap extension (Horton et al., 1989) using primers AF1 and AF4. The product was 
digested with SmaI and EcoRI and cloned into synthetic early/late plasmid (pSEL) (Bartlett et 
al., 2004) downstream of a VACV synthetic early/late promoter (Davison and Moss, 1990) 
forming pSEL-Ecogpt/GFP (also called pAFA). 
 
The flanking regions of gene C16L were amplified from VACV WR genomic DNA using 
primers AF5 (5’-GACGGTATGTATTGTAGATGCTCTCATGG-3’) and AF6 (5’-
CGTCAAACAATCATTCCCGGGTATAATATCTAGAGGTAGAGG-3’) for the 395-bp 
upstream region and primers AF7 (5’-
CCTCTAGATATTATACCCGGGAATGATTGTTTGACGAATCACG-3’) and AF8 (5’-
GGAGATCATACTACCACAACTTATTATTATGC-3’) for the 383-bp downstream 
flanking region. These PCR products were ligated together using a SmaI site (indicated in 
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italics) and then cloned into pGEMT by restriction digestion with EcoRI and NotI to form 
pGEMT-∆C16L plasmid (pAFC). 
 
The cassette containing pSEL driving Ecogpt/EGFP was excised from pAFA with SmaI and 
ligated into SmaI-digested pAFC to place the Ecogpt/EGFP cassette between the C16L 
flanking regions. This resultant plasmid, pGEMT-∆C16L-Ecogpt/EGFP (also called pAFB) 
was used to construct the C16L deletion virus. To make a revertant virus, in which the C16L 
gene was re-inserted into its natural loci, the C16L gene and flanking regions was amplified 
from VACV strain WR genomic DNA using primers AF5 and AF8. The product was 
restricted with EcoRI and NotI, ligated into pGEMT that had been digested with the same 
enzymes and termed pAFD. 
 
2.7.2  Production of VACV recombinants 
A VACV deletion mutant wherein both copies of the C16L gene were replaced with the 
Ecogpt/EGFP cassette was constructed by transfecting pAFB into CV-1 cells that had been 
infected with a plaque-purified VACV WR (vC16). Recombinant viruses were selected in the 
presence of 25 µg/ml mycophenolic acid (MPA), 15 µg/ml hypoxanthine, 250 µg/ml xanthine 
(Boyle and Coupar, 1988). Control infections were conducted using wild type WR virus and 
virus vSAD3 Ecogpt+ virus (Duncan and Smith, 1992) in the presence and absence of 
selection drugs. Recombinant viruses were also screened for EGFP expression by fluorescent 
microscopy and, after further rounds of plaque purification on BSC-1 cells, were analysed by 
PCR to ensure replacement of both copies of the C16L gene with the Ecogpt/EGFP cassette. 
The resultant plaque-purified virus was called v∆C16/Ecogpt/EGFP. 
 
To remove the Ecogpt/EGFP cassette from the C16L locus, plasmid AFC was transfected into 
v∆C16/Ecogpt/EGFP-infected cells and Ecogpt-negative viruses were selected using 1 µg/ml 
6-thioguanine (6-TG) on hypoxanthine guanine phosphoribosyltransferase (HGPRT)- D98OR 
cells (Kerr and Smith, 1991). The deletion mutant virus was called v∆C16. A revertant virus 
was constructed in a similar manner by transfection of plasmid AFD into 
v∆C16/Ecogpt/EGFP-infected cells to create vC16Rev. Viruses were analysed by PCR using 
primers AF5 and AF8 to characterise the C16L locus.  
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 2.7.3  Identification of VACV recombinants 
   Screening by PCR 
To prepare crude VACV DNA for rapid PCR screening of VACV plaque isolates, 50 µl of 
each plaque suspension was used to infect BSC-1 cells in a flat bottom 96-well plate until 
CPE was evident. DNA was extracted by Proteinase K extraction as detailed above. A series 
of PCR analyses using 2 µl extracted DNA solution as template were conducted to verify 
deletion from or integration of C16L or the Ecogpt cassette into the VACV WR genome. 
PCR A used primer AF11 (5’-CCAGAGGGAGATGGATATTGTTTACACG-3’) and AF12 
(5’- GATTCCAAAAATACTGAATACAAAGTCC-3’), specific for regions of the WR 
genome external to the C16L-flanking regions incorporated into pGEMT-∆C16 plasmid to 
amplify that section of the genome. This determined whether there was a 2100-bp fragment 
(Ecogpt cassette – substitution virus), a 1900-bp fragment (C16L – revertant virus and WR), 
or an 800-bp fragment (deletion virus) in the progeny virus. PCR B used a primer upstream 
of the 5’ C16L-flanking region in the WR genome (AF11), and a primer downstream of the 
3’ C16L-flanking region in the pGEMT vector (AF13 – 5’-
CGAATTGGGCCCGACGTCGCATGC-3’). PCR C used one primer downstream of the 3’ 
C16L flanking region in the WR genome (AF12) and upstream of the 5’ C16L flanking 
region in the pGEMT (AF14 – 5’-CGTTGGGAGCTCTCCCATATGG-3’). The absence of 
products in both PCR B and C excludes the possibility of single homologous integration of 
the whole pGEMT-∆C16L/Ecogpt/GFP vector into the WR genome. VACV WR genomic 
DNA was used as a positive control for C16L amplification. DNA from uninfected CV-1 
cells was used as a negative control.  
 
Further analytical PCRs were undertaken to verify that the insert had integrated into both 
ITRs, and that the DNA around the insert, at the border between the ITR and the US at either 
end of the genome had not been altered, at least in length. These PCRs used a primer just 
inside the left US of WR (10629–10608) termed AF15 (5’-
CACCCATATGTTAATGCCGACG-3’), a primer further into the left US of WR (11722–
11702) termed AF16 (5’- CAATGAACTCGGATGTCCTCC-3’), and a primer just inside the 
ITR (9606–9629) termed AF17 (5-CGTATCGCCGGAAGGGACTATATG-3’). Similar 
PCRs were devised for the right unique sequence of WR using a primer just inside the US 
(183932-183956) termed AF18 (5’- GACTGGACTATCGGCGTACTATCC-3’) and a 
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primer further inside the US (182047-182073) termed AF19 (5’- 
GGGAATTGGTCACGACGACAGAAAGC-3’) and AF17 as before.  
 
  Amplification of recombinants 
The final plaque purification was freeze-thawed and sonicated and 200 µl used to infect a 25 
cm2 flask of BSC-1 cells. The cells were incubated at 37 ˚C for 2–3 days until CPE was seen, 
scraped into the growth medium, centrifuged at 1500 x g for 5 min at 4 ˚C (Beckman GPR 
centrifuge, GH-3.7 rotor) and resuspended in 500 µl of DMEM (2.5 % FBS). This master 
stock was freeze-thawed 3 times and sonicated for 15 sec and 250 µl used to infect a 175 cm2 
flask of cells. After 2–3 days, the cells were harvested in 1 ml DMEM (2.5 % FBS), freeze-
thawed 3 times and sonicated for 30 sec. The virus titre of this sub-master stock was then 
determined by plaque assay and a larger preparation (working stock) of virus was grown. 
 
2.8  Analysis of recombinant VACV 
2.8.1  Plaque phenotype analysis 
Monolayers of BSC-1, CV-1, TK-143 or RK-13 cells were infected with enough virus 
to give approximately 50 plaques per monolayer. After overlaying with 1.5 % CMC, cells 
were incubated for 72 h and stained with crystal violet. Plaques were analysed on a Zeiss 
microscope. Photographs of approximately 40 plaques were taken for each virus on each cell 
type. The size of each plaque was calculated using the measurement function on the 
ImagePro software by drawing a circle of best fit to the edge of the plaque and calculating the 
area of the circle. 
 
2.8.2  Growth kinetic analysis 
Monolayers of BSC-1 cells were infected with either 10 or 0.01 p.f.u./cell for measurement of 
one-step or multistep growth kinetics, respectively. After infecting for 1.5 h, the virus 
inoculum was removed, the cells were washed twice in PBS to remove unbound virus and 
then incubated in DMEM containing 2.5 % FBS. At the indicated times p.i., the culture 
medium was removed and centrifuged at 1500 x g at 4 ˚C for 10 min to collect detached cells. 
Attached cells were scraped into the growth medium, added to the cells collected from the 
culture supernatant, freeze-thawed 3 times, sonicated for 15 sec and then the cell-associated 
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virus (including IMV, IEV and CEV) titres were determined by plaque assay using BSC-1 
cells. The titre of virus released into the medium (mostly EEV but with some IMV released 
from broken cells) was also determined. 
 
2.8.3  Preparation of secreted and cellular proteins for immunoblotting 
Confluent monolayers of cells were infected with 10 p.f.u./cell of the appropriate virus isolate 
for 2 h as described above. Following 3 washes with ice-cold PBS, cells were overlaid with 
DMEM and incubated at 37 ˚C for 2–24 h. 
 
Supernatants and cells were harvested from infected 175 cm2 flasks as follows. Supernatants 
were removed and clarified by centrifugation at 3000 x g (GH-3.7 rotor) for 5 min, followed 
by 31000 x g for 1 h at 4 ˚C, then concentrated 30-fold using Centricon-10 concentrators 
(Millipore) according to the manufacturer’s instructions. The preparation of supernatants for 
protein gel analysis is described below. Cellular material from infected flasks was scraped 
into 10 ml of ice-cold PBS and centrifuged at 3000 x g (GH-3.7). The pellet was resuspended 
in 2 ml RIPA buffer, incubated on ice for 10 min and insoluble material including cell nuclei 
was removed by centrifugation at 3000 x g (GH-3.7 rotor) for 10 min. The supernatant 
fraction was retained, 0.1 % (w/v) SDS was added and aliquots were stored at -20 ˚C. To load 
on to a protein gel, cellular material was mixed with an appropriate volume of 6x Laemmli 
buffer as detailed in 2.2.1 
 
2.8.4  Investigation of timing of C16 protein expression 
BSC-1 monolayers in 6-well plates were infected with recombinant VACV at 10 p.f.u./cell in 
the presence or absence 40 µg/ml cytosine β-D-arabinofuranoside (AraC), for the appropriate 
length of time. The cell monolayer was washed with 3 ml of PBS, scraped into PBS, 
centrifuged at 1500 x g for 5 min at 4 ˚C (Beckman GPR centrifuge, GH-3.7 rotor), dissolved 
in 200 µl of protein loading buffer and 20 µl of each cell lysate was resolved by SDS-PAGE 
and analysed by immunoblotting with anti-C16 Ab and anti-A56 Ab (Sanderson et al., 
1998a). 
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2.9  Virulence Assays in murine models 
2.9.1  Intranasal infection model 
Groups of female Balb/c mice, between 6 and 8 weeks old, were anaesthetised and inoculated 
intranasally with sucrose-purified VACV diluted in 20 µl PBS (Alcami and Smith, 1992). 
Mice were weighed daily before and after infection. Signs of illness were also scored using 
the following measures: 
1 – hair ruffling 
2 – back arching 
3 – reduced mobility 
4 – severe pneumonia 
Animals that lost more than 30 % of their original body weight or were judged to have severe 
pneumonia were sacrificed. Titres of inocula were confirmed by plaque assay. 
 
2.9.2  Intradermal infection model 
Groups of female C57Bl/6 mice, between 6 and 8 weeks old, were anaesthetised and 
inoculated with sucrose-purified VACV in 10 µl of PBS into each ear pinna (Tscharke et al., 
2002). Mice were examined daily and the diameter of lesions at the inoculation site was 
measured using a micrometer. Titres of inocula were confirmed by plaque assay. 
 
2.9.3  Vaccination and challenge model 
Groups of female Balb/c mice, between 6 and 8 weeks old were anaesthetised and inoculated 
with sucrose-purified VACV in 10 µl of PBS in one ear pinna as above. Ears were monitored 
over the subsequent 7 days to establish “take”. Twenty-eight days later, mice were 
anaesthetised and inoculated i.n. with a lethal dose (greater than 5 x 104 p.f.u) of VACV WR 
in 20 µl PBS. Mice were weighed daily before and after infection. Signs of illness were also 
scored as above. Titres of inocula on both vaccination and challenge days were confirmed by 
plaque assay. 
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2.9.4  Extraction of cells from infected tissues 
   Bronchoalveolar lavage (BAL) 
BAL was harvested in Hanke’s buffered salt solution (HBSS) containing 0.001 mg/ml 
Lidocaine (Sigma-Aldrich), and 5 mM EDTA and centrifuged at 800 x g for 5 min to obtain 
BAL cells. Cells were resuspended in erythrocyte-lysis buffer for 3 min, before the lysis 
reaction was stopped by adding Royal Park Memorial Institute (RPMI) medium containing 
10 % FBS (RPMI-10), and the cells were centrifuged as before. Cells were resuspended in 
300 µl RPMI-10 per BAL sample and enumerated using a haemocytometer and trypan blue 
exclusion (Clark et al., 2006). 
 
   Lung 
Lungs were harvested in RPMI-10 and chopped into smaller pieces. Digestion medium 
containing 1 mg/ml collagenase (Sigma-Aldrich, crude type XI) and 0.003 % DNaseI 
(Sigma-Aldrich) was added to the lung tissue and incubated for 75 min at 37 ºC. Lung tissue 
was passed through cell strainers and centrifuged at 800 x g for 5 min. Cells were 
resuspended in erythrocyte lysis buffer for 3 min before RPMI-10 was added and cells were 
centrifuged again as before. Cells were resuspended in 20 % Percoll in RPMI-10, centrifuged 
at 800 x g for 20 min and resuspended in 1 ml RPMI-10 per lung and cells were enumerated 
using a haemocytometer and trypan blue exclusion (Belkaid et al., 1996). 
 
   Ear 
Ear lobes from infected mice were collected, rinsed in 70 % ethanol and allowed to dry. The 
central and dorsal dermal sheets were separated using fine forceps and transferred 
immediately to RPMI-10 containing 1 mg/ml collagenase (Sigma-Aldrich, crude type XI) and 
0.003 % DNaseI (Sigma-Aldrich) and incubated for 75 min at 37 ºC. The cells were passed 
through cell strainers and centrifuged at 800 x g for 5 min. Cells were resuspended in 
erythrocyte lysis buffer for 3 min before RPMI-10 was added and cells were centrifuged as 
before. Cells were enumerated using a haemocytometer and trypan blue exclusion. 
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2.9.5 Virus analysis from infected tissues. 
The titres of virus in tissues extracted as above were determined by plaque assay on duplicate 
monolayers of BSC-1 cells. 
 
2.9.6 Analysis of infiltrating cells at the site of infection 
Live cells were counted, washed with flow assisted cell sorting (FACS) buffer (0.1 % BSA, 
0.1 % NaN3 in PBS), blocked with FACS blocking buffer containing 10 % normal rat serum, 
and a 1:500 anti-CD16/CD32 Fc γ receptor in FACS buffer for 30 min at 4 ºC. Cells were 
stained with appropriate combinations of FITC-, phycoerythrin (PE)-, allophycocyanin 
(APC)- or tricolour-labelled antibodies in 10 µl FACS block solution per 2 x 105 cells . These 
were grouped into anti-CD69, anti-CD3, anti-CD8, anti-CD4 for T lymphocytes, anti-DX5 on 
natural killer cells in the Balb/c analysis or anti-B220 on natural killer cells in C57/Bl6 mice, 
anti-TCRγδ for TCR γδ cells, anti-Ly6G on neutrophils and anti-F480 on macrophages. 
Isotype controls for each fluorophore were obtained from BD biosciences as described 
(Jacobs et al., 2006), as well as single stains for each Ab to allow compensation between the 
different fluorophores to be judged accurately. These solutions were incubated with the cells 
for 30 min at 4 ºC in the dark. Cells were washed three times in FACS buffer. The presence 
of cell-surface markers was determined on a FACSCalibur flow cytometer with CellQUEST 
software (BD Biosciences). A lymphocyte gate was used to analyse data from at least 20000 
events (BAL) and 50000 events (lung or ear). 
 
 2.9.7  Analysis of cytokines at the site of infection 
   IL-6 enzyme linked immunosorbent assay (ELISA) 
Cell supernatants from transfected RAW 264.7 cells were clarified, or lung samples were 
homogenised and analysed in an IL-6 ELISA kit (R&D Diagnostics) as per the 
manufacturer’s instructions. Cell supernatant samples were analysed directly, while lung 
homogenates were diluted fivefold prior to analysis. 
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   Luminex 
Concentrations of cytokines in BAL and lung homogenates were assessed using Multiplex 
Bead Immunoassays (BioSource International, Camarillo, CA) in conjunction with the 
Luminex LabMAP system, following the manufacturer's instructions. The cytokines 
examined and their levels of sensitivity were as follows: TNF-α, 5 pg/ml; IFN-γ, 1 pg/ml; IL-
1β, 10 pg/ml; IL-2, 15 pg/ml; IL-4, 5 pg/ml; IL-5, 10 pg/ml; IL-6, 10 pg/ml; IL-10, 15 pg/ml; 
IL-12 (p40/p70), 15 pg/ml; GM-CSF, 10 pg/ml. A standard curve containing sequential 
dilutions of the recombinant cytokines in an appropriate range to the sample readings was 
constructed and showed R2 values of between 0.9675–0.9982. This standard curve was used 
to assess the concentrations of cytokines in each sample. BALs were analysed directly, while 
lung samples were dilute 5-fold prior to analysis. Samples from 3 mice were analysed per 
group per day. 
 
2.9.8 Analysis of antibodies in blood sera 
Blood samples were taken as 50 µl aliquots by tail-bleed from mice at indicated days p.i., and 
allowed to coagulate at 37 ºC for 30 min. Samples were centrifuged at 10000 x g for 10 min, 
and the serum supernatant was harvested. The complement component was heat-treated at 55 
ºC for 30 min.  
 
Plates were coated with proteins B5, A33, A27 and H3, which had been purified by affinity 
chromatography (Putz et al., 2006) at a concentration of 100 ng/well for B5, A33 and A27 or 
50 ng/well for H3. UV-inactivated VACV-infected cell lysate corresponding to 105 p.f.u./well 
was also used. These proteins and VACV-infected cell lysate were kindly provided by Dr. 
Mike M. Putz. The antigens were incubated in wells of a 96-well plate overnight at 4 ºC in 50 
mM NaHCO3, (pH 7.6). The plates were washed with washing buffer [2 mM Trisma, 154 
mM NaCl, 0.2 % Tween 20, (pH 7.4)] using an automatic 96-well plate washer (Wellwash 
384, Thermo). Plates were then blocked with blocking buffer [5 % nonfat dried milk, in 15 
mM Tris-Acetate, 136 mM NaCl, 2 mM KCl (pH 7.4)] for 2 h at RT. The serum samples 
were diluted initially 1:100 in dilution buffer [1 % nonfat dried milk, 0.1 % Tween, 15 mM 
Tris-Acetate, 136 mM NaCl, 2 mM KCl (pH 7.4)], and then seven sequential 3-fold dilutions 
were made to yield a final dilution of 1:218700 of the original serum samples. The blocked 
plates were washed with washing buffer and incubated with the serum dilutions for 90 min at 
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RT. The plates were again washed with washing buffer and incubated with 1:1000 dilution of 
an anti-mouse monoclonal α-IgG antibody conjugated to alkaline phosphatase (Sigma-
Aldrich) in dilution buffer for 60 min at RT. The plates were washed extensively with 
washing buffer, before p-nitrophenol phosphate (p-NPP) substrate solution (prepared from 
Sigma-Aldrich FAST pNPP tablets and FAST pNPP buffer as per manufacturer’s protocol) 
was added to the wells. The plates were incubated for 60 min at RT before being read by a 
96-well plate ELISA Reader (Multiskan Ascent, Thermo) at an OD of 405 nm. Linear-
regression plots were determined for each serum sample and end-point titres were defined as 
dilutions corresponding to twice the mean OD values obtained with BSA. 
 
2.10  Functional protein analysis 
2.10.1 Luciferase assays 
HEK293T cells were seeded at 1 x 105 per well of a 96-well plate the day prior to 
transfection. The NFκB-firefly-luciferase reporter construct (NFκB-luc), AP-1-firefly-
luciferase reporter construct (AP-1-luc), and ISRE-firefly-luciferase reporter construct 
(ISRE-luc) and a TK-Renilla-luciferase (TK-Renilla luc) construct were all obtained from the 
Promega PathDetect system. Cells were transfected with 60 ng of NF-κB-luc/AP-1-luc/ISRE-
luc, 10 ng of TK-Renilla-luc, and 60 ng (or the indicated amount) of the expression vectors of 
interest with PEI transfection reagent (Sigma-Aldrich). The total amount of DNA was kept 
constant by supplementation with pCI. After 36 h, cells were harvested in passive lysis buffer 
(Promega) and freeze-thawed to lyse the cells. Firefly luciferase activity was measured by 
adding firefly luciferase reagent (8 mg/ml luciferin [Lux Biotechnology], 270 µM acetyl co-
enzyme A [Sigma-Aldrich], 530 µM ATP, 33 mM DTT, 0.1 mM EDTA, 2.67 mM MgSO4, 
20 mM Tricine) to the cell lysates. Renilla luciferase activity was measured by adding renilla 
luciferase reagent (2 µg/ml Coelenerazine [Lux Biotechnology] in PBS) to the cell lysates the 
relative stimulation of reporter Luciferase activity was measured as relative light units 
(RLUs) in a Luminoskan Luminometer (Labsystems). Reporter activity was calculated by 
normalizing firefly luciferase activity with Renilla luciferase activity.  
 
In all cases, data shown are from one of 2-4 independent experiments with similar qualitative 
results. Experiments were performed in quadruplicate and data are expressed as means ± SD. 
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 2.10.2  Apoptosis assays  
  2.10.2.1 PARP Cleavage assays  
HeLa cells were seeded the day prior to infection at 1 x 105 cells per well of a 96-well plate. 
Cells were infected with 1 p.f.u./cell of the indicated viruses for 90 min. The inoculum was 
removed and replaced with DMEM supplemented with 2.5 % FBS for 3 h. The medium was 
then replaced with either fresh medium, or fresh medium containing 2 µM ST (Sigma-
Aldrich). Cells were incubated for 2 h at 37 ºC. Cells were then lysed with RIPA buffer and 
harvested. The cell lysates were resuspended in Laemmli buffer and separated by SDS-
PAGE, before immunoblotting with Abs to cleaved PARP, tubulin and C16. 
 
  2.10.2.2 Mitochondrial dysfunction assays  
HeLa-TRex cells were grown to 80 % confluency and transfected with FuGene HD 
containing 5 µg plasmid and 1 µg CD20 per 6-cm2 dish. After 24 h, the cells were treated 
with 0.5 µM ST for 1 h. Cells were washed with PBS and incubated with PBS-EDTA for 10 
min. Cells were washed from the plate with a Pasteur pipette and transferred to FACS tubes 
where they were centrifuged at 800 x g for 5 min before being washed with PBS and then 
resuspended in 1 ml PBS. A 10 µl aliquot of anti-CD20-APC Ab was added to each sample, 
and incubated in the dark at 4 ºC for 30 min. Cells were centrifuged at 800 x g for 5 min and 
washed twice with PBS. As a positive control for mitochondrial dysfunction, 50 µM of the 
uncoupler carbonyl cyanide m-chlorophenylhydrazonea (CCCP) was added to one set of 
empty vector–transfected cells and incubated at 37 ºC for 5 min. Then 2 µM of 5, 5, 6, 6-
tetrachloro-1, 1, tetraethylbenzimidazolocarbo-cyanine iodide (JC-1) was added to all cells 
and incubated at 37 ºC, in 5 % CO2 for 30 min. Cells were washed 3 times in 20 ºC PBS, and 
finally resuspended in 0.5 ml PBS and analysed on a flow cytometer with 488 nm excitation 
using emission filters appropriate for APC and R-PE. A sample of cells only was used to gate 
the cells, excluding any dead cells. The CCCP-treated sample was used to perform standard 
compensation.  
 
 2.10.3  In vitro kinase assay 
In vitro assays for phosphorylation of C16 by recombinant protein kinase A (PKA, Sigma-
Aldrich), or by casein kinase II (CKII, Biomol) were undertaken in collaboration with Dr. R. 
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Chen. Control substrates kemptide (Sigma-Aldrich) or CKII substrate (Biomol) were used as 
positive controls and BSA (Sigma-Aldrich) was used as a negative control. The proteins were 
incubated in the kinase buffer (20 mM HEPES/KOH [pH 7.4], 25 mM β-glycerophosphate, 2 
mM DTT, 20 mM MgCl2). The kinase assay was performed in a final volume of 20 µl of 
kinase buffer containing 10 µM ATP, 5 µCi of [γ-32P] ATP and 2.7 µM of each of the other 
proteins. After incubation for 10 min at 30 °C, the reaction was stopped by the addition of 5 x 
Laemmli buffer. Proteins were separated by SDS-PAGE and stained by Coomassie blue. 32P-
labelled proteins were visualised by autoradiography. 
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Chapter 3 
Analysis of C16L open reading frame 
 
3.1 Introduction 
The VACV WR C16L gene (Genbank accession number YP_232892) is predicted to encode 
a 38.5-kDa proteinwww.poxvirus.org. As the C16L gene is found in the left ITR of the 
VACV genome, an exact paralogue is found in the right ITR (Genbank accession number 
YP_233091). A previous study identified the C-terminal region of C16 as having a potential 
icIL-1Ra motif (Kluczyk et al., 2002). In particular, the 6 aa active peptide component of IL-
1Ra (VKRFYF) is conserved in C16 and a 12 aa peptide fragment synthesised from this 
region of C16 has a similar immunosuppressive quality (Kluczyk et al., 2004; Kluczyk et al., 
2002). However, a characterisation of VACV WR C16 protein has not been reported.  
 
In this chapter, bioinformatic analysis of the C16 protein is undertaken to assess how 
conserved C16 is through the Poxviridae and to identify any related proteins. The C16L gene 
was analysed further to identify a promoter sequence and likely temporal regulation pattern. 
Further, the C16 protein was investigated for any secretory, transmembrane or conserved 
motifs. Then a basic characterisation of the protein product of the C16L ORF was undertaken. 
This identified the size, time of expression and localisation of C16, and showed that C16 
orthologues were expressed in every strain of VACV tested. The C16 protein was expressed 
in E. coli and partially purified with a view to downstream structural analysis. 
 
3.2  Bioinformatic analysis of C16 protein 
 3.2.1 Comparative Analysis 
Computational analysis found no cellular proteins similar to the VACV WR C16 protein. 
However, bioinformatics established that C16 is highly conserved throughout a range OPVs, 
which is unusual for genes located in the ITRs (Gubser et al., 2004; Wittek, 1982; Wittek et 
al., 1978). C16 orthologues with 95-99 % identity are predicted to be encoded by four OPV 
species including all sequenced VACV strains, VARV, CPXV and ectromelia virus (ECTV) 
(detailed in Table 3.2.1 and shown graphically in Figure 3.2.2). Only a few strains of VACV 
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contain two copies of C16L (i.e. both paralogues) as indicated in Table 3.2.1. Closer analysis 
of the genomes of sequenced strains of MPXV, camelpox virus (CMLV), and taterapox virus 
(TATV) show that the C16L-like genes in these viruses have mutations that disrupt the ORF 
to produce shorter protein products, that might not be expressed or might be unstable. These 
are illustrated in comparison to the full length products in Figure 3.2.2. The evolution of these 
mutations shows that the full length C16 protein is non-essential for viral replication and for 
survival of these viruses in their hosts.  
 
Table 3.2.1  
 Diploid % Identity % Similarity Aa of C16 
VACV WR (010, 209) Yes 100 100 1- 331 aa 
VACV Lister (m8007L) No 100 100 - 
VACV CVA (012, 218) Yes 99 100 - 
VACV COP (C10) No 99 100 - 
VACV MVA (6L) No 98 98 - 
CPXV GRI90 (C6L) No 99 99 - 
CPXV Brighton Red 
(C6L) No 95 97 - 
ECTV Moscow (011) No 98 98 - 
VARV major India 
(D3L) No 98 99 - 
VARV  minor Garcia 
(B4L) No 98 98 - 
Horsepox virus (017) No 97 99 - 
     
CMLV CMS (13L)  97 97 76-181 
CMLV CMS (12L)  96 96 255-313 
TATV Dahomy 1968  99 100 43-126 
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(14) 
TATV Dahomy 1968 
(13)  91 92 120-225 
TATV Dahomy 1968 
(12)  100 100 223-283 
MPXV Zaire (D4L)  95 99 1-79 
 
Table 3.2.1. Amino acid comparison of C16-like proteins to VACV WR C16 - Percentage 
identity and similarity. Protein sequences were compared to VACV WR C16 on the 
www.poxvirus.org website to give a table highlighting the level of conservation of the C16 
protein through the vaccinia virus strains and within the OPV genus. The diploid column 
indicates which strains of VACV contain two copies (paralogues) of C16L-like genes. For 
viruses that do not, the relevant region of C16 is indicated on the right. These may not 
express stable proteins. 
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 Figure 3.2.2 Amino acid alignment of C16-like proteins. Protein sequences were compared 
by ClustalW via Biology Workbench 3.2 website (see workbench.sdsc.edu). Yellow, green 
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and cyan indicate conserved, identical and similar residues, respectively. VACV_WR: 
VACV strain WR; VACV_Lister: VACV strain Lister; VACV_TianTan: VACV strain Tian 
Tan; VACV_COP: VACV strain Copenhagen; VACV_MVA: VACV strain MVA; 
CPXV_GRI90: CPXV strain GRI-90; CPXV_BR: CPXV strain Brighton Red; RPXV-UTR: 
RPXV strain Utrecht; VARV_IND: VARV major strain India; VARV_GAR: VARV minor 
strain Garcia; TATV_DAH: TATV Dahomy strain; CMLV_CMS: CMLV strain CMS; 
MPXV_ZRE: MPXV strain Zaire 
 
It is also possible that the acquisition of these mutations may be unimportant due to the 
presence of a separate protein, VACV WR C4, which has sequence similarity to C16. The 
function of C4 may overlap with that of C16. The C4 protein is also conserved in several 
OPVs and these have a 40-44 % aa identity and 60-65 % aa similiarity to VACV WR C16 
(Table 3.2.3). Notably C16 and C4 are most highly conserved in the C-terminal 100 aa, 
where they share 55 % identity and 70 % similarity. The level of conservation of C4 within 
OPVs is more substantial than that of C16, and two of the viruses which do not express C16 
viruses (CMLV and MPXV) are predicted to express full length C4 proteins (Figure 3.2.4). 
Only the VACV TianTan strain encodes a truncated C4 protein. The C4 proteins all express a 
variant on the VTRFYF terminal sequence highlighted earlier (which showed the IL-1Ra-
similar immunosuppressive quality) present in all C16 orthologues (Kluczyk et al., 2004; 
Kluczyk et al., 2002). The C4 variant is VTKYYI as indicated in the circle in Figure 3.2.4.  
 
Table 3.2.3  
 
% C16 
Identity 
%C16 
similarity 
% C4 
Identity 
% C4 
Similarity 
Aa of 
C4 
VACV WR 
(C4) 44 64 100 100 1-316 
VACV 
Lister 
(m80023) 43 64 100 100 - 
VACV Tian 
Tan (C4L) 40 60 99 99 254 
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VACV COP 
(027) 43 64 100 100 - 
CXPV -  
GRI90 
(030) 44 63 99 100 - 
CXPV 
Brighton 
Red (033) 44 63 95 99 - 
VARV 
major India 
(D11L) 44 63 96 99 - 
VARV 
minor 
Garcia 
(B17L) 44 63 97 99 - 
CMLV 
CMS (22L) 44 63 97 99 - 
MPXV 
(D13L) 44 65 95 97 - 
TATV 
Dahomy 
1968 (025) 44 63 97 99 - 
 
Table 3.2.3 Amino acid comparison of C16 and C4-like proteins to VACV WR C16- 
Percentage identity and similarity. Protein sequences were compared to VACV WR C16 by 
sequence comparison on the www.poxvirus.org website to give a table illustrating the level of 
identity and similarity between the C16 protein from VACV WR strain and C4 proteins from 
a range of vaccinia virus strains and from the orthopoxvirus genus. For truncated proteins, the 
relevant region of C4 is indicated on the right. 
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 Figure 3.2.4 Amino acid alignment of C16 and C4-like proteins.  Protein sequences were 
compared by ClustalW via Biology Workbench 3.2 website (see workbench.sdsc.edu). 
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Yellow, green and cyan indicate conserved, identical and similar residues, respectively. A 
circle indicates the VTRFYF sequence of IL-1Ra similarity. 
 
A third group of poxvirus proteins related to C16 include proteins with much lower sequence 
similarity. This set is comprised of proteins from poxviruses outside the OPV genus, namely 
goatpox virus (GPXV), lumpy skin disease virus (LSDV), sheeppox virus (SPPV) (Capripox 
genus), Yaba monkey tumour virus (YMTV) (Yatapoxvirus genus) and deerpox virus 
(DPXV) (unclassified) (Figure 3.2.6). These proteins are more like the C16 protein than C4, 
but bear similarity to both (Table 3.2.5). Of the proposed IL-1Ra C-terminal amino acid 
sequence, YTRFYF, a highly conserved consensus sequence of Y-R-YF remains as indicated 
in Figure 3.2.6. 
 
Table 3.2.5 
 
C16% 
Identity 
C16% 
Similarity 
C4% 
Identity 
C4% 
Similarity 
DPXV-W848 83 
007 37 61 32 54 
GPXV Pellor 005 33 55 25 48 
LSDV-1959-007 33 55 26 49 
SPPV-NISKHI-005 31 52 26 48 
YMTV-RPV-001 27 45 26 48 
Table 3.2.5 Amino acid comparison of C16 and C4-like proteins from viruses outside 
the orthopoxvirus genus to VACV WR C16 - Percentage identity and similarity. Protein 
sequences were compared initially by sequence comparison on the www.poxvirus.org 
website to give a table illustrating the level of identity and similarity between the C16 protein 
from VACV WR strain and C4 proteins from a range of VACV strains and from the OPV 
genus. 
 
 
 122
  
 123
Figure 3.2.6 Amino acid alignment of C16-like proteins from other poxviruses. Protein 
sequences were compared by ClustalW via Biology Workbench 3.2 website (see 
workbench.sdsc.edu). Yellow, green and cyan indicate conserved, identical and similar 
residues, respectively. A circle indicates the VTRFYF sequence of IL-1Ra similarity. 
 
The phylogenetic relationships of all these proteins are summarised in a rooted tree (Figure 
3.2.7) produced from the aligned aa sequences. Group I proteins are the C16 orthologues 
from other OPVs as aligned in Figure 3.2.2. The group II proteins are formed from the C4 
family of proteins as detailed in Figure 3.2.4. While the third group (III) of proteins 
comprises the more distantly related proteins from other chordopoxviruses including goatpox 
virus (GPXV), lumpy skin disease virus (LSDV), sheeppox virus (SPPV) (all genus 
Capripoxvirus), fowlpox virus (FWPV) and canarypox virus (CNPV) (genus Avipoxvirus), 
Yaba monkey tumour virus (YMTV) (genus Yatapoxvirus) and deerpox virus (DPXV) 
(unclassified) as shown in Figure 3.2.6.  
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Figure 3.2.7 Phylogenetic tree of C16-like proteins. A rooted phylogenetic tree of VACV 
WR C16 and related poxvirus proteins. Aa sequences from C16-like proteins 
 125
(www.poxvirus.org) were aligned using programme CLUSTAL W and a rooted tree was 
derived from this alignment using PHYLIP (phylogeny inference package, version 3.67). The 
bootstrap values for 1000 replica samplings are indicated, values of 1000 are indicated by *. 
The scalebar indicates the branch length of 0.1 substitutions per site.  
 
3.2.2 Analysis of C16 promoter and termination sequences 
The transcription of early genes is regulated by specific A/T-rich promoter sequences that are 
located immediately upstream of the RNA start sites, and these specify the site of 
transcriptional initiation (Cochran et al., 1985; Ink and Pickup, 1989; Weir and Moss, 1987a). 
A consensus sequence has been identified from -28 and -13 (relative to the RNA start site) of 
AAAAAATGAAAAAAA/TA, although variations are found normally in all early genes 
(Davison and Moss, 1989a). This is separated by a T-rich spacer sequence from -12 to -2, 
which is followed by a 7-bp region (-1 to +6) within which initiation occurs, usually with a 
purine (Davison and Moss, 1989a). The 3’-ends of VACV early mRNA transcripts are 
formed 20-50bp downstream of the sequence TTTTTNT, where N represents any nucleotide 
(Piacente et al., 2008; Rohrmann and Moss, 1985; Yuen and Moss, 1986; Yuen and Moss, 
1987). 
 
The sequence of the C16L gene and the surrounding region of genome were studied to 
identify promoter and termination sequences.  Analysis of the DNA sequence upstream of 
C16L identified an upstream A/T-rich sequence as occurs most frequently in early promoters 
(Figure 3.2.8; highlighted in light blue). It is difficult to identify an exact consensus sequence 
comparable to the early promoter sequence identified (Davison and Moss, 1989a). The 
closest sequence to this is highlighted in light blue. As predicted four nucleotides downstream 
is a T-rich spacer sequence as indicated in light green (Davison and Moss, 1989a).  The 3’-
ends of VACV early mRNA transcripts are formed downstream of the sequence TTTTTNT, 
where N represents any nucleotide (Piacente et al., 2008) and two potential stop early 
termination signals are indicated in dark blue (Figure 3.2.8) 
 
Analysis of the sequence of the upstream region of C16 shows the sequence of an 
intermediate gene promoter upstream, TAAA (both underlined in Figure 3.2.8). However, 
intermediate gene promoters consist of two important regions. The TAAA is accompanied 
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14-bp upstream by an A/T-rich 14-bp – this cannot tolerate non A/T residues at positions -22, 
-21, -19 to -17 and -15 to -13. Both the potential TAAA sequences upstream of C16, do not 
contain just A/T at these essential residues (Baldick et al., 1992) and hence these TAAA 
sequences are unlikely to act as intermediate initiation signals. There is a potential late 
initiation sequence, the underlined and shadowed TAAAAT moiety as indicated on Figure 
3.2.8. The other requirement of a late transcription initiation sequence is an A/T rich region 
upstream of this TAAAAT which can be seen upstream of C16.  
 
Transcript analysis published recently has seen C16 mRNA transcripts from as early as 0.5 
h.p.i. indicating that this is an early gene (Assarsson et al., 2008). This study, combined with 
the presence of a suggested early initiation consensus sequence and an exact early 
termination sequence, implies that C16 is expressed early in infection. This will be 
investigated further in section 3.3 
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AAACATTACTAAAAAAATATATTGTTCTGTTTTTCTTTCACATCTTTAATTATGA
AAAAGTAAATCATTATGAGATGGACGAGATTGTACGCATCGTTCGCGACAGTATG
TGGTACATACCTAACGTATTTATGGACGACGGTAAGAATGAAGGTCACGTTTCTG
TCAACAATGTCTGTCATATGTATTTCACGTTCTTTGATGTGGATACATCGTCTCA
TCTGGTAATATACAATTCCATAACCCATTGACAGTTGTTATACATCAAAATTGCA
ATTCTTTTGATTACGATGTTATAAGAATGTAGTTAATTGATGTATGATGTTAATG
TGTCCTCTTTCCTCTTATAACATCGTAATCAAAAACTTTTTTATAATATATACCT
AATAATGTGTCTTAATAGTTCTCGTGATTCGTCAAACAATCATTCTTATAAAATA
TAATAAAGCAACGTAAAACACATAAAAATAAGCGTAACTAATAAGACAATGGA
TAAA
TA
TTTACGACGATAAAGGTCTACAGACTATTAAACTGTTTAATAATGAATTTGATTG
TATAAGGAATGACATCAGAGAATTATTTAAACATGTAACTGATTCCGATAGTATA
CAACTTCCGATGGAAGACAATTCTGATATTATAGAAAATATCAGAAAAATACTAT
ATAGACGATTAAAAAATGTAGAATGTGTTGACATCGATAGTACAATAACTTTTAT
GAAATACGATCCAAATGATGATAATAAGCGTACGTGTTCTAATTGGGTACCCTTA
ACTAATAACTATATGGAATATTGTCTAGTAATATATTTGGAAACACCGATATGTG
GAGGCAAAATAAAATTATACCACCCTACAGGAAATATAAAGTCGGATAAGGATAT
TATGTTTGCAAAGACTCTAGACTTTAAATCAAAGAAAGTGTTAACTGGACGTAAA
ACAATTGCCGTTCTAGACATATCCGTTTCATATAATAGATCAATGACTACTATTC
ACTACAACGACGACGTTGATATAGATATACATACTGATAAAAATGGAAAAGAGTT
ATGTTATTGTTATATAACAATAGATGATCATTACTTGGTTGATGTGGAAACTATA
GGAGTTATAGTCAATAGATCTGGAAAATGTCTGTTAGTAAATAACCATCTAGGTA
TAGGTATCGTTAAAGATAAACGTATAAGCGATAGTTTTGGAGATGTATGTATGGA
TACAATATTTGACTTTTCTGAAGCACGAGAGTTATTTTCATTAACTAATGATGAT
AACAGGAATATAGCATGGGACACTGATAAACTAGACGATGATACAGATATATGGA
CTCCCGTCACAGAAGATGATTACAAATTTCTTTCTAGACTAGTATTGTATGCAAA
ATCTCAATCGGATACTGTATTCGACTATTATGTTCTTACTGGTGATACGGAACCA
CCCACTGTATTCATTTTCAAGGTAACTAGATTTTACTTTAATATGCCGAAA
AAATTTTTGTATAATATCTAGAGGTAGAGGTATTGTTTAGATAAATACAAATAAC
ATAGATACATCGCATACTTAGCATTTTTAT
 
Figure 3.2.8 Analysis of VACV WR C16L sequence. This shows the sequence of C16 from 
the ATG start codon to the TAA stop codon as indicated in read. The sequence of C16L 
shows the presence of an A/T rich sequence which is most common in early promoters (light 
blue), followed by a T-rich spacer sequence (light green). The potential intermediate start 
sites are underlined, while the well-characterised late promoter TAAAT element is indicated 
underlined and shadowed. A consensus sequence for the early termination sequence is 
indicated at the end of the gene in dark blue. 
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3.2.3 Bioinformatic analysis of C16 protein 
There is no putative signal sequence in the C16 protein indicating that the C16 protein is not 
secreted from the cell. A hydrophobicity plot (Kyte and Doolittle, 1982) rejects any proposal 
that C16 is likely to be a membrane-integrated protein or one that contains transmembrane 
domains. Therefore, it is probable that C16 is an intracellular protein. Analysis of the 
intracellular localisation of C16 (four topology prediction programmes on 
(http://ca.expasy.org/tools/) indicates that C16 lacks a nuclear localisation signal, or a signal 
targeting C16 to any other intracellular compartment. Prediction of the secondary structure of 
the protein using three different online prediction programmes (http://ca.expasy.org/tools/) 
suggests that C16 is predominantly β-sheet in secondary structure. The C16 protein contains 
3 potential N-linked glycosylation sites although these are probably irrelevant given its 
predicted subcellular location. A number of predicted phosphorylation sites were identified 
using online search programmes online (www.ctds.tdk.eu). One of the consistent predictions 
is a PKA phosphorylation site at serine 211, which is found within the region 
RGSKCnLLVN, which is conserved within the C16 and C4 protein of viruses both within 
and outside of the OPV genus. A further region of high conservation surrounds threonine 
309, a proposed site of CKII phosphorylation.  
 
3.3  Expression of C16 in VACV-infected cells 
To identify the C16 protein in infected cells required the production of a polyclonal rabbit 
anti-C16 serum, raised against the C16 protein expressed in E. coli. This was used in 
immunoblot and immunoprecipitation analyses to determine if and when the protein is 
expressed, its size, location and expression in a range of OPVs. 
 
 3.3.1. Production of a rabbit anti-C16 polyclonal serum 
Rabbit anti-C16 polyclonal serum was raised against a His6–C-tagged-C16 protein which had 
been prepared by large scale expression by Dr. Richard H Clark. This is detailed more fully 
in Materials and Methods (section 2.3). In summary, blood was removed from two New 
Zealand white rabbits to act as pre-immune sera and this was checked by immunoblot 
analysis against VACV-infected cells to ensure that there was a minimal background. The 
rabbits were then immunised subcutaneously with 100–200 µg of protein in complete 
Freund’s adjuvant. Four boosters were made in incomplete Freund’s adjuvant at 
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approximately four weekly intervals and 10 to 20 ml of blood was removed 10 days after 
each immunisation. One rabbit produced antibodies to a VACV-specific protein after the 
second immunisation, which increased in avidity up to the terminal bleed. The terminal bleed 
from this rabbit was used in all immunoblotting and immunofluorescence analysis which 
follows. 
 
 3.3.2 C16 is expressed as a 37-kDa protein in VACV-infected cells.  
The first experiments undertaken after the production of the C16 antibody aimed to establish 
the expression patterns of C16 in WR and to confirm its absence in the deletion virus. 
 
BSC-1 cells were infected with either vC16, or the deletion mutant, v∆C16, in which both 
copies of the C16L gene had been deleted (viruses described in chapter 4). Proteins 
concentrated from the cell culture medium and those present in the the cell lysates were 
resolved by SDS-PAGE and then immunoblotted using the anti-C16 serum, detailed above. A 
protein of 37 kDa, approximately the predicted size for C16, was detected in the cell lysates 
of the vC16-infected cells but not in the ∆C16-infected cells showing that the C16L gene is 
expressed and confirming the Ab specificity (Figure 3.3.1). The absence of C16 in the 
concentrated cell supernatants also shows that C16 is not secreted, indicating that any 
functional homology to the IL-1Ra protein would be exerted in the context of the intracellular 
roles of this protein (icIL-1Ra) (Kluczyk et al., 2002).  
 
In addition to the 37-kDa protein, a 25-kDa protein was also detected by the anti-C16 Ab. 
This protein is also absent from the deletion virus suggesting it may be a fragment of the C16 
protein.  
 
The absence of any protein between 30 and 40 kDa in v∆C16-infected cells or supernatants 
shows that the anti-C16 antibody does not recognise the C4 protein despite their sequence 
similarity.  
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To establish that infections with both viruses were comparable, the samples were probed with 
a rabbit anti-A41 serum, raised against the VACV A41 protein, a 30-kDa protein that is 
secreted from infected cells (Ng et al., 2001) and with a mAb against the D8 protein present 
in infected cells and the IMV surface (Niles and Seto, 1988). As expected, A41 was found in 
the supernatant fraction of from cells infected with either vC16 or v∆C16. Similarly, D8 was 
detected in both cell lysates.  
C16
A41
D8
C S C S
v∆C16vC16
36
22
36
22
22
36
 
Figure 3.3.1. Immunoblot analysis of C16 expression in VACV-infected cells. 
Monolayers of BSC-1 cells were infected at 10 p.f.u./cell with vC16 or v∆C16. Cells and 
supernatants were harvested at 16 h.p.i. and the cells were lysed with RIPA buffer. The 
supernatants were concentrated using a Centricon YM-3 concentrating filter. Equivalent 
samples of proteins from supernatant (S), and cell lysates (C) were separated by SDS-PAGE, 
transferred to nitrocellulose and detected with anti-C16 antibody diluted 1:2000. Blots were 
stripped and reprobed with antibodies to either D8, a cellular protein, (1:1000) or A41, a 
secreted protein (1:500). Bound antibodies were detected with HRP-conjugated goat anti-
rabbit IgG antibody (Sigma-Aldrich) (C16 and A41) or HRP-conjugated goat anti-mouse IgG 
antibody (Sigma-Aldrich) (D8) both diluted 1:2000 and ECL reagents (Amersham). Positions 
of molecular mass markers are shown on the left with sizes in kDa.  
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  3.3.3 C16 is expressed early during VACV infection 
Gene analysis had indicated that the C16L gene might be expressed early during infection. To 
investigate this, the time of C16 expression was followed by harvesting infected cells at 
various times p.i. and immunoblotting the cell lysates with anti-C16 Ab (Figure 3.3.2). The 
cell lysates were also blotted with a rabbit serum for a late VACV protein, A56, to confirm 
that these infections and timepoints were characteristic of published analysis. AraC is an 
inhibitor of DNA synthesis that consequently shuts down expression of late VACV proteins. 
The C16 protein was first detected 0.5 h.p.i. confirming that this is indeed an early protein. At 
later times, the level of expression increased and was still detectable 24 h.p.i., C16 expression 
was unaffected by the presence of AraC. Therefore, the C16 protein is expressed early during 
infection, prior to DNA replication. In contrast, A56 was first detected at 6 h.p.i., and its 
expression was shutdown in the presence of AraC, indicating that while this protein was 
predicted to be an early/late protein (Sanderson et al., 1998a), under these conditions, 
expression is only seen at late time points, and in the absence of AraC.  
 
The 25-kDa C16 protein was first detected at 4 h.p.i., but was not detected in the presence of 
AraC. This may indicate that this protein is cleaved by a viral protease, expressed late during 
infection or by a cellular protease activated late during infection. Alternatively, there may be 
a cryptic late promoter sequence in the middle of the C16L gene or an internal initiation 
sequence, prompting late expression of a shorter C16 product. The latter possibility was 
investigated bioinformatically later (Section 3.5) 
36
22
98
64
A56
C16
0.5 2 4 6 8 12 16 24 h.p.i.2412
+AraC
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Figure 3.3.2 C16 is expressed early during infection 
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BSC-1 cells were infected with vC16 or v∆C16 at 10 p.f.u./cell in the absence or presence of 
AraC. At the indicated times p.i., cells were harvested, cell lysates were prepared. These were 
separated by SDS-PAGE (12 % acrylamide) and analysed by immunoblotting. Blots were 
detected initially with anti-C16 (1:2000), then stripped and redetected with anti-A56 
(1:1000). The molecular mass markers are shown on the left with sizes in kDa.  
 
3.3.4 C16 localises to the nucleus and the cytoplasm of HeLa cells 
Biochemical analysis of localisation 
The subcellular localisation of C16 was investigated by immunoblotting and by 
immunofluorescence. Cells were either mock-infected or infected with VACV vC16, v∆C16 
or vC16Rev (described in chapter 4). Cell lysates were then fractionated into nuclear and 
cytoplasmic fractions before proteins were separated by SDS-PAGE and immunoblotted 
(Figure 3.3.3). Cellular proteins, tubulin and lamin A+C, known to localise to either the 
cytoplasm or nucleus respectively, were used as controls, together with the viral cytoplasmic 
protein, D8. These proteins localised to the expected compartments demonstrating that the 
fractionation process was efficient. C16 was detected in both the nuclear and the cytoplasmic 
fractions, in the vC16 and vC16Rev, but was absent in the fractions from the deletion virus 
and mock-infected samples. This is despite the absence of an obvious nuclear localisation 
signal (NLS) in the C16 protein. The presence of D8 in the cytoplasmic samples confirmed 
equivalent infection with all viruses. The smaller C16 product was not seen in the nucleus, 
even with over-exposed blots.   
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Figure 3.3.3 C16 localises to the cytoplasm and nucleus as determined by biochemical 
analysis. Cells were mock-infected or infected with v∆C16, vC16, or vC16Rev 10 p.f.u./cell 
for 16 h, before cells were harvested and fractionated into cytoplasmic and nuclear fractions. 
Proteins were separated by SDS-PAGE (12 % acrylamide) and immunoblotted with 
antibodies to the proteins indicated above. The positions of molecular mass markers are 
shown with sizes in kDa.  
 
 Immunofluorescence analysis of localisation 
The subcellular localisation of C16 was analysed further by immunofluorescence. Cells were 
either mock-infected or infected for the indicated time with vC16 and then fixed with PFA, 
permeabilised by treatment with Triton-X 100 and probed with anti-C16 rabbit serum 
followed by secondary conjugate. Microscopic analysis showed only minimal background in 
uninfected cells or time 0 h time point cells (Figure 3.3.4a, b). In vC16-infected cells, C16 
showed a cytosolic and nuclear localisation pattern (Figure 3.3.4c and d) with marked 
 134
exclusion from the nucleoli at late time points in infection (Figure 3.3.4d). At 4 h and 8 h.p.i., 
the localisation was predominantly nuclear (Figure 3.3.4). Immunoblotting analysis at 16 
h.p.i. (Figure 3.3.3) and immunofluorescence analysis at 16 h.p.i. (Figure 3.3.5) show that at 
later time points, C16 distribution accumulates in the cytoplasm and the nucleus. 
 
Uninfected vC16 0h
vC16 4h vC16 8h
d)
a)
c)
b)
10um
5um 5um
10um 10um
 
Figure 3.3.4 C16 localises to the cytoplasm and nucleus as determined by 
immunofluorescence analysis.  Cells were mock-infected or infected with vC16 for 0 h, 4 h 
or 8 h. Cells were fixed with PFA, permeabilised and probed with an anti-C16 antibody at a 
1:500 dilution, and an anti-rabbit TritC-conjugated secondary antibody. Phase contrast and 
merged images are also shown, scale bars are 5 µm or 10 µm as indicated.  
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 C16 is shuttled in and out of the nucleus 
C16 is present in the nucleus, but it was unclear if this was due to passive diffusion or active 
import. To investigate this HeLa cells were infected for 16 h, and then cells were treated with 
LMB, an inhibitor of nuclear export protein Crm1 for 2 h (Figure 3.3.5). This showed that 
C16 accumulated in the nucleus on inhibition of nuclear export (Figure 3.3.5e), and therefore 
the presence of C16 in the nucleus is because of active transport rather than passive diffusion. 
As a control, cells were also probed with a mAb that detects the p65 protein subunit of NF-
κB, which is actively translocated between the cytoplasm and the nucleus (Figure 3.3.5b, f). 
The p65 protein also accumulated in the nucleus on treatment with LMB indicating nuclear 
export was inhibited under these conditions (Figure 3.3.5f). 
a)Anti-C16
Untreated Treated with leptomycin B 
f) Anti-p65b)Anti-p65 e)Anti-C16
g)c) d)
5um 5um
h)  
Figure 3.3.5 C16 actively translocates in and out of the nucleus.  HeLa cells were infected 
with vC16 for 16 h and then incubated in the presence or absence of LMB for 2 h. Cells were 
fixed with PFA, permeabilised and probed with an anti-C16 Ab followed by an anti-rabbit 
TritC-conjugated secondary antibody. Cells were also stained with an anti-p65 mouse mAb 
followed by an anti-mouse FITC-conjugated secondary Ab. The localisation of C16 (a, e) and 
NF-κB subunit p65 (b, f) were analysed. Phase contrast and merged images are also shown 
(c, g) and (d, h) respectively. Scale bar = 5 µm. 
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  Immunofluorescence analysis of localisation in transfected cells 
C16 lacks an obvious NLS and therefore must either have a novel NLS or associate with 
another protein which possesses the necessary signals to translocate in and out of the nucleus. 
This may be a cellular or a viral protein. To investigate this, the localisation of C16 was also 
investigated in uninfected cells after expression of C16 by transfection. Cells were 
transfected with pCI-C16 (a plasmid in which the C16L ORF is positioned downstream of the 
human cytomegalovirus immediate early promoter) for 24 h. Cells were then fixed, 
permeabilised and stained with anti-C16 (Figure 3.3.6). C16 was expressed in approximately 
25 % of cells and a clear difference was evident in transfected (yellow arrow) and 
untransfected (blue arrow) cells. Notably in the absence of other VACV proteins C16 still 
localised predominantly in the nucleus.  
 
10um
d) Anti-C16 f) Anti-IL-1Ra
d)
b) Anti-IL-1Ra 
backgrounda) Anti-C16
c)b) f)e)
10um
 
Figure 3.3.6 C16 shows a nuclear localisation pattern in transfected cells.  Cells were 
transfected with pCI-C16 for 24 h. The localisation of C16 (a, d) was analysed. Cells were 
fixed with PFA, permeabilised and probed with an anti-C16 polyclonal rabbit antibody at a 
1:500 dilution. Phase contrast and merged images are also shown (c, g) and (b, f) 
respectively. Scale bar = 10 µm. 
 
3.3.5 C16 is expressed by all VACV and CPXV strains examined 
The bioinformatic analysis (section 3.2) indicated that the sequenced stains of CPXV and 
VACV strains all encode C16. In our laboratory we have several other strains of VACV 
(VACV strains Tashkent, Patwadangar, IHD-J, IHD-W, Dairen, USSR, King’s Institute, 
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Buffalopox, Copenhagen, Wyeth, Evans, Lister and MVA) and other OPVs (CMLV and two 
CPXV strains), most of which have not been sequenced. Therefore, to investigate if these 
strains also expressed C16, BSC-1 cells were infected by each virus and cell lysates were 
analysed by immunoblotting for C16 and D8 (Figure 3.3.7). The D8 protein was evident in all 
virus-infected cell lysates, including that of the deletion virus, indicating cells were infected. 
Similarly, C16 was expressed by all viruses, except v∆C16. C16 had some small size 
differences between viruses, and in some strains the putative cleavage product of C16 was 
not detected (see section 3.5). 
 
C16 is expressed by all 14 VACV strains investigated experimentally. Sequence analysis had 
shown that of the 16 sequenced VACV strains (4 of which were also investigated 
experimentally), all contain intact C16L ORFs with 98 % identity to VACV WR C16L. Thus 
all strains of VACV analysed, either by immunoblotting or bioinformatics on published 
sequences, indicating that C16 is a highly conserved VACV protein. 
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Figure 3.3.7 The C16 protein is expressed by all VACV and CPXV strains tested. BSC-1 
cells were mock-infected or infected at 10 p.f.u./cell with the indicated viruses. At 16 h.p.i., 
cells were harvested and lysed. The proteins were separated by SDS-PAGE and 
immunoblotted with the anti-C16L rabbit Ab (1:2000) or anti-D8 mouse mAb (1:2000). 
Positions of molecular mass markers are shown on the left with sizes in kDa. 
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 3.4  Expression of the C16 protein in E. coli 
The C16L ORF from WR was amplified by PCR using genomic DNA templates by Dr. 
Richard H. Clark and Miss Emily Glyde. The pET28a plasmid was chosen for expression of 
C16 protein because it would add a C-terminal six-histidine tag enabling purification of C16 
by nickel affinity chromatography.  The C16L ORF was amplified by PCR using primers 
AF9 (5’-AGATCCATGGGTGATATTTACGACGATAAAGGTCTACAG-3’) and AF10 (5’-
AGATGAATTCCCGCTGCCGCGCGGCACCAGTTTCGGCATATTAAAGTAAAATC-3’) 
and VACV WR DNA as template. The product was digested with NcoI and EcoRI (indicated 
in italics) and cloned into NcoI- and EcoRI-digested pET28a (Novagen) and the resultant 
plasmid, pET28a-C16L-CHis, was termed pAFE and was verified by DNA sequencing.  
 
This was used to transform E. coli strain BL21 for protein production. After analysis of 
protein expression and solubility under a range of different induction conditions (undertaken 
by Dr. Richard H. Clark and Miss Emily Glyde, so not shown in this thesis), it was 
determined that cultures of transformed E. coli grown to an OD600 of 0.4 and then induced for 
expression with 0.5 mM IPTG at 30 ºC for 5 h produced the greatest percentage of soluble 
C16 protein as examined by SDS-PAGE and immunoblotting. 
 
Purification of C16 was attempted to provide material for in vitro assays (section 3.5) and for 
structure determination by protein crystallography.  However, this purification of C16 also 
garnered details of the oligomeric state of recombinant C16. Bacterial cells induced to 
express C16-CHis were harvested, sonicated, centrifuged and the soluble fraction was applied 
to a 5 ml His-trap column (GE Healthcare) as detailed in Materials and Methods (section 
2.3.3). After extensive washing to remove unbound protein, bound material was eluted with 
imidazole and the resulting chromatogram (Figure 3.4.1a) revealed a single sharp peak of 
eluted protein. Analysis of these fractions by SDS-PAGE and stained by Coomassie staining 
showed a 37-kDa protein (Figure 3.4.1c). The fractions were also immunoblotted with an 
anti-His antibody (Figure 3.4.1b) and this detected both the 37-kDa protein and a smaller 
protein of approximately 25 kDa, the nature of which was then investigated in the next 
section.  
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Figure 3.4.1 Expression and purification of His-tagged C16 from E. coli. a) After 0.5 mM 
IPTG induction, the cell extract containing CHis-C16 was applied to a HisTrap column. 
CHis-C16 was eluted from the Ni2+ affinity column with an increasing imidazole gradient. 
Protein was monitored by absorbance at A280nm (blue line) and fractions collected are 
indicated by red lines. The indicated fractions were analysed by SDS-PAGE (12 % 
acrylamide) and detected by immunoblotting with a monoclonal mouse antibody against the 
His tag (b) and by Coomassie blue staining (c). The sizes of molecular mass markers are 
indicated in kDa. 
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 To purify C16 further, fractions 12-20 from the HisTrap column were pooled, concentrated 
using a Centricon YM-10 filter and loaded on a Superdex 200 column for size-exclusion 
chromatography. C16 eluted at multiple peaks (Figure 3.4.2a). Comparison with protein size 
markers indicated that C16 eluted at sizes that are approximately those of a putative monomer 
(fraction 10), dimer (fraction 7) and tetramer (fraction 5). The smaller protein detected by 
anti-His mAb eluted in fractions 13-16 and was therefore excluded from fractions containing 
most of C16. 
 
This protein identified in fraction 16 was initially thought to be a C16 cleavage product. 
However, this was not recognised by the anti-C16 antibody (even on overexposed blots), but 
was detected by the anti-His antibody. This protein is most likely an E. coli protein, YodA, 
known for its histidine-rich nature, which eluted in small quantities in the C16 fractions from 
the His-column, and was detected by the anti-His Ab. Notably this contaminant was removed 
by separation by size-exclusion chromatography.  
 
The multimeric state of C16 in these fractions was analysed by native non-reducing PAGE 
(Figure 3.4.2b). These multiple bands of distinct sizes indicate that recombinant C16 can 
form multimers. This native non-reducing PAGE gel was transferred and blotted for C16. 
This shows that C16 is only present in fractions 5, 7 and 10 (Figure 3.4.2c). The fractions 
were also analysed by denaturing reducing SDS-PAGE analysis (Figure 3.4.2d) which 
indicates that only fractions 5, 7 and 10 contain pure C16 protein (even on overexposed 
blots). The denaturing reducing gel (Figure 3.4.2d) was also transferred and immunoblotted 
with an anti-His antibody (Figure 3.4.2e).  
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Figure 3.4.2 Purification of C16 by size-exclusion chromatography. a) Fractions 
containing CHis-C16 from His-Trap column (Figure 3.4.1) were pooled and concentrated, 
before being loaded in 0.5ml onto a Superdex 200 gel filtration column. Protein was 
monitored by absorbance at A280nm (blue line) and the fractions collected are indicated by 
 142
red lines. These were analysed by native gel electrophoresis and detected by Coomassie 
staining (b) as well as immunoblotting with anti-C16 Ab (c). The fractions were also 
separated by SDS-PAGE and immunoblotted with an anti-His antibody (c). The sizes of 
molecular mass markers are indicated in kDa. 
 
3.5  Proposed post-translational modifications of C16  
3.5.1 C16 25-kDa protein 
As it was established that recombinant C16 expressed as a full-length 37-kDa protein in 
bacterial expression systems, the nature of the smaller C16 product seen in viral infections 
(Section 3.3) was analysed further. The 25-kDa protein detected by the anti-C16 Ab might 
have been formed by proteolytic cleavage of the full length protein or different translation. 
This cleaved product was seen in vC16-infected cells (Figure 3.3.1), but was not seen at 
comparable levels in transfected cells (Figure 3.5.1b) or in a bacterial expression system 
(Figure 3.5.1a). This implies that the shorter product is not merely the product of inherent 
protein instability.   
 
Furthermore, while this shorter product is evident in vC16-infected cells (Figure 3.3.1), it is 
not present in cells infected with VACV strains COP, Dairen and Tashkent (Figure 3.3.7). 
This indicates that the generation of the shorter protein product is the product of a specific 
viral event and that a difference either in the C16 sequence or in one of the other virus 
proteins in vC16 and VACV COP is responsible for generation of this 25-kDa C16 product. 
Another potential clue as to the origin of the protein is that this smaller product is not present 
when virus-infected cells are treated with AraC, an inhibitor of late viral gene expression. 
 
These data suggest 2 hypotheses for how the C16 shorter product might be formed: 1) the 
product is translated from a shorter mRNA because of a cryptic late promoter or termination 
sequence within the C16L ORF, which is present in VACV WR and most other VACV 
strains, but not in VACV COP, Tashkent and Dairen; and 2) the 25-kDa protein is formed by 
proteolytic cleavage of the 37-kDa C16 protein and this requires a late virus protein either as 
the protease, or as a co-factor to a cellular protease. A difference in the presence or activity of 
this protein in VACV WR and VACV COP would be needed to explain the difference 
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between these viruses. To investigate these possibilities the nucleotide sequences of VACV 
WR C16L and VACV COP C10L ORF (Figure 3.5.2a) and the protein sequence of VACV 
WR C16 and VACV COP C10 proteins was analysed (Figure 3.5.2b). 
 
Late mRNAs are transcribed from a late promoter consensus sequence (see section 1.4.4), 
and are long and heterogeneous in length (Ahn and Moss, 1989; Mahr and Roberts, 1984). 
Hence it is highly unlikely that the differences seen between VACV strains COP and WR can 
be attributed to a late termination sequence. However, there could be a late promoter in 
VACV WR but not COP, which is translated to give the 25-kDa C16 protein. To address this, 
the nucleotide sequence within 100 bp of the relevant region of C16 (i.e. that which would 
give an appropriately sized protein) (in the region between the # symbols in Figure 3.5.2a) 
was analysed. This does not contain a TAAAT sequence (late transcription initiation site) 
ruling out standard initiation of late transcription. To analyse whether there may be a cryptic 
late transcription initiation site, comparison between VACV WR and VACV COP was 
undertaken. This showed no difference in nucleotide sequence between C16L (WR) and 
C10L (COP), ruling out the possibility of a cryptic late shorter transcription event to produces 
a shorter form of C16 in WR, but not in COP. 
 
To analyse any potential for difference in proteolytic cleavage, the protein sequence was 
analysed. This shows only three changes in protein sequence between C10 and C16. One of 
these changes is two aas from the C terminus and so cannot be a site for cleavage leading to 
generation of a 25-kDa product. The other two are approximately midway through the 
sequence, and would generate products of 19.3 and 19.1 kDa (for site i) as indicated on 
Figure 3.5.2b) or 20.4 and 18 kDa, respectively (for site ii) as indicated on Figure 3.5.2b). 
Hence these changes are unlikely to result in the 25 kDa product as seen in vC16-infected 
cells. 
   
Pulse-chase analysis will be necessary to identify a precursor-product relationship between 
C16 and the shorter product. In the absence of such data, and in the context of the rest of the 
data presented, it seems that C16 may be cleaved by a proteolytic event instigated or 
activated by a late viral protein, the activity of which diverges between VACV WR and 
VACV COP. 
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Figure 3.5.1 Expression of C16 in bacterial expression and cellular expression systems. 
(a) C-His- and N-His-tagged C16 was expressed in E. coli and the bacteria were lysed as 
above. Proteins in the soluble fraction were separated by SDS-PAGE and immunblotted with 
the anti-His mAb (b) Plasmids encoding C16 were transfected into HeLa cells and 24 h 
later extracts were prepared and analysed by SDS-PAGE and immunoblotting with anti-HA 
mAb (left panel) or anti-C16 Ab (right panel). The positions of protein size markers (in kDa) 
are shown.  
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COP_C10       MDIYDDKGLQTIKLFNNEFDCIRNDIRELFKHVTDSDSIQLPMEDNSDIIENIRKILYRR
WR_C16        MDIYDDKGLQTIKLFNNEFDCIRNDIRELFKHVTDSDSIQLPMEDNSDIIENIRKILYRR
COP_C10       LKNVECVDIDSTITFMKYDPNDDNKRTCSNWVPLTNNYMEYCLVIYLETPICGGKIKLYH
WR_C16        LKNVECVDIDSTITFMKYDPNDDNKRTCSNWVPLTNNYMEYCLVIYLETPICGGKIKLYH
COP_C10      PTGNIKSDKDIMFAKTLDFKSKKVLTGRKTIAVLDISVSYNRS I N
M D
L
P
TTIHYNDDV IDIHTD
WR_C16        PTGNIKSDKDIMFAKTLDFKSKKVLTGRKTIAVLDISVSYNRS TTIHYNDDV IDIHTD
COP_C10      KNGKELCYCYITIDDHYLVDVETIGVIVNRSGKCLLVNNHLGIGIVKDKRISDSFGDVCM
WR_C16        KNGKELCYCYITIDDHYLVDVETIGVIVNRSGKCLLVNNHLGIGIVKDKRISDSFGDVCM
COP_C10      DTIFDFSEARELFSLTNDDNRNIAWDTDKLDDDTDIWTPVTEDDYKFLSRLVLYAKSQSD
WR_C16        DTIFDFSEARELFSLTNDDNRNIAWDTDKLDDDTDIWTPVTEDDYKFLSRLVLYAKSQSD
COP_C10      TVFDYYVLTGDTEPPTVFIFKVTRFYFNM K
WR_C16        TVFDYYVLTGDTEPPTVFIFKVTRFYFNM K
b)
COP_C10          TCTTAATAGTTCTCGTGATTCGTCAAACAATCATTCTTATAAAATATAATAAAGWR_C16           TCTTAATAGTTCTCGTGATTCGTCAAACAATCATTCTTATAAAATATAATAAAG
*COP_C10         CAACGTAAAAACACATAAAAATAAGCGTAACTAATAAGACA*ATGGATATTTACGACGATA
*WR_C16          CAACGTAAAA-CACATAAAAATAAGCGTAACTAATAAGACA*ATGGATATTTACGACGATA
COP_C10          AAGGTCTACAGACTATTAAACTGTTTAATAATGAATTTGATTGTATAAGGAATGACATCA
WR_C16           AAGGTCTACAGACTATTAAACTGTTTAATAATGAATTTGATTGTATAAGGAATGACATCA
COP_C10          GAGAATTATTTAAACATGTAACTGATTC GATAGTATACAACTTCCGATGGAAGACAATTWR_C16           GAGAATTATTTAAACATGTAACTGATTC GATAGTATACAACTTCCGATGGAAGACAATT
##COP_C10        CTGATATTATAGAAAATATCAGAAAAATACTATATAGACGATTAAAAAATGTAGAATGTG
##WR_C16         CTGATATTATAGAAAATATCAGAAAAATACTATATAGACGATTAAAAAATGTAGAATGTG
COP_C10          TTGACATCGATAGTACAATAACTTTTATGAAATACGATCCAAATGATGATAATAAGCGTA
WR_C16           TTGACATCGATAGTACAATAACTTTTATGAAATACGATCCAAATGATGATAATAAGCGTA
COP_C10          CGTGTTCTAATTGGGTACCCTTAACTAATAACTATATGGAATATTGTCTAGTAATATATT
WR_C16           CGTGTTCTAATTGGGTACCCTTAACTAATAACTATATGGAATATTGTCTAGTAATATATT
##COP_C10        TGGAAACACCGATATGTGGAGGCAAAATAAAATTATACCACCCTACAGGAAATATAAAGT##WR_C16         TGGAAACACCGATATGTGGAGGCAAAATAAAATTATACCACCCTACAGGAAATATAAAGT
COP_C10          CGGATAAGGATATTATGTTTGCAAAGACTCTAGACTTTAAATCAAAGAAAGTGTTAACTG
WR_C16 CGGATAAGGATATTATGTTTGCAAAGACTCTAGACTTTAAATCAAAGAAAGTGTTAACTG
COP_C10          GACGTAAAACAATTGCCGTTCTAGACATATCCGTTTCATATAATAGATCAAT ACTACTAWR_C16           GACGTAAAACAATTGCCGTTCTAGACATATCCGTTTCATATAATAGATCAAT ACTACTA
COP_C10          TTCACTACAACGACGACGTT ATATAGATATACATACTGATAAAAA GGAAAAGAGTTATWR_C16           TTCACTACAACGACGACGTT ATATAGATATACATACTGATAAAAA GGAAAAGAGTTAT
COP_C10          GTTATTGTTATATAACAATAGATGATCATTACTTGGTTGATGTGGAAACTATAGGAGTTAWR_C16           GTTATTGTTATATAACAATAGATGATCATTACTTGGTTGATGTGGAAACTATAGGAGTTA
COP_C10          TAGTCAATAGATCTGGAAAATGTCTGTTAGTAAATAACCATCTAGGTATAGGTATCGTTAWR_C16           TAGTCAATAGATCTGGAAAATGTCTGTTAGTAAATAACCATCTAGGTATAGGTATCGTTA
COP_C10          AAGATAAACGTATAAGCGATAGTTTTGGAGATGTATGTATGGATACAATATTTGACTTTTWR_C16           AAGATAAACGTATAAGCGATAGTTTTGGAGATGTATGTATGGATACAATATTTGACTTTT
COP_C10          CTGAAGCACGAGAGTTATTTTCATTAACTAATGATGATAACAGGAATATAGCATGGGACA
WR_C16           CTGAAGCACGAGAGTTATTTTCATTAACTAATGATGATAACAGGAATATAGCATGGGACA
COP_C10          CTGATAAACTAGACGATGATACAGATATATGGACTCCCGTCACAGAAGATGATTACAAATWR_C16           CTGATAAACTAGACGATGATACAGATATATGGACTCCCGTCACAGAAGATGATTACAAAT
COP_C10          TTCTTTCTAGACTAGTATTGTATGCAAAATCTCAATCGGATACTGTATTCGACTATTATG
WR_C16           TTCTTTCTAGACTAGTATTGTATGCAAAATCTCAATCGGATACTGTATTCGACTATTATG
COP_C10          TTCTTACTGGTGATACGGAACCACCCACTGTATTCATTTTCAAGGTAACTAGATTTTACT
WR_C16           TTCTTACTGGTGATACGGAACCACCCACTGTATTCATTTTCAAGGTAACTAGATTTTACT
*COP_C10         TTAATATGC GAAATAA*AAAATTTTTGTATAATATCTAGAGGTAGAGGTATTGTTTAGAT
*WR_C16          TTAATATGC GAAATAA*AAAATTTTTGTATAATATCTAGAGGTAGAGGTATTGTTTAGAT
COP_C10          AAATACAAATAACATAGATACATCGCATA TTAGCATTTTTATAAATATACATAAGAWR_C16           AAATACAAATAACATAGATACATCGCATA TTAGCATTTTTATAAATATACATAAGA
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i ii
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Figure 3.5.2 Analysis of sequence divergence between VACV WR and VACV COP (a) 
The DNA sequence of VACV WR and VACV COP was compared. ## indicates the region 
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within the C16 ORF wherein an initiation site should be found in order to generate a protein 
of 25 kDa. Any divergent nucleotides are highlighted in red (b) The protein sequence of 
VACV WR and VACV COP was compared. Divergent aas are highlighted in red and termed 
(i) and (ii) as indicated. 
 
3.5.2 Multimerisation 
After high level expression of C16 in bacteria, it appeared that C16 was present in multimeric 
complexes. To assess whether the putative multimerisation was detected in other systems, a 
directed yeast-two-hybrid interaction analysis was undertaken. The C16L gene was cloned 
into two yeast two hybrid vectors, pGADT7 and pGBKT7, as indicated in Section 2.2.10. 
The icIL-1Ra gene was also cloned into these plasmids to assess any potential dimerisation of 
icIL-1Ra and whether the two proteins may heterodimerise.  
 
After co-transformation of the relevant plasmids into competent yeast cells, plating on 
selection plates allowed assessment of whether the plasmids had been cotransformed and 
whether the cloned proteins interact with each other. Yeast cells were grown on SD medium 
lacking tryptophan or leucine, (as individual dropouts), tryptophan and leucine (double 
dropout), tryptophan, leucine and histidine (triple dropouts) or plates lacking tryptophan, 
leucine and histidine but containing 100 mM 3-AT (the 3-AT triple dropout plate). The single 
drop-out plates indicate that either plasmid was transformed into the yeast cells. The double 
drop-out plates indicated that there has been co-transformation of both plasmids into some 
yeast cells. Yeast will only grow on the triple dropout plate if the proteins of interest interact, 
so yeast growing on this plate demonstrates an interaction. The 3-AT triple dropout plate 
selects (through 3-AT) for a self-transactivating property of the bait protein (the protein in 
pGADT7) when interacting with the prey protein (the protein in pGBKT7), and so acts as a 
further stringency control for any interaction. The plasmids containing p53 and SV40-TAg 
acted as positive interaction control and formed colonies on both triple knock-out plate and 
the 3-AT triple knock-out plate, while p53 and lamin act as negative controls and do not form 
colonies on the triple or 3-AT triple dropout plates.  Initial analysis involved directed 
interaction analysis to assess whether C16 oligomerised within the yeast two hybrid system. 
This proved negative, in comparison with the kit-provided positive controls (3.5.3 a, b, c), 
suggesting that in this system, the C16 protein does not dimerise. Similar analysis of icIL-
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1Ra indicated that this protein did not interact with itself in this system (Figure 3.5.3 d). This 
preliminary analysis was concluded with an icIL-1Ra versus C16 screen and indicated that 
these proteins did not interact (Figure 3.5.3 e). 
 
a)
e)
c) d)
b)
 
Figure 3.5.3 Analysis of direct interactions in the yeast two hybrid system. C16 and icIL-
1Ra were cloned into two yeast plasmids, pGADT7 and pGBKT7. (a) p53 and SV40 TAg act 
as positive interaction controls and form colonies on both triple and quadruple knock-out 
plates, (b) p53 and lamin act as negative controls and do not form colonies on the triple or 
quadruple drop-out plates, (c) C16 does not interact with C16, (d) icIL-1Ra does not interact 
with icIL-1Ra, (e) icIL-1Ra does not interact with C16. 
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3.5.3 Phosphorylation 
Bioinformatic analysis (section 3.2) indicated that of the putative phosphorylation motifs in 
C16, the phosphorylation consensus sequences of PKA and of CKII were most conserved, 
and were detected by multiple phosphorylation identification screens. To investigate if C16 
was phosphorylated in infected cells at 4 h.p.i., C16 was immunoprecipitated with anti-C16 
Ab and the immunoprecipitates were immunblotted with anti-phosphoserine and anti-
phosphothreonine antibodies. Although no phosphorylation was seen, there was no positive 
control for this assay. Hence I investigated whether C16 could be phosphorylated in vitro by 
specific kinases. These assays were done in cooperation with Dr. Ron A.-J. Chen. Equivalent 
molarities of BSA, purified C16, and characterised peptide substrates for each of the kinases 
(Kemptide for PKA, and CKII substrate for CKII) were incubated with the relevant kinase 
buffer, [γ-32P]-ATP and the indicated kinase for 10 min. The reaction was then stopped, the 
proteins were separated by SDS-PAGE and 32P-labelled proteins were visualised by 
autoradiography (Figure 3.5.4 a and b). Initial analysis (15 minute autoradiograph, Figure 
3.5.4 a) shows that PKA phosphorylates kemptide, but there was no phosphorylation of C16. 
Equally, CKII phosphorylates its substrate (red arrow), but not C16. However, overnight 
exposure of this radiograph (Figure 3.5.4 b) shows specific phosphorylation of a protein at 
the correct size for C16, suggesting that C16 might be phosphorylated weakly by PKA. Many 
phosphorylation events require either the presence of scaffolding proteins, or other activation 
steps before phosphorylation can take place, hence the absence of efficient phosphorylation 
of C16 by the two putative kinases in vitro does not rule out an effect in the infected cell. 
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Figure 3.5.4 a) In vitro phosphorylation assay of C16. C16, BSA, or the indicated control 
substrates (all at a concentration of 2.7 µM) were incubated with 4 U of PKA or CKII as 
indicated, and 5 µCi [32Pγ]-ATP in kinase buffer for 10 min at 30 °C. The kinase assay was 
terminated by adding protein loading buffer and the mixture was resolved and analysed by 
autoradiography. Protein mass markers (kDa) are indicated on the left. b) Overnight exposure 
of the kinase assay autoradiograph. Accomplished in collaboration with Dr. Ron A-J. Chen. 
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3.6  Conclusions 
The C16 protein is a highly conserved in 4 OPVs (VACV, VARV, ECTV and CPXV) and 
some poxviruses outside the OPV family, namely DPXV, SPPV, LSDV, CNPV, YMTV and 
FPV. Analysis of the putative promoter region of C16L indicates that the gene is likely to be 
transcribed early in infection, which is confirmed by recent transcriptome analysis which 
shows C16 mRNA to be an early viral transcript (Assarsson et al., 2008). Analysis of the 
predicted protein sequence shows that it lacks a signal peptide or transmembrane domain, but 
has a number of putative phosphorylation consensus sequences, and there is a highly 
conserved motif close to the C terminus that is conserved in IL-1ra. 
 
C16 is expressed early in infection, and is an intracellular protein. It localises to the cell 
nucleus and cytoplasm, and is actively translocated in and out of the nucleus despite the 
absence of a NLS. This localisation pattern is evident in infected and transfected cells, 
indicating that the translocation is independent of other viral proteins.  
 
Recombinant C16 was expressed in bacteria and purified by affinity column chromatography 
and size exclusion chromatography. Size-exclusion chromatography, indicated that C16 
exists in oligomeric states when over-expressed from E. coli. This multimerisation of C16 is 
also in evidence in infected cells, as will be detailed in chapter 4, where C16 is found as a 
member of an unidentified protein complex which is between 440 and 690 kDa in mass.  
However, neither C16 nor the related icIL-1Ra dimerised in a yeast-two-hybrid screen, and 
these proteins did not interact with each other. Analysis of post-translational modifications of 
C16 show it may be weakly phosphorylated by PKA but not CKII. A smaller (25 kDa) C16 
protein was detected late after infection by most, but not all, VACV strains, and how this is 
formed and the significance of this protein are unknown.  
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Chapter 4  
Analysis of the role of the C16 protein in cell culture 
 
4.1  Introduction 
The generation of VACVs with specific gene deletions or mutations is a powerful tool to 
investigate VACV gene function. To analyse the role of C16L in VACV, a family of 
recombinant viruses were constructed. Firstly, a substitution virus (v∆C16/Ecogpt/EGFP) 
was constructed wherein the C16L gene in both ITRs was replaced by a selectable marker 
comprising a VACV promoter driving expression of the Ecogpt (Boyle and Coupar, 1988) 
and EGFP proteins (BD Biosciences). Secondly, this cassette was deleted from 
v∆C16/Ecogpt/EGFP to form a clean deletion mutant (v∆C16) so as to control for any 
phenotypic effect of the Ecogpt/EGFP insert. Lastly, a “revertant” virus, vC16Rev, was 
constructed from the substitution mutant by re-inserting the C16L gene back into the C16L 
ORF. As such the “revertant” virus is not a true revertant of deletion virus, but a clone of the 
substitution virus into which the C16L ORF has been reinserted. This virus ensures that any 
experimental phenotype found with a deletion virus is due solely to the removal of the gene 
of interest, and not a result of an alteration elsewhere in the virus genome that may have 
arisen during the process of virus isolation. Analysis of the genomes of the C16 recombinant 
viruses was undertaken to confirm the predicted gene alterations.  
 
To determine whether the absence of C16 has an effect on virus replication, the plaque 
morphology and growth rates of the different viruses in tissue culture were compared.  
 
Functional analysis of the role of C16 in vitro was undertaken, in the context of infected and 
transfected cells. Initial assays attempted to ascertain whether C16 could inhibit effect of pro-
IL-1α on IL-6 production, as icIL-1Ra does. Given these results, gel filtration analysis was 
undertaken to understand whether C16 interacted in a complex or not, as well as attempted 
pulldowns of the putative interaction partner of IL-1Ra. C16 was then assayed in a range of 
reporter assays to ascertain whether C16 took part in downregulating any of the gene 
expression pathways which play key roles in innate immunity. Finally, these results were 
used to inform our understanding of potential roles that C16 might play, and assays were set 
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up to monitor the effect of the presence or absence of C16 on the phosphorylation state of a 
number of different key signalling molecules. 
 
4.2  Construction of C16 deletion viruses in the WR strain of VACV 
To generate v∆C16/Ecogpt/EGFP (as illustrated in Figure 4.2.1), where the Ecogpt/EGFP 
cassette is inserted in the place of the C16 gene in both loci, a p∆C16/Ecogpt/EGFP plasmid 
(Section 2.7.1) was constructed from plasmid pSJH7. The plasmid formed contained the 
Ecogpt cassette driven by a constitutive VACV promoter as a selectable marker (Boyle and 
Coupar, 1988; Coupar et al., 1988) and flanked by the C16L flanking sequences to allow for 
homologous recombination. The construction of this plasmid was accomplished by Miss 
Emily Glyde and Dr. Richard H. Clark. The selection cassette Ecogpt enables growth of 
recombinant viruses in the presence of MPA. MPA inhibits inosine monophosphate 
dehydrogenase and results in blockage of purine synthesis, which results in a blockage of 
VACV replication in most cell lines. However, VACV that express the Ecogpt enzyme are 
able to overcome purine synthesis inhibition by MPA and replicate if, the substrates xanthine 
(2,6-dihydroxypurine) and hypoxanthine (6-hydroxypurine) are also provided in the culture 
medium. The inclusion of the EGFP cassette allows selection of green plaques by 
fluorescence microscopy.  
 
Plasmid p∆C16/Ecogpt/EGFP contained the C16L flanking regions A and B (as illustrated in 
Figure 4.2.1) and was transfected into cells that had been infected by wild type plaque-
purified VACV WR (vC16). Subsequently, the virus harvested from this 
transfection/infection was seeded onto fresh cell monolayers in the presence of MPA. 
Consequently, replication of wild type VACV was inhibited but replication of any virus in 
which the p∆C16/Ecogpt/EGFP cassette was present was possible. Initial 
transfection/infection and the first round of plaque purification were undertaken by Miss 
Emily F. Glyde and Dr. Richard H. Clark. This virus was then plaque purified twice more 
with selective pressure (+MPA) and with selection of green clones by fluorescence 
microscopy, and twice more without selective pressure to ensure isolation of a pure virus 
clone. 
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Figure 4.2.1 Overview of construction of viruses. A plasmid was generated containing the 
sequences which flank the C16 locus in the WR VACV genome surrounding an Ecogpt and 
EGFP cassette under the control of the VACV synthetic early/late promoter in the pGEMT 
plasmid (p∆C16/Ecogpt/EGFP plasmid). This plasmid was used to replace C16L from VACV 
WR with the Ecogpt/EGFP cassette by homologous recombination following 
infection/transfection (section 2.7.2) to generate the substitution virus, p∆C16/Ecogpt/EGFP. 
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This was purified by selection with MPA and by selecting green plaques by fluorescence 
microscopy. Plasmids which contained either just the sequences which flank the C16L locus 
(p∆C16) or the flanking sequences and the gene, C16L (pC16 plasmid) were then used 
individually in infection/transfection protocols with the substitution virus. Plasmid 
construction was accomplished by Miss Emily F. Glyde and Dr. Richard H. Clark. This could 
replace the Ecogpt/EGFP cassette with C16L to generate a revertant virus, and generate a 
virus with no gene sequence between the C16L flanking sequences, the deletion virus. These 
could be selected for using 6-TG on D98 cells, and by selecting non-green plaques by 
fluorescence microscopy.   
 
To generate vC16Rev and v∆C16, CV-1 cells were infected with v∆C16/Ecogpt/EGFP and 
transfected with either pC16 plasmid to generate a revertant virus (vC16Rev), or with p∆C16 
to generate a deletion virus (v∆C16) (Figure 4.2.1). The infection/transfection progeny were 
harvested and used to infect D98 cells in the presence of 6-TG. Ecogpt converts 6-TG into 
toxic anti-metabolites that inhibit VACV replication (Section 2.7.1) and so only Ecogpt 
negative viruses can replicate in cells deficient in HGPRT in the presence of 6-TG. Plaques 
were analysed by fluorescence microscopy and non-green plaques were picked. 6-TG-
resistant viruses were plaque purified on D98 cells followed by further plaque purification on 
BSC-1 cells.  
 
Individual plaque isolates were screened by PCR using crude viral DNA extracted from 
infected cells. PCR using primers flanking the C16L gene locus were used to ascertain the 
virus clones and purity. This PCR generated a 2.1-kb DNA fragment in the presence of the 
Ecogpt/EGFP cassette, a 1.9-kb fragment in the presence of C16L and a 0.8-kb fragment in 
the absence of any insert. Analysis of the purified virus clones is shown (Figure 4.2.2a) and 
this confirms that vC16 and vC16Rev yield a 1.9-kb fragment, v∆C16 yields a 0.8-kb 
fragment and v∆C16/Ecogpt/EGFP yields a 2.1-kb fragment. As C16 is present in two 
copies, it is necessary that these PCRs yield single bands as shown so that it is clear that 
recombination has occurred at both C16 loci.  
 
Further PCR analysis with primers specific for the plasmid vector was used to identify virus 
clones in which a double homologous recombination event had occurred, rather than a single 
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homologous recombination event. In the case of a single homologous recombination event, 
the cassette of interest, as well as the rest of the plasmid vector, would have integrated into 
the VACV genome. Hence PCR analysis using vector-specific primers was necessary to rule 
out this possibility (Figure 4.2.2 b). This showed that in one of the purified clones (clone 60) 
a single homologous recombination event had occurred which yielded a positive PCR. vC16, 
v∆C16, vC16Rev and v∆C16/Ecogpt/GFP did not yield a fragment in this PCR, indicating 
that only the cassette of interest in each case integrated, rather than the cassette and the 
vector.  
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Figure 4.2.2 Analysis of recombinant VACV genomes by PCR. Virus DNA was extracted 
from cells that had been infected with the indicated viruses and used as a template for PCR 
using the indicated primers PA, PB, PC and PD flanking the C16L gene in either the virus 
(PA and PB) (a) or the outside the C16L flanking sequences in the vector construct (b), as 
indicated. PCR products were analysed by agarose gel electrophoresis (0.8 % gel). The 
positions of DNA size markers in kb are indicated. 
 
4.3  Genome analysis of recombinant VACVs 
To identify other mutations that may have arisen during construction of recombinant viruses, 
a number of other checks on the genome integrity were undertaken. PCR analysis was used to 
identify alterations in the ITR/US boundaries at either end of the genome (Figure 4.3.1). A 
primer was chosen from the ITR sequence adjacent to the C16L insert. Primers were 
generated from four sites within the unique sequence, two at either end of the VACV genome 
as detailed in the appendix. One primer was close to the ITR/US boundary, while the other 
was 1 kb distant from the boundary. These were distinct for the left and right end of the US of 
the VACV genome. This generated fragments consistent with the expected lengths indicating 
that no large deletions or insertions had occurred in these regions. 
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Figure 4.3.1 Analysis of ITR/US boundary of recombinant VACV genomes. (a) Analysis 
of left ITR/US boundary of recombinant VACV genomes and (b) Analysis of right ITR/US 
of recombinant VACV genomes by PCR. Virus DNA was extracted from cells that had been 
mock-infected or infected with the indicated viruses and used as a template for PCR using the 
primers indicated relevant to each ITR/US boundary. PCR products were analysed by agarose 
gel electrophoresis (0.8 % agarose).The positions of DNA size markers are indicated in kb. 
The primer in the ITRs is indicated in blue, the primers which are used to analyse the left 
ITR/US boundary are indicated in red, and those used to analyse the right ITR/US boundary 
are indicated in green. 
 
4.4  Analysis of recombinant VACVs in cell culture 
4.4.1  Plaque phenotypes 
The plaque phenotype of v∆C16 was compared to control viruses in 3 different cell types, 
BSC-1, CV-1 and RK-13 (Figure 4.4.1). After infection, the cells were overlaid with semi-
solid medium to prevent the formation of secondary plaques (Section 2.8.1). After 72 h, the 
infected monolayers were stained, photographed and the diameter of single plaques (n=50 per 
virus) was measured for each virus on each cell type. The plaques formed by v∆C16 were 
significantly smaller (p < 0.06) than those formed by vC16 in all cell types. The plaque size 
was reduced by 18.1 % (+/- 2.7 %), 23.5 % (+/- 3.6 %) in BSC-1 and RK-13 cells 
respectively between vC16 and v∆C16. Interestingly, the most significant difference is in 
RK-13 cells. This cell line is non-permissive for VACV lacking K1, a putative interaction 
partner of C16 (McCraith et al., 2000). K1 functions by inhibiting the activation of NF-κB 
(Shisler and Jin, 2004), and the protein is a host range restriction factor in rabbit cells through 
an independent mechanism which acts via ankyrin repeats and a GTPase-activating protein 
(Bradley and Terajima, 2005; Chung et al., 1997). 
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Figure 4.4.1 Plaque formation in the absence of C16. Monolayers of BSC-1, RK-13 or 
CV-1 cells were infected by vC16, v∆C16, v∆C16/EcogptGFP or vC16Rev and were 
overlaid with DMEM/2.5 % FBS/1.5 % CMC. After 72 h, the monolayers were stained with 
0.1 % crystal violet in 15 % ethanol and photographed. The diameters of 40 isolated plaques 
were measured using an ImagePro measuring tool. Data are expressed as the average 
diameter (measured in unit area) plus or minus SD. The diameter of plaques formed by 
viruses lacking C16 was compared with control viruses by Student’s t-Test, p<0.06 
 
Possible explanations of this plaque phenotype were that C16 affects virus yield per cell or 
C16 affects virus spread. These possibilities were investigated below.  
 
 4.4.2  Growth kinetics of recombinant VACVs 
To examine if C16 affected virus replication and growth kinetics, the growth of each virus 
was compared on BSC-1 cells after high (Figure 4.4.2 a, b) or low (Figure 4.4.2 c, d) MOI. 
At the indicated time p.i., the medium was collected and detached cells were collected by 
centrifugation to be pooled with the attached cells. The infectious virions from the clarified 
culture medium or the cells were defined as medium or cell-associated viruses, respectively. 
After infection at 10 p.f.u./cell there were no differences between the virus groups at 12 and 
24 h.p.i. Small differences in replication of viruses are often more evident during multi-step 
growth kinetics as the virus spreads from cell to cell. However, even after infection at 0.01 
p.f.u./cell there were no differences between the virus groups were indistinguishable at the 
time points measured (Figure 4.4.2 a, b).  
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 BSC-1 cells were infected with recombinant viruses at 10 p.f.u./cell to ensure that all cells 
were fully infected. At various time points post infection, supernatant and cells were 
separated and titrated to determine virus levels. The amount of virus in the supernatant 
provides a good estimate of EEV production, although a small proportion may represent IMV 
released through cell lysis. Cell-associated virus would include IMV, IEV and CEV. The 
titrated results did not isolate a difference within the virus groups. There is no trend or 
significant difference in the virus growth properties.   
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Figure 4.4.2 Growth kinetic analysis of recombinant viruses. BSC-1 cells were infected 
with indicated viruses at 10 p.f.u./cell (a, b) or 0.01 p.f.u./cell (c, d). At the indicated times 
p.i., the culture supernatants were removed and clarified by low speed centrifugation. Cellular 
material was scraped, pooled with the pellet obtained from clarification of the supernatant 
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and lysed by freeze-thawing and sonication. Virus levels in extracellular (a, c) and 
intracellular (b, d) fractions were quantified by plaque assay on BSC-1 cells.  
 
 4.4.3  Actin tail formation  
Actin tail formation from the surface of infected cells is an important mechanism by which 
VACV spreads efficiently from cell to cell. Any mutants defective in the formation of actin 
tails form smaller plaques as the cell-cell spread is impaired. Therefore, the formation of actin 
tails in HeLa cells infected with v∆C16 was compared to vC16 (Figure 4.4.3). After infection 
at 10 p.f.u./cell for 12 h, the cells were fixed, permeabilised and stained with rhodamine-
conjugated phalloidin to detect polymerised actin (actin tails). Cells were also stained with 
anti-B5 rat mAb (Schmelz et al., 1994) to determine that cells had been infected as well as to 
determine that the actin tails were associated with a virus particle. Figure 4.4.3 shows that the 
removal of C16 did not abolish or impair the formation of actin tails. Therefore, C16 is not 
essential for the formation of actin tails in VACV-infected cells. The small plaque phenotype 
of v∆C16 cannot be attributed to loss of actin tail formation. 
 
vC16 v∆C16  
Figure 4.4.3 Deletion of C16 did not inhibit actin tail formation. HeLa cells were infected 
at 10 p.f.u./cell with (a) vC16, (b) v∆C16. After 16 h, the infected cells were fixed and then 
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F-actin was stained with rhodamine-conjugated phalloidin. Cells were also stained with 
Alexa-Fluor488-conjugated B5 mAb. The images (two different magnifications shown) were 
obtained with a laser scanning confocal microscope. Infected cells were photographed using 
Z-stack confocal microscopy to determine actin tails at different cell depths. Red: B5; Green: 
F-actin. Scale bars indicate 10 µm. 
 
These growth kinetics and analysis of actin tail formation indicate that loss of C16 protein did 
not affect either the replication or spread of virus under the conditions tested. These results do 
not explain the difference in plaque size.  
 
4.5 C16 does not inhibit apoptosis 
Several VACV proteins affect induction of apoptosis and this might lead to changes in plaque 
size. Accordingly, HeLa cells were transfected with a plasmid expressing C16, the anti-
apoptotic protein Bcl-xL or the empty vector. Cells were then treated with ST, an inducer of 
apoptosis, and the effect on the transfected proteins on the cleavage of the cellular PARP 
protein (a marker of apoptosis) was monitored (Figure 4.5a). As expected, cells transfected 
with Bcl-xL displayed some resistance to apoptosis and showed reduced levels of cleaved 
PARP relative to the empty vector-transfected cells, using tubulin as a loading control. 
However, no comparable reduction was seen by C16 at 4 h post treatment, although there was 
slightly less PARP cleavage than empty vector at 2 h.p.i.  
 
Due to the qualitative nature of this experiment, a more rigorous quantitative experiment was 
undertaken in collaboration with Dr. S. Cooray. In this analysis, cells were again transfected 
with Bcl-xL, C16 or an empty vector but co-transfected with CD20.  Again, these cells were 
stimulated with staurosporine, and then cells were stained for uptake of JC-1 (an indicator of 
mitochondrial dysfunction, a marker of cellular apoptosis) as well as for CD20 (the 
transfection control). Cells were sorted by CD20-positive staining for transfected cells, and 
analysed by FACS analysis for uptake of JC-1 (Figure 4.5b). Bcl-xL provides protection 
against apoptosis to both untreated and treated cells. In contrast, C16 seems to exhibit a mild 
pro-apoptotic effect. This experiment was performed once though in triplicate. IL-1Ra has 
been postulated to exert one of its intracellular effects by preventing IL-1α from exerting its 
anti-apoptotic effects. Alternatively, IL-1Ra has been shown to upregulate ICE, the caspase-
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like protein which can also initiate the apoptotic caspase-cleavage cascade (Sumitomo et al., 
1999). Hence a pro-apoptotic role for C16 could possibly be through IL-1Ra mimicry.  
 
Tubulin
-+2 +2 +2+4 +4 +4
Staurosporine 
(h)
C16
BCl-xL C16 EV
0
25
50
75
Untreated
Staurosporine
%
 d
yi
ng
 c
el
ls
%
 d
yi
ng
 c
el
ls
PARP
75
36
50
BCl-xL C16 EVa)
b)
--
 
Figure 4.5 Effect of C16 on apoptosis (a) The effect of C16 on staurosporine-induced 
apoptosis was monitored by assessing PARP cleavage. HeLa cells were transfected with the 
Bcl-xL,, C16, or an empty vector (pCI). 24 h later were treated for 2 h or 4 h (as indicated +2, 
+4) with 1 µM staurosporine. Cells were lysed in RIPA buffer and immunoblotted for the 
indicated proteins. (b) The effect of C16 on staurosporine-induced apoptosis was monitored 
by assessing JC-1 uptake into mitochondria. HeLa cells were transfected with Bcl-xL, C16, or 
an empty vector (pCI) as well as CD20 and 24 h later were treated for 1 h with 0.5 µM 
staurosporine. Cells were gently detached from the wells with PBS and incubated with 2 µM 
JC-1 for 30 min, and a CD20 PE-conjugated antibody as a transfection control for 30 min. 
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Cells were analysed by FACS analysis and the percentage of transfected cells (i.e. CD20+ 
cells) taking up JC-1 is represented as a proportion of the transfected cells. Accomplished in 
collaboration with Dr. S. Cooray. 
 
4.6. Effect of C16 on pro-IL-1α-induced cytokine production 
As one of the effects of icIL-1Ra is to downregulate pro-IL-1α-mediated induction of 
cytokine production (in particular of IL-6 and IL-8), a possible role for C16 in this pathway 
was investigated. The murine macrophage line RAW264.7 cells were transfected with a 
plasmid expressing pro-IL-1α and the extent that this could induce IL-6 production was 
measured by ELISA of the cell supernatants a) 36 h post transfection. In an initial screen, the 
transfection of pro-IL-1α could stimulate a 20-fold increase in IL-6 production relative to 
cells transfected with an empty vector (Figure 4.6a). Co-transfection of icIL-1Ra reduced this 
production significantly, as did co-transfection of C16. To determine if this effect of C16 was 
dose-dependent, cells were co-transfected with the indicated amounts of the C16 plasmid and 
IL-6 secretion was measured at 24 h post transfection (Figure 4.6b). This showed that C16 
reduced pro-IL-1α-induced IL-6 production to a level similar to that of the unstimulated cells 
transfected with the empty vector, and a preliminary experiment shows that C16 inhibits IL-6 
production in a dose-dependent fashion. 
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Figure 4.6 C16 inhibits pro-IL-1α-induced production of IL-6. a) RAW 264.7 cells were 
transfected with the indicated plasmids and the level of IL-6 seen in the cell medium 36 h 
post transfection was measured by ELISA. Cells were transfected in triplicate and significant 
differences (p < 0.05) are indicated. b) RAW 264.7 cells were transfected with the indicated 
plasmids, with varying amounts of plasmid expressing C16 as indicated. The level of IL-6 in 
the cell medium 24 h post transfected was measured by ELISA. As cells were not analysed in 
triplicate, error bars are not calculated, nor significant differences available to be estimated. 
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4.7.  Analysis of C16 modulation of downstream IL-1Ra signalling pathways 
 4.7.1 Co-fractionation by gel filtration 
Given that both C16 and IL-1ra downregulated pro-IL-1α-induced expression of IL-6, it was 
possible that C16 might interact with similar proteins in cells. IL-1Ra interacts with CSN3 
(Banda et al., 2005), a member of the COP9 signalosome complex. To determine whether 
C16 interacts with CSN3, extracts of infected cells were fractionated by size exclusion 
chromatography and the resultant fractions were blotted for the presence of C16 and proteins 
from the signalosome complex (Figure 4.7.1). C16 eluted in fractions 12-14 equivalent to a 
complex size of approximately 440 - 669 kDa. This indicates that C16 is present in a complex 
because a C16 monomer is 37 kDa. Notably, C16 elutes in fractions very similar to the CSN 
complex: for instance, CSN1, CSN2 and CSN8 peak in fraction 13, while C16 peaks at 
fraction 14. In contrast, CSN3 is present in a larger complex, indicating that CSN3 and C16 
are unlikely to interact directly. 
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Figure 4.7.1 Purification of C16 by gel filtration. A cytoplasmic extract from HeLa cells 
infected with VACV for 6h was subjected to gel filtration on a Superose 6 column. Fractions 
were resolved by SDS-PAGE and analysed by immunoblotting with the indicated antibodies. 
The position of protein size markers is indicated in kDa at the top.  
 
Analysis of the fractionation patterns of icIL-1Ra and pro-IL-1α were also attempted, but 
neither of these proteins could be detected by western blotting under two different conditions 
analysed. The fractionation patterns of these proteins will inform our understanding of any 
overlap between the functions of icIL-1Ra and C16. 
 
 4.7.2 Immunoprecipitation  
Cells were infected for 6 h , lysed in gentle (CHAPS) or more stringent (RIPA) buffers and 
then incubated with protein A sepharose beads and antibodies either to C16 (Figure 4.7.2a) or 
CSN3 (Figure 4.7.2b). C16 and CSN3 were pulled down by antibodies directed to these 
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proteins, however under the conditions analysed neither protein could co-immunoprecipitate 
with the other protein. A weakness of this experiment is the lack of a positive control for an 
interaction as a K1 antibody was not available at the time, and immunoblotting with IL-1Ra 
did not detect a protein in cell lysates or immunoprecipitated samples. Hence, the absence of 
an interaction between C16 and CSN3 remains to be validated.  TAP-tagged C16 has been 
constructed and should provide a better tool for analysis of proposed binding partners, as well 
as the identification of novel binding partners. 
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Figure 4.7.2. C16 does not interact with CSN3 by immunoprecipitation. Cells were 
infected for 6 h, lysed in the indicated buffer and incubated with Protein A sepharose beads 
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and either C16 (a) or CSN3 (b). After 2 h, the beads were washed five times with buffer. 
Beads were then resuspended in Laemmli buffer and the proteins were separated by SDS-
PAGE and immunoblotted with C16 or CSN3 
 
It has been shown through yeast two hybrid analysis that C16 interacts with VACV protein 
K1 (McCraith et al., 2000). K1 blocks IκB degration and NF-κB activity (Shisler and Jin, 
2004). icIL-1Ra also has an impact on NF-κB signalling pathway (Garat and Arend, 2003). 
Due to these two reasons, size-exclusion chromatography fractions as above were 
immunoblotted for NF-κB and IκBα (Figure 4.7.3) 
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Figure 4.7.3. Analysis of C16 complex by gel filtration. A cytoplasmic extract from HeLa 
cells infected with VACV was subjected to gel filtration on a Superose 6 column. Fractions 
were resolved by SDS-PAGE and analysed by immunoblotting with the indicated antibodies. 
The position of protein size markers is indicated in kDa at the top. 
 
This analysis showed that NF-κB and IκB-α eluted in fractions 10-13 and 11-14, respectively, 
overlapping with the majority of C16. Therefore, it is possible that C16 interacts with either 
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NF-κB or IκBα alone or via its reported binding partner K1L. Interestingly, the 25-kDa C16 
protein eluted in fractions 10 to 12, in a larger complex than that of C16.  
4.8. Analysis of the effect of C16 on gene expression reporter assays 
Given that C16 partially co-purified with NF-κB and IκBα its effect on NF-κB-induced gene 
expression was examined.  HEK293T cells were co-transfected with plasmids pCI, pCI-C16 
or pCI-B14 (which downregulates NF-κB activation by inhibition of IKK kinase) (Chen et 
al., 2008), together with pNF-κB-Luc and pRenilla-Luc as a transfection control (Figure 
4.8.1a). The cells were stimulated with IL-1α, IL-1β, or TNF-α and the level of cytokine-
induced NF-κB gene expression was determined. These data were expressed as the mean fold 
inductions relative to the cells expression empty vector (pCI). While B14 inhibited NF-κB 
gene expression, C16 was unable to inhibit NF-κB activation induced by either IL-1 or TNF-
α. 
  
Similarly, the activation of the related AP-1 pathway was analysed (Figure 4.8.1b). The AP-1 
protein is a heterodimeric protein composed of proteins belonging to the c-Fos, c-Jun, ATF 
and JDP families. AP-1 is activated by several cytokines (such as IL-1α) and leads to 
expression of inflammatory mediators such as the matrix metalloproteases, Fas ligand and 
cytokines (i.e. IL-4, IL-5) and chemokines (i.e. IL-8). Cells expressing C16 or B14 were 
stimulated with IL-1α and the level of AP-1 dependent gene expression was measured as 
above. These data show that C16 had no effect on the AP-1 pathway, in contrast to B14 that 
gives a slight stimulation. 
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Figure 4.8.1 C16 has no effect on the induction of (a) NF-κB or (b) AP-1 reporter gene 
expression. HEK293T cells were co-transfected with plasmids encoding either NF-κB-luc or 
AP-1-luc, as well as Renilla-TK-luc and C16, B14 or an empty vector as indicated. At 36 h 
following transfection, cells were stimulated with 100 ng/ml IL-1α, IL-1β, TNF-α or PMA 
for 8 h. Luciferase activity was then measured in quadruplicate wells. Data were normalised 
by TK-Renilla Luciferase intensity in the same well and expressed as a meanfold induction 
compared to the average of normalised luminescence unit value in the pCI-transfected cells.  
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The effect of C16 on IFN-stimulated pathways was also measured.  HEK293T cells were co-
transfected with plasmids pCI, pCI-C16 or pCI-K7 (which downregulates the ISRE pathway 
through interaction with TANK), and ISRE-Luc. Again Renilla-Luc was used as a 
transfection control. The cells were stimulated with IFN-α and harvested and the level of 
ISRE gene expression was determined. These data were expressed as the mean fold 
inductions relative to the cells expression empty vector (pCI). Initial data (Figure 4.8.2.a) 
indicated that C16 and K7 could both inhibit the ISRE activation pathway. A repeat assay 
showed that C16 inhibited ISRE-induced gene expression in a dose-dependent manner 
(Figure 4.8.2b). 
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Figure 4.8.2 C16 inhibits ISRE-dependent gene expression. (a)  HEK293T cells were co-
transfected with plasmids encoding ISRE-luc, Renilla-TK-luc and either an empty vector or 
a) 60 ng C16 or 60 ng K7 or (b) varying quantities of C16 or K7 as indicated. The quantity of 
C16 transfected was varied. At 36 h following transfection, cells were stimulated with 500 
U/ml or 1000 U/ml of human IFN-α as indicated for 6 h. Luciferase activity was then 
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measured in quadruplicate wells. Data were normalised by TK-Renilla Luciferase intensity in 
the same well are expressed as a meanfold induction compared to the average of normalised 
luminescence unit value in the pCI-transfected cells.  
 
The effect of C16 on IRF3-responsive pathways was also measured. C6, a VACV 
immunomodulator determined to downregulate ISRE expression in an IRF3-dependent 
fashion (Postigo and Smith, personal communication) was used as a positive control. 
HEK293T cells were co-transfected with plasmids pCI, pCI-C16 or pCI-C6 and either 
ISG56-Luc or IFN-β-Luc, both of which are known to be stimulated primarily by IRF-3 
transcription factor, in contrast to the ISRE-Luc construct which is primarily activated by 
STAT1 activation. Again Renilla-Luc was used as a transfection control. The cells were 
stimulated with poly I:C and harvested and the level of reporter gene expression was 
determined. These data were expressed as the mean fold inductions relative to the cells 
expression empty vector (pCI). Initial data (Figure 4.8.3) indicated that C6 could inhibit the 
ISG56.1 activation pathway (Figure 4.8.3b), and that K7 could inhibit the IFN-β reporter 
(Figure 4.8.3a). The activity of K7 in this pathway is due to its interaction with TBK/IKKε, a 
signal transducer involved in both the IRF3 and STAT1 activation pathways. In contrast, C16 
showed no activity in the regulation of these reporter constructs (Figure 4.8.3) 
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 Figure 4.8.3 C16 does not affect IRF3-dependent gene expression.  HEK293T cells were 
co-transfected with plasmids encoding (a) IFN-β-Luc or (b) ISG56.1-Luc, Renilla-TK-luc 
and either an empty vector or a) 60 ng C16 or 60 ng K7 as indicated. At 36 h following 
transfection, cells were stimulated with of 25 µg/ml poly I:C as indicated for 6 h. Luciferase 
activity was then measured in quadruplicate wells. Data were normalised by TK-Renilla-Luc 
intensity in the same well are expressed as a meanfold induction compared to the average of 
normalised luminescence unit value in the pCI-transfected cells.  
 
4.9 Analysis of the upstream effectors of ISRE gene expression 
The upstream modulators of the ISRE activation pathways were investigated to understand 
how C16 may be modulating this system. As STAT1 is one of the primary transcription 
factors activated by IFN-α to modulate ISRE gene expression, the phosphorylation of this 
molecule in the presence or absence of C16 was assessed (Figure 4.9.1a).  
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Cells were infected with the indicated viruses and after 4 h were washed and stimulated with 
IFN-α. Cell lysates were prepared at the indicated time points, and analysed for the 
expression of STAT1 and whether it was phosphorylated (Figure 4.9.1a). This showed that 
STAT1 was phosphorylated within 5 min of IFN-α in mock-infected cells. In contrast, 
STAT1 phosphorylation was blocked comprehensively in the presence of either vC16 or 
v∆C16. While there is marginally less total STAT in the presence of C16, this slight change 
is mirrored in the tubulin loading control, and is unlikely to be significant. However, any 
effect of C16 on this pathway might be diminished in virus-infected cells, due to the presence 
of both the VACV IFN-α binding protein, B18 (Alcami et al., 2000), and the VACV STAT1-
phosphatase, H1 (Najarro et al., 2001).  
 
The existence of B18 and H1 does not preclude an ISRE-related role for C16 because there 
are several innate immune pathways targeted by multiple VACV proteins. For example, the 
NF-κB pathway is targeted by B14 to inhibit the IKK kinase (Chen et al., 2008), K1 that 
prevents IκBα degradation (Shisler and Jin, 2004), M2 that inhibits an upstream kinase of 
IKK (Gedey et al., 2006), and N1 that blocks IL-1-induced NF-κB activation (Cooray et al., 
2007). Therefore, STAT1 phosphorylation in transfected cells expressing C16 or icIL-1Ra 
was analysed (Figure 4.9.1 b). Under the conditions tested neither protein affected either the 
steady state levels of STAT1 or its phosphorylation. One reservation of this analysis is that 
any effect of C16 may be mediated in cooperation with another viral protein, hence 
expression of C16 alone may not be representative of the role of C16 in virus infection. 
However, given the effect of C16 on the ISRE reporter system, it is clear that C16 can 
function independently to downregulate this pathway.  Therefore, if it accomplishes this 
inhibition via modulation of STAT1 phosphorylation this should be evident in a transfection 
system. 
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Figure 4.9.1 a) C16 does not affect the phosphorylation of STAT1 in infected cells. Cells 
were infected with 10 p.f.u./cell of vC16 or v∆C16 or mock-infected for 4 h. The infected 
cells were washed three times and then stimulated with 1000 U IFNα / ml for 5, 15 or 30 min. 
Cells were harvested and lysed in RIPA buffer containing phosphatase inhibitors, and the 
proteins were separated by SDS-PAGE, before immunoblotting for the indicated proteins. b)  
C16 does not affect the phosphorylation of STAT1 in transfected cells. Cells were 
transfected with C16 or IL-1Ra or an empty vector for 36 h, treated with IFN-α, harvested, 
lysed and immunoblotted as above. 
 
The ability of C16 to block ISRE-induced gene expression but inability to affect STAT1 
phosphorylation or expression level might be explained by the fact that there are alternative 
activators of the ISRE system, which act in a STAT1-independent fashion. In particular, p38 
MAPK participates in the activation of ISRE-dependent gene expression. In view of this the 
nuclear and cytoplasmic fractions described in chapter 3 were reprobed for the presence of 
STAT1 and p38 MAPK (Figure 4.9.2). p38 MAPK was present in both compartments, 
whereas STAT1 was exclusively cytoplasmic, consistent with the lack of IFN-α stimulation 
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in this experiment. Notably, the level of p38 MAPK and its distribution were unaffected by 
the presence of C16.   
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Figure 4.9.2 Localisation of ISRE effectors in infected cells BSC-1 cells were infected 
with the indicated viruses, or mock-infected. At 16 h.p.i., the cells were fractionated into 
nuclear and cytoplasmic fractions, which were separated by SDS-PAGE and probed with Abs 
for the indicated proteins. Tubulin and lamin A+C were used as control proteins for the 
cytoplasmic and nuclear fractions respectively. The positions of molecular mass markers is 
shown in kDa. 
 
To evaluate whether p38 MAPK is involved in the C16-directed inhibition of the ISRE gene 
expression, the ISRE reporter assay was repeated in the presence of a pharmacological 
inhibitor of p38 MAPK, SB203580 (Figure 4.9.3). This showed that whereas C16, K7 and 
icIL-1Ra can each partially inhibit IFN-α-induced activation of the ISRE-dependent gene 
expression, inhibition of p38 MAPK activity by addition of SB203580 affected the inhibitory 
activity of these antagonists differently. When p38 MAPK was inhibited K7 inhibited the 
IFN-α induced gene expression completely whereas C16 and IL-1Ra no longer had inhibitory 
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activity. This result indicates that C16 and IL-1Ra blocks ISRE-induced gene expression only 
via inhibition of p38 MAPK, whereas K7 works only by blocking the STAT1-dependent 
pathway. A prediction of this result is that K7 and C16 would together provide a more 
complete inhibition of ISRE-induced gene expression than either protein can acting alone.  
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Figure 4.9.3 C16 can no longer inhibit ISRE-dependent gene expression in the presence 
of an inhibitor of p38 MAPK.  HEK293T cells were co-transfected with plasmids encoding 
ISRE-luc, Renilla-TK-luc and C16, K7, IL-1Ra or an empty vector as indicated. At 36 h 
following transfection, cells were pretreated with 10 µM SB203580 for 2 h, before being 
stimulated with 500 U / ml IFN-α for 6 h. Luciferase activity was then measured in 
quadruplicate wells. Data were normalised by TK-Renilla Luciferase intensity in the same 
well. Significant differences (p<0.05) are indicated. 
 
p38 MAPK is activated by phosphorylation, and therefore its phosphorylation status was 
examined in the presence or absence of C16. Cells were infected with vC16, v∆C16 or mock-
infected for 4 h before being stimulated with IFN-α or IL-1α for the indicated lengths of time 
(Figure 4.9.4). Cell lysates were prepared, resolved by SDS-PAGE and immunoblotted for 
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phosphorylated MAPK, unphosphorylated MAPK and C16 (Figure 4.9.4). Neither of these 
stimuli induced significant phosphorylation of p38 MAPK in mock-infected cells. In contrast, 
p38 MAPK was marginally more phosphorylated in virus-infected cells (whether vC16 or 
v∆C16), though the timing of this phosphorylation was curious. In particular, vC16 and 
v∆C16-infected cells showed phosphorylation of p38 MAPK in unstimulated cells in 
comparison to the mock-infected sample, and this difference was still evident at 5 minutes 
post IFN-α stimulation. However, at 15 min post stimulation, no difference could be seen, 
while at 30 min, again more p38 MAPK is phosphorylated in the virus-infected cells relative 
mock-infected cells. Similar analysis was undertaken in IL-1α-stimulated cells (Figure 
4.9.4b). While a marginal difference in v∆C16 levels of p38 MAPK phosphorylation can be 
seen relative to vC16 and mock-infected cells at 5 min post stimulation, again no difference 
in phosphorylated MAPK levels was observed between stimulated and unstimulated mock 
cells. Hence, this data currently needs further investigation to determine, the phosphorylation 
state of p38 MAPK in unstimulated cells, and to gain an understanding of the reproducibility 
of IFN-α and IL-1α stimulation of p38 MAPK phosphorylation in mock-infected cells before 
further analysis can be undertaken as to the effect of the deletion of C16.  
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Figure 4.9.4 The effect of C16 on the phosphorylation of MAPK in infected (a) IFN-α-
stimulated, (b) IL-1α-stimulated cells is currently undetermined. (a,b) Cells were 
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infected with vC16 or v∆C16 or mock-infected for 4 h. The infected cells were washed three 
times, and then stimulated with (a) 1000 U/ml of IFN-α  or (b) 100 ng/ml IL-1α for 5, 15 or 
30 min. (c) Cells were harvested and lysed in RIPA buffer containing phosphatase inhibitors, 
and the proteins were separated by SDS-PAGE, before immunoblotting for the indicated 
proteins. 
  
To assess whether C16 may be in a complex with either STAT1 or p38 MAPK in an IFN-
stimulated fashion, infected cells were stimulated with IFN-α, fractionated by size-exclusion 
chromatography, and the resultant fractions were blotted for p38 MAPK, STAT1, C16 and 
IL-1Ra (Figure 4.9.5). Again C16 eluted in a large complex of between 440 and 669 kDa. 
STAT1 eluted in similar fractions – between 12 and 15. In contrast, the majority of p38 
MAPK eluted in fractions wherein the complexes are smaller – approximately 158 kDa. This 
indicates that C16 is more likely to interact with STAT1 rather than p38MAPK, a facet which 
doesn’t correspond to the p38MAPK pharmacological inhibitor data.  
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Figure 4.9.5 Analysis of the gel filtration profiles of p38 MAPK and STAT1. A 
cytoplasmic extract from HeLa cells infected with VACV for 2 h was stimulated with 500 U 
IFN-α for 4 h before the cells were lysed and fractionated by gel filtration on a Superose 6 
column. Proteins in each fraction were resolved by SDS-PAGE and analysed by 
immunoblotting with the indicated Abs. The position of protein size markers is indicated in 
kDa at the top.  
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4.10 Conclusions 
A collection of viruses that do or do not express C16 were constructed and used to investigate 
the effect of deleting the C16L gene in vitro and in vivo. v∆C16 forms a significantly smaller 
plaque in all cell types analysed. However, analysis of the growth kinetics of v∆C16 set in 
tissue culture did not identify a difference from controls. This kinetic analysis indicates that 
C16 is neither involved in virus replication nor virus spread. Consistent with this observation, 
C16 was not required for the production of actin tails from the surface of the infected cell. 
Therefore, the mechanism by which loss of C16 causes a reduction in plaque size remains 
unknown and awaits further investigation. 
 
The effect of C16 on apoptosis was assayed to determine whether a marginally accelerated 
rate of apoptosis may be responsible for the difference in plaque size phenotypes. C16 seems 
to have a marginal pro-apoptotic effect in staurosporine-treated cells.  
 
C16 reduced the pro-IL-1α-induced secretion of the cytokine, IL-6 in a dose-dependent 
manner, confirming one role in mimicking IL-1Ra activity, which also inhibits IL-6 
production by this stimulation. However, in contrast to IL-1Ra, an interaction between C16 
and the COP9 signalosome complex protein, CSN3, was not observed and the proteins eluted 
in distinct fractions by gel filtration. C16 did partially co-purify with IκBα, and given the role 
of the proposed C16-interacting viral protein, K1, in the downregulation of this NF-κB 
pathway, this prompted investigation of the effect of C16 on NF-κB-dependent gene 
expression. However, C16 neither affected NF-κB- nor AP-1 -dependent expression. 
 
C16 did, however, show dose-dependent inhibition of the IFN-stimulated response element 
genes without affecting the phosphorylation state of STAT1. The C16-induced inhibition of 
the ISRE system was not evident in the presence of an inhibitor of p38 MAPK, a molecule 
known to provide a STAT-independent activation of ISREs. Nonetheless, C16 did not affect 
p38 MAPK phosphorylation in infected cells, though these experiments remain to be 
validated. The phosphorylation state of STAT2, the dimerisation of STAT1 and STAT2, as 
well as the interaction with IRF9, and the final binding of this ISGF3 complex to the ISRE 
DNA sequences should all be analysed to determine conclusively whether C16 is modulating 
ISRE-dependent expression in a STAT-dependent or independent mechanism. Alternatively, 
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C16 may affect the localisation, rather than the phosphorylation of either STAT1 or p38 
MAPK. 
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Chapter 5  
Characterisation of recombinant VACVs lacking C16 in vivo 
 
5.1  Introduction 
In chapter 4, data were presented showing that the deletion of C16 had only a minimal effect 
on in vitro growth properties of the virus, reducing plaque sizes but not affecting virus growth 
kinetics. However, there are many examples of poxvirus proteins that do not affect virus 
replication in tissue culture, but have a significant effect on the outcome of in vivo infections. 
Examples include secreted proteins such as the vaccinia vIL-1βR (encoded by the WR B15R 
gene) (Alcami et al., 1999; Spriggs et al., 1992a), and vIFNα/βR (WR B18R) (Symons et al., 
1995) as well as intracellular proteins such as B14 (Chen et al., 2006) and N1 (Bartlett et al., 
2002). In each case, the protein in question down-regulates the functioning of a component of 
the host immune system. Furthermore, the functions that C16 may be implicated in – mimicry 
of IL-1Ra in the downregulation of IL-6 production, as well as putative downregulation of 
ISRE expression – may have a substantial role on virus virulence in vivo. In line with this 
hypothesis, the virulence of the C16 deletion virus was compared to the WR and revertant 
viruses in a murine i.n. and i.d. infection model.  
  
In the i.n. model there is virus replication in the lungs, dissemination to other organs 
including the brain and induction of a serious systemic infection (Williamson et al., 1990). In 
severe infections, death is attributed to pneumonia since a marked consolidation of the lungs 
can be observed (Turner, 1967). The progression of infection in this model is measured by 
monitoring weight loss and grading signs of illness (Alcami and Smith, 1992) (Section 2.9.1). 
Mice are sacrificed if they lose a pre-defined proportion of their initial body weight or show 
signs of severe infection to comply with animal welfare legislation.  
 
In contrast, the i.d. model causes a highly localised infection and produces a local skin lesion 
in the infected ear with little if any virus spread to other sites (Tscharke et al., 2002). In the 
i.d. model, virulence is measured by the size of the lesion (as described in section 2.9.2). 
Virus replication at various times p.i. can be determined by extraction and plaque assay. 
 
Notably, mutant VACVs that have specific genes deleted may show a phenotype in one 
model but not the other, both models, or neither model (Tscharke et al., 2002). Also gene 
deletion may either increase or decrease virulence. 
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 The infectious titres of v∆C16 and control viruses was measured after infection via the i.n. or 
i.d. route to assess whether the loss of the C16L gene affected virus replication in primary 
cells, and whether virus clearance was affected by loss of the C16 protein. The inflammatory 
cells recruited to the sites of infection were also analysed at multiple days p.i., to assess if 
C16 influenced the inflammatory response. Serum Ab levels against VACV induced by 
v∆C16 and control viruses were assessed to determine the effect of C16 on the acquired 
immune system. Finally, preliminary analysis of the cytokines involved in the onset of 
inflammation was undertaken. 
 
Finally, the ability of v∆C16 to induce protective immunity was compared to control viruses. 
To do this, mice were immunised i.d. with the recombinant viruses, and then challenged i.n. 
28 days p.i. with a lethal dose of VACV WR (Clark et al., 2006). The protective efficacy of 
each virus was thus analysed by monitoring the weight loss and signs of illness after this 
challenge.  
 
5.2  Intranasal infection model 
 5.2.1 Intranasal infection 
Groups of 5 mice (female, BALB/c, 6-8 weeks old) were infected with vC16, vC16Rev and 
v∆C16 at either 1 x 104 or 5 x 103 p.f.u. in 20 µl of PBS and monitored daily for weight 
change and signs of illness.  
 
The results are shown in Figure 5.2.1. After infection with the lower dose, a significant 
difference in weight loss was observed between days 5 and 11 in animals infected with 
v∆C16 compared to the control viruses (Figure 5.2.1a). Indeed, v∆C16-infected animals lost 
no weight at all. Similarly, v∆C16-infected mice showed minimal signs of illness peaking at 
an average ranking of 1 (out of 4) by day 8 (Figure 5.2.1b). This numerical change reflects 
some minor hair ruffling in some of the mice, whereas in contrast, control-infected mice had 
reached this level of illness signs by day 4 and showed rankings of up to 2 (out of 4) by the 
peak of infection, reflecting substantial hair-ruffling and back arching. 
 
After infection at the higher dose, all viruses induced some weight loss, but the weight lost 
after infection with v∆C16 was lower than controls and was of shorter duration (Figure 
5.2.1c). This significant difference (p<0.05) was also reflected in the signs of illness (Figure 
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5.2.1d).  This significant reduction of weight loss and signs of illness in the v∆C16-infected 
mice was maintained until day 12 p.i. when all mice had almost regained their original 
weight. These data indicate that C16 contributes to VACV virulence.  
 
An initial experiment which included v∆C16/EcogptGFP is now found in Appendix 1. 
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Figure 5.2.1 Loss of C16 affects virus virulence in a murine intranasal model. Groups of 
five mice were infected intranasally with 5 x 103 (a,b)  or 1 x 104 (c,d) p.f.u. of vC16, 
vC16Rev, or v∆C16. (a,c) The body weight of each mouse was monitored daily. The mean 
weight of each group of animals on each day is expressed as a percentage of the mean weight 
of the same group of animals on day zero. (b,d) The signs of illness were ranked daily 
according to a defined list of characteristic signs of illness detailed in Materials and Methods. 
The mean score of each group of animals on each day is shown. These data are presented as 
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the indicated mean +/- SEM. The bar indicates days when the difference between the v∆C16 
and both controls was significant (p<0.05, Student’s T-test). 
 
5.2.2 The effect of C16 on virus titres 
To investigate the reason for the reduced weight loss caused by infection with v∆C16, the 
titre of infectious virus in lungs was measured during infection (Figure 5.2.2). At the 
indicated days p.i., mice were sacrificed, their lungs were removed, and the titres of virus in 
infected lungs was determined by plaque assay. Data are presented either as total virus titres 
(per ml lung extract) (Figure 5.2.2a) or as a percentage of the virus titres in vC16-infected 
lungs (Figure 5.2.2b). At day 2 p.i., comparable levels of virus are seen in all lungs and in the 
lungs alone the viruses had all increased in titre by about 20-fold from the initial inoculum 
titre. This indicates that the deletion virus can replicate with the same efficiency as the 
control viruses in primary cells, and in the context of an in vivo virus infection. 
 
However, from day 4 p.i. onwards, the titre of infectious virus in the lungs was significantly 
lower in the v∆C16-infected lungs relative to the controls. The reductions in the titre of 
v∆C16 compared to controls suggest that C16 enhances virus virulence in vivo, in part by 
influencing virus clearance. 
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Figure 5.2.2 a) Measurement of infectious virus in infected lungs. Mice were infected i.n. 
with 104 p.f.u. and at the indicated days p.i., the animals were sacrificed, the lungs were 
removed, and infectious virus was determined by plaque assay on duplicate monolayers of 
BSC-1 cells. Data are means +/- SD of infectious viral titres per ml of lung homogenate (5 
ml). Asterisks indicate the days on which the titre of virus present in lungs infected with 
v∆C16 was significantly different from both vC16- and vC16Rev-infected tissues (n=5, 
Student’s T-test, p<0.05) (b) Proportional virus titres in infected lungs Data represented in 
a) are reformatted to show the virus titres as a proportion of the vC16 virus titre on the 
indicate day p.i. (n=5, Student’s T-test, p<0.05) 
 
 
5.2.3 The effect of C16 on recruitment of leukocytes. 
To start to address the mechanism by which C16 affects the outcome of infection in this i.n. 
model, the cells in the infected lungs and BAL fluid were collected. BAL cells were 
quantified by trypan blue exclusion. The number of cells recruited to the BAL of the mice 
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infected with v∆C16 was significantly higher at day 3 p.i., equivalent at day 7, and 
significantly lower at 10 day p.i. (Figure 5.2.3). The cells recruited to the BAL were further 
analysed by flow cytometry (section 2.9.6).The early difference in overall cell numbers is 
partly attributable to a marginally higher number of macrophages and neutrophils in lungs 
infected with v∆C16 at day 3. The converse is true for day 10. However these differences are 
not significant.   
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Figure 5.2.3 Characterisation of infiltrating leukocytes in the BAL of Balb/c mice by i.n. 
infection. The total number of viable cells in BAL was determined by trypan blue exclusion 
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(a). Data are means +/- SD of cell counts. In these cells, macrophages (b) and neutrophils (c) 
were identified by FACS using corresponding surface markers described in Methods. The 
means +/-SD of data from 5 infected mice were analysed as a group at indicated times by 
staining and flow cytometry. Asterisks indicate the days on which the data for v∆C16 are 
significantly different from both vC16 and vC16Rev groups (P<0.05, student’s T-test). 
 
5.2.4 The effect of C16 on recruitment and activation of T cells 
 
No significant differences in macrophages or neutrophils were seen and therefore T cells 
(Figure 5.2.4), NK cells and γδ T cells (Figure 5.2.5) in infected lungs were also analysed. 
There was an increase in the percentage of T cells present in the lungs infected by the 
deletion virus at day 3. Furthermore, there was a statistically significant (p<0.05) increase in 
the percentage of activated T-cells (CD69+) in the lungs early in infection (day 3) with 
v∆C16. This was true for both CD4+/CD3+ and CD8+/CD3+ subsets. By day 7 p.i., the overall 
number of T cells and their activation status was equivalent between the viruses. By day 10 
p.i., the overall T cells present in the lungs were significantly reduced in the v∆C16. These 
data indicate that the presence of C16 slows down the activation of T cells at the site of 
infection, and hence participates in slowing down the course of the infection. 
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Figure 5.2.4 Characterisation of T cells infiltrating into the lungs in Balb/c mice infected 
i.n. The percentage of T cells in infected lungs from 5 mice was analysed on day 3 (a), 7 (b) 
and 10 (c) p.i. CD4+ and CD8+ T cells were differentiated by corresponding surface markers. 
These cells were analysed further by identification of the activation marker CD69 on the cell 
surface, and the percentage of activated cells in each T cell cohort is shown. Asterisks 
indicate when v∆C16 cell levels are significantly different from both vC16 and vC16Rev 
groups (P<0.05, student’s T-test). 
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The proportion of NK, NK T and TCR γδ cells in infected lungs was also analysed (Figure 
5.2.5). The recruitment of these cells was not significantly different between v∆C16 and the 
control viruses at all timepoints analysed. 
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Figure 5.2.5 Characterisation of NK, NK T, TCRγδ cells infiltrating into the lungs of 
Balb/c mice by i.n. infection. The percentage of a) NK cells, b) NK T cells and c) TCRγδ in 
infected lungs of 5 mice was analysed on day 3, 7 and 10 p.i. NK cells were identified by 
staining for DX5 and data are expressed as a percentage of the total lymphocyte population. 
NK T cells were identified by co-staining for DX5 and CD3. TCR γδ cells were positive for 
the γδ receptor and CD3.  
 192
 5.2.5  The effect of C16 on humoral immunity 
As C16 modulates the cellular arm of the primary immune response, analysis of the humoral 
immune response was also undertaken. Mice were infected i.n. with 1 x 104 p.f.u. and blood 
samples were taken at day 7, 14, 21, and 28 p.i. The blood was allowed to coagulate and the 
serum was harvested and heated at 55 ºC to inactivate complement. Whole UV-inactivated 
VACV strain WR IMV, EEV proteins B5 and A56, and IMV proteins A27 and H3 were pre-
coated onto ELISA plates, and incubated with the serum from four individual mice from each 
virus set (as well as BSA-conjugated plate as a negative control). The serum was analysed for 
each of the five antigens at day 7, 14, 21 and 28 (Figure 5.2.7). End point titres were 
calculated for each antigen and presented graphically (Figure 5.2.6 and 5.2.7). VACV-
specific Abs were barely detectable at day 7 (Figure 5.2.7 but by day 14 p.i., Ab responses to 
each antigen examined were evident (Figure 5.2.6a). For each antigen, there was no 
significant difference between the Ab responses after immunisation with v∆C16 or control 
viruses. 
 
At 21 day p.i., a robust antigen response was seen (Figure 5.2.6b). Antibody titres were 
marginally higher in sera from the v∆C16-infected mice for every individual antigen on day 
21 p.i. (Figure 5.2.7) though none of these increases were significant. Antibody titres 
continued to rise up to day 28 (Figure 5.2.7) though there were no consistent differences 
between sera from v∆C16-infected mice and control mice.  
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Figure 5.2.6 Antibody levels in mouse serum at day 14, 21 and 28 p.i. Mice were 
inoculated intranasally with 1 x 104 p.f.u. of vC16, v∆C16 or vC16Rev  and serum from three 
individual mice was harvested and analysed by sequential dilution ELISAs against EEV (B5, 
A56) and IMV (A27, H3) surface proteins and virus-infected cell lysates (VACV). 
  
 
 194
VACV
Day 14 Day 21 Day 284.5
5.0
5.5
Lo
g 1
0(
A
nt
ib
od
y 
tit
re
s)
A56
Day 14 Day 21 Day 283
4
5
6
Lo
g 1
0(
A
nt
ib
od
y 
tit
re
s)
Day 14 Day 21 Day 28
4
5
Lo
g
10
(A
nt
ib
od
y 
tit
re
s) H3
A27
Day 14 Day 21 Day 280
1
2
3
4
5 vC16
v∆C16
vC16Rev
Lo
g 1
0(
A
nt
ib
od
y 
tit
re
s)B5
Day 14 Day 21 Day 283
4
5
Lo
g 1
0(
A
nt
ib
od
y 
tit
re
s)
Lo
g 1
0(
A
nt
ib
od
y 
tit
re
s)
Lo
g 1
0(
A
nt
ib
od
y 
tit
re
s)
Lo
g
10
(A
nt
ib
od
y 
tit
re
s)
Lo
g 1
0(
A
nt
ib
od
y 
tit
re
s)
Lo
g 1
0(
A
nt
ib
od
y 
tit
re
s)
 
Figure 5.2.7 Antibody end-point titres. Antibody end-point titres against EEV (B5, A56) 
and IMV (A27, H3) surface proteins and virus-infected cell lysates (VACV) were detected by 
ELISA at day 14, 21 or 28 post intranasal inoculation with 1 x 104 p.f.u. vC16, v∆C16 or 
vC16Rev in three mice for each group.   
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 5.2.6  The effect of C16 on inflammatory cytokines 
In chapter 4, data showed that C16 can inhibit IL-6 production in vitro. To assess whether 
C16 may exercise a similar role during in vivo infection, IL-6 production in the i.n. infection 
model was assayed. Mice were infected with v∆C16 and the control viruses, and IL-6 
production in lungs was quantified by ELISA. The analysis focussed early after infection 
because the changes in cellular recruitment were seen by day 3 p.i. (Figure 5.2.8).  IL-6 is 
upregulated in v∆C16 infected animals on days 2 and 3 p.i. (and the difference is significant 
on day 3). By day 4, no difference between the groups was seen. These data show that C16 
acts to suppress IL-6 production in vivo as well as in vitro. 
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Figure 5.2.8 IL-6 production in infected lungs. Mice were inoculated intranasally with 1 x 
104 p.f.u. of vC16, v∆C16 or vC16Rev as indicated. At day 1, 2, 3 or 4 p.i. infected pairs of 
lungs were harvested in RPMI-10, homogenised and lysed in RIPA buffer. The quantity of 
IL-6 in each pair of lung sample (n=3) was analysed by ELISA. (p<0.05, Student’s T Test) 
  
To confirm that C16 modulates of IL-6 production, the levels of ten distinct cytokines in the 
lung and BAL samples were analysed by multiplex assay. Again, an increase in IL-6 was 
seen in the lungs of mice infected with v∆C16 (Figure 5.2.9a). This was evident from days 1-
4 p.i., and, although with the sample number analysed (3 mice per virus), this was not 
significant on any of the days analysed, a consistent increase in IL-6 was evident. By day 7 
p.i., there was no difference between the viruses. The deletion of C16 does not affect the 
production of IL-1α which peaks early in infection (days 1 and 2), and drops afterwards 
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(Figure 5.2.9b). While no difference between the different viruses were found in IL-2, IL-5, 
IL-10, GM-CSF, IFN-γ or TNF-α, on days 1 and 2 p.i. there was a slight increase in IL-4 and 
IL-12 (Figure 5.2.9c,d). This implies that C16 may be involved in the downregulation of IL-4 
and IL-12 early in infection. By day 3 and 4 there is no change evident between the viruses 
for these cytokines.  
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Figure 5.2.9 Cytokine production in infected lungs Mice were inoculated intranasally with 
1 x 104 p.f.u. of vC16, v∆C16 or vC16Rev as indicated. At day 1, 2, 3, 4 or 7 p.i., infected 
pairs of lungs were harvested in RPMI-10, homogenised and lysed in RIPA buffer. The 
quantities of the indicated cytokines (a) IL-6, (b) IL-1β, (c) IL-4 and (d) IL-12 in the lung 
extracts (n=3) were analysed simultaneously by Luminex assay as detailed. 
 
BAL samples were also analysed (Figure 5.2.10). In these, IL-6 was significantly increased 
only on day 1 p.i. in the v∆C16-infected lungs (Figure 5.2.10a), but on days 2 and 3 was 
similar to that of the control viruses. IL-6 was even decreased in v∆C16-infected BAL 
samples relative to control viruses at day 4 and day 7 p.i. This acceleration in the course of 
IL-6 production is reminiscent of the accelerated recruitment and activation of T cells and in 
reduced virus titres later in infection. As in lung tissue, there were no changes in IL-2, IL-5, 
IL-10, GM-CSF or TNF-γ in BAL fluids from v∆C16 infection compared to controls. 
However, as was seen in the lung tissue, IL-4 and IL-12 was increased in BAL after v∆C16 
infection compared to control viruses. This was evident only at day 1 p.i. for both cytokines. 
 
The levels of IFN-γ in BAL fluids are also presented (Figure 5.2.10d).  In contrast to IL-6, 
IL-4 and IL-12, this cytokine was only seen above basal level after day 4 p.i. (Figure 
5.2.10d). Recent work has shown that IFN-γ is crucial to the mouse anti-viral response to 
vaccinia {Martinez, 2008 #355}, and it seems clear that VACV mechanisms exist to delay its 
synthesis until later than day 4 p.i. Given the data shown on IL-12, a molecule known to 
induce IFN-γ synthesis, it is clear that VACV may use multiple proteins to target IFN-γ 
regulation indirectly to limit its production early in infection (Alcami et al., 1999) 
 198
IL-6
1 2 3 4 7
0
10
20 vC16
v∆C16
vC16Rev
pg
/m
l
IL-4
1 2 3 4
0
50
100
150
pg
/m
l
IL-12
1 2 3 4 7
0
25
50
75
100
pg
/m
l
IFN- γ
1 2 3 4 7
0
250
500
750
pg
/m
l
a)
c) d)
b)
Days post infection Days post infection
pg
/m
l
pg
/m
l
pg
/m
l
pg
/m
l
pg
/m
l
pg
/m
l
pg
/m
l
pg
/m
l
pg
/m
l
pg
/m
l
pg
/m
l
 
 
Figure 5.2.10 Cytokine production in infected BAL Mice were inoculated intranasally with 
1 x 104 p.f.u. of vC16, v∆C16 or vC16Rev as indicated. At day 1, 2, 3, 4 or 7 p.i., BAL from 
three infected mice were harvested in PBS-EDTA. The quantities of the indicated cytokines 
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(a) IL-6, (b) IL-4, (c) IL-12 and (d) IFN-γ in the BAL of three mice from each group from 
each time point were analysed simultaneously by Luminex assay as detailed. 
 
5.3  Intradermal infection model  
 5.3.1 Intradermal infection 
To examine if loss of C16 affected virus virulence in the i.d. model, groups of 5 mice 
(female, C57Bl/6, 6-8 weeks old) were anaesthetized and infected i.d. in the ear pinnae with 
104 p.f.u. in 10 µl of PBS per ear as described previously (Tscharke et al., 2002). The titre of 
each virus inoculum used for infection was checked by titration of diluted virus samples on 
BSC-1 cells and the infectious doses administered were found to be within 1.5-fold for all the 
different viruses. The size of the VACV-induced lesions were measured daily with a 
micrometer (see section 2.9.2) and results are presented in Figure 5.3.1.  
 
In the i.d. model, v∆C16 showed no difference in virus virulence compared to control viruses 
and induced a similar sized lesions (n=5, p<0.05, Student’s T-test) throughout infection 
(Figure 5.3.1a). All lesions resolved completely by day 17. This observation indicated that 
C16 does not influence virus virulence in the i.d. model.  
 
The formation of skin lesions in the mouse i.d. model is likely to be due to a combination of 
direct tissue damage caused by virus replication and immunopathology resulting from the 
host response to virus infection. To further analyse the influence of the C16 protein in the i.d. 
infection, levels of VACV replication in infected ears were determined.  
 
There was no difference in the levels of virus in infected ears at days 5, 8 and 11 p.i. (Figure 
5.3.1b). This reaffirms that C16 does not affect virus replication in vivo, and indicates that the 
differences in virus clearance, which are effective in the lungs of mice infected i.n., are not 
reproduced in the i.d. infection model. 
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Figure 5.3.1 (a) C16 does not affect virulence in the i.d. model. Female C57BL/6 mice 
(n=5) were infected i.d. with 104 p.f.u. of the indicated viruses and the size of the lesion was 
measured daily. Data are means +/-SD of the lesion size. (b) C16 does not affect virus titres 
in the i.d. model. Female C57BL/6 mice (n=5) were infected i.d. with 104 p.f.u. of the 
indicated viruses in both ears. At the indicated day p.i. the animals were sacrificed, the ears 
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were removed and infectious virus was determined by plaque assay on duplicate layers of 
BSC-1 cells. Data are means +/- SD.  
 
5.3.2 The effect of C16 on the recruitment of leukocytes 
To assess whether C16 affected the inflammatory infiltrate, the migratory cells in the infected 
ears were collected by collagenase-based extraction (Jacobs et al., 2006) and analysed by 
flow cytometry. There was no difference in the overall number of infiltrating cells in v∆C16-
infected ears compared to controls (Figure 5.3.2a). Similarly there was no difference in 
numbers of neutrophils (Figure 5.3.2b), macrophages (Figure 5.3.2c) or T cells (Figure 
5.3.2d) at the site of infection at each time point measured.  
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Figure 5.3.2 Characterisation of leukocytes infiltrating into the ears of C57Bl/6 mice 
infected i.d. Mice (n=5) were infected in both ears with 1 x 104 p.f.u. of v∆C16 and control 
viruses and at the indicated times p.i. cells that migrated into each ear of each infected mouse 
were pooled. The total number of viable cells was determined by trypan blue exclusion. Data 
are expressed as means +/- SD of cells counts. In this cell population the neutrophils (b), 
macrophages (c) and T cells (d) were identified by appropriate surface markers as described 
in Methods. The means +/-SD of data from 5 infected mice were analysed by cell staining 
and flow cytometry at the days indicated.  
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5.4  Vaccination and challenge model 
To characterise further the immune response to the v∆C16, the effectiveness of this virus as a 
vaccine was compared to that of the wild type controls. Mice were vaccinated subcutaneously 
with 104 p.f.u. of vC16, v∆C16 or vC16Rev, and were challenged i.n. at 28 days p.i. with a 
lethal dose of vC16. The doses chosen were 100 LD50 or 50 LD50 for Balb/c mice of this age 
and hence even vaccinated mice begin to lose weight rapidly.  
 
For mice challenged with 106 p.f.u of virus (Figure 5.4.1 a and b), a similar trend in weight 
loss was observed for mice vaccinated with each of the three viruses (vC16, v∆C16 and 
vC16Rev). The mice lost up to 15 % of their body weight between day 1 and 2 post 
challenge, but recovery of this weight loss was rapid, with most mice starting to recover 
weight by day 3 post challenge, and had recovered completely by day 8. The trends were 
indistinguishable for the three groups. Only mild signs of illness were observed, and the mice 
returned to full health by day 5 post challenge. 
 
For mice challenged with 5 x 106 p.f.u. (Figure 5.4.1 c and d), weight loss was rapid and was 
maximal at day 3 post challenge, but as with the lower virus challenge dose there was no 
difference in the protection induced by immunisation with either v∆C16 or the control 
viruses. Mice started to gain weight by day 4 and had recovered their original body weight by 
day 8. The signs of illness were also equivalent between the different immunisation groups 
(Figure 5.4.1d).  Signs of illness peaked at day 4 when all mice showed hair ruffling. 
Thereafter, recovery was rapid, and animals returned to apparently full health by day 6. 
Given the dramatic weight loss, or up to 25 %, it was remarkable that the signs of illness were 
so limited. 
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Figure 5.4.1 Weight change and signs of illness of mice immunised i.d. with indicated 
vC16 viruses and challenged i.n. with vC16. Five mice were vaccinated i.d. with 104 p.f.u. 
of the indicated virus. All mice (a,b) were challenged i.n. 28 days p.i. with 1 x 106 p.f.u. of 
vC16 and weight change (a) and signs of illness (b) were measured daily. All mice (c,d) were 
challenged i.n. 28 days p.i. with 5 x 106 p.f.u. of vC16 and weight change (c) and signs of 
illness (d) were measured daily. The data are presented as the indicated mean +/- SEM. 
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5.5  Conclusions 
The deletion of C16 from the VACV WR genome causes attenuation of virus virulence in the 
murine i.n. model. This attenuation was manifested in significant differences in weight loss 
and signs of illness. Although, v∆C16 virus titres in infected lungs was equivalent to control 
virus-infected lungs at early times p.i., at later times, the virus titres were significantly 
reduced in v∆C16-infected lungs. This indicated that in the absence of C16, the virus can 
replicate efficiently in primary cells but that on induction of the immune response, in the 
absence of C16, virus clearance is quicker and more effective.  
 
Investigation of the infiltrating leukocytes supports this hypothesis. This showed a greater 
recruitment of all leukocytes after infection by v∆C16. In particular, more T cells were 
recruited early in infection, and more of these T cells expressed the activation marker CD69. 
By day 7 these differences between the virus groups had disappeared, but by day 10 there 
were fewer T cells after infection by v∆C16. These data fit with the more rapid clearance of 
virus from mice infected with v∆C16. 
 
Further investigation in the i.n. model showed that while there was no significant difference 
in the kinetics or titre of VACV-specific Abs after infection by the different viruses, there 
were notable differences in the cytokine responses to infection. IL-6 was shown in two 
separate assays to be significantly increased in the absence of C16. This supports the in vitro 
data showing that C16 can inhibit pro-IL-1α-induced IL-6 production, and suggests that this 
is one role for C16 in modulating the host response to infection. 
 
Furthermore, there was an increase in IL-4 and IL-12 levels early p.i. with v∆C16-infected 
BAL and lungs. While both cytokines are involved in CD8+ and CD4+ T cell expansion and 
proliferation, the balance between these two cytokines helps determine whether a Th1 or Th2 
response ensues, hence it is unusual that both seem to be elevated. Given the spike in IL-12 
levels in the v∆C16-infected mice, it is also surprising that the IFN-γ levels don’t see a 
concomitant increase, but it is possible that other immunomodulatory mechanisms can target 
multiple facets of these pathways (Alcami and Smith, 1995). 
 
Characterisation of v∆C16 in the i.d. model showed no significant differences in lesion size 
compared to control viruses. Virus titres from infected ears were also unaffected. Concurrent 
scrutiny of the cells recruited to the site of infection indicated that there were no differences 
 206
in total numbers of cells infiltrating into ears infected by v∆C16 compared to control viruses, 
nor were there differences in the numbers of T cells, macrophages and neutrophils recruited.  
 
Despite the reduction of virulence of v∆C16 in the i.n. model, the virus was able to induce 
protective immunity to lethal challenge as well as control viruses. These data indicate that, 
despite the difference in T cell recruitment and activation in a primary infection in the 
absence of C16, the virus lacking C16 was no less protective as a vaccine.  
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Chapter 6 
Discussion 
 
6.1  Introduction 
Since the eradication of smallpox, research with VACV has remained intense. Two overall 
goals direct these research interests. The first is to increase our understanding of VACV-host 
interactions. This holds the dual potential of increasing our understanding of the host immune 
system, and further enlightening us as to how VACV exercises its myriad of mechanisms to 
subvert these immune responses. Understanding these immunomodulatory mechanisms also 
offers potential to develop new immunoregulatory treatments. The second broad arm of 
VACV research is focussed on the development of vaccine vectors. The large size of the 
VACV genome, the ease of genetic manipulation, and the broad host cell range are factors 
which, when added to an improving safety profile, combine to propel VACV to the forefront 
of vaccine delivery vehicles. 
 
Numerous VACV proteins interfere with the host immune response to infection. 
Identification and characterisation of these proteins is necessary both to understand better the 
viral interaction with the host, but also to enable improvement of VACV immunogenicity. 
These immunomodulatory proteins can be divided into two main groups. Proteins such as 
B18, B8, B15, C12 and CrmE are secreted from the infected cells and bind inflammatory 
cytokines IFN-α/β, IFN-γ, IL-1β, IL-18 and TNF-α respectively. These prevent the activation 
of the inflammatory cascades initiated by these cytokines, and impede the host immune 
response to infection. Others act within the cell to downregulate the intracellular signalling 
cascades that coordinate the host anti-viral responses. Proteins such as A46, A52, K7, B14, 
K1 and M2 inhibit the intracellular TLR/IL-1 receptor pathway and NF-κB activation, while 
F1 and N1 inhibit pathways leading to apoptosis. 
 
However, while the proteins detailed above have been identified and their roles in infection 
have been delineated, there are many VACV proteins that remain ill-defined. At the outset of 
this project, C16 was one of these uncharacterised constituents of the VACV genome. It was 
noted that the C terminus of C16 contained a 6 aa stretch that was identical to the 
immunosuppressive peptide fragment of the IL-1Ra protein (Kluczyk et al., 2002). IL-1Ra is 
most well-characterised as a secreted protein, which competitively inhibits binding of IL-1α 
and IL-1β to the IL-1R, and so inhibits IL-1R signalling (Arend and Gabay, 2000). VACV 
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already targets the IL-1 pathway by several mechanisms, indicating the importance of IL-1 in 
host defence against poxvirus infections. VACV restricts the formation of IL-1α and IL-1β in 
infected cells by expressing a caspase 1 inhibitor (Dobbelstein and Shenk, 1996; Kettle et al., 
1997) and blocks the function of IL-1β systemically by the expression of a soluble IL-1β 
receptor (Alcami and Smith, 1992; Alcami and Smith, 1996; Spriggs et al., 1992a). 
Furthermore, VACV expresses intracellular proteins such as A46 (Bowie et al., 2000; Stack 
et al., 2005), A52 (Bowie et al., 2000; Harte et al., 2003) and B14 (Chen et al., 2006; Chen et 
al., 2008) that inhibit IL-1α- or IL-1β-induced signalling from the IL-1R. 
 
The goals of this thesis were thus to characterise C16, a potential immunomodulatory protein, 
and assess whether it made any contribution to virus virulence. Additionally, characterisation 
of the basic properties of the C16 protein was prioritised so as to understand where, when and 
how C16 might exert its function. Finally, the mechanisms by which C16 affects the host 
immune response were investigated in well-characterised in vitro and in vivo systems. 
 
6.2  Discussion 
 6.2.1 C16L gene and protein product 
 
The C16L gene is located in both ITRs of the VACV WR genome and is surrounded by 
immunomodulatory genes. For example, the gene upstream of C16L encodes the VACV 
growth factor (Buller et al., 1988; Twardzik et al., 1985), which promotes cell growth, and 
the ORF two genes downstream from C16L encodes the IL-18-binding protein (Reading and 
Smith, 2003; Smith et al., 2000; Symons et al., 2002a). The C16L gene is predicted to encode 
a 331 aa protein with a mass of 38.5 kDa (www.poxvirus.org). Bioinformatic analysis 
indicated that very closely related proteins (95-99 % aa identity) are encoded by 5 OPV 
species (VACV, VARV, ECTV, CPXV and HSPV) but that the C16L ORF is disrupted in 3 
others (TATV, CLMV, MPXV). In addition, C16 is related to a family of OPV proteins 
exemplified by C4 from VACV WR, and another more distantly related group from other 
chordopoxviruses, including DPXV, SPPV, LSDV, GPXV, YMTV and FWPV. The C16 
protein was expressed by all VACV and CPXV strains tested and was synthesised early 
during infection. This early expression profile was consistent with analysis of the C16L 
promoter and a genome-wide transcriptome analysis that detected C16 mRNA by 1 h.p.i. 
(Assarsson et al., 2008). The independence of C16 expression from viral DNA replication 
may be consistent with a role for C16 in protecting infected cells from immune attack as 
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efficiently and quickly as possible. Notably, some of the other VACV proteins involved in 
interference with the IL-1 pathway are also made early during infection (Bowie et al., 2000; 
Harte et al., 2003; Kettle et al., 1997; Stack et al., 2005).  
 
The intracellular location of the C16 protein makes its postulated function as an IL-1Ra-like 
protein that mediates extracellular blockade of signalling from the IL-1R (Kluczyk et al., 
2004; Kluczyk et al., 2002) unlikely. C16 would only be in a position to modulate signalling 
from the IL-1R after release due to lysis of infected cells, and while this might happen very 
late during infection, such a function is unlikely to be its primary role given it early 
expression. Future work should be undertaken to determine whether C16 protein can bind to 
IL-1R in vitro to establish whether this post-cell lysis function is possible. However, there are 
also icIL-1Ra proteins, produced by differential splicing (Butcher et al., 1994; Malyak et al., 
1998a; Malyak et al., 1998b) and whose functions remain poorly defined. These icIL-1Ra 
isoforms were reported to downregulate the IL-1 pathway (Arend et al., 1998; Banda et al., 
2005; Watson et al., 1995). It is therefore more likely that C16 functions by mimicking icIL-
1Ra. Interestingly, the DPXV protein 054 shares 89 % aa identity with the secreted IL-1Ra 
protein from Bos Taurus (Afonso et al., 2005) and is significantly more likely to mimic 
extracellular sIL-1Ra  activity than C16, but does not have a counterpart in VACV or other 
OPVs.  
 
Biochemical fractionation and immunofluorescence analysis showed that C16 localised to the 
nucleus and cytoplasm in infected and transfected cells. Early after infection the localisation 
was strongly nuclear, while at later times the localisation was more equivalent between the 
cytoplasm and the nucleus. This presence in the nucleus was shown to be the result of active 
translocation rather than passive diffusion. C16 lacks a recognisable NLS and nuclear export 
signal, suggesting it might be transported in a complex with another protein. The partial 
nuclear localisation of C16 is interesting because it is one of only a few nuclear proteins 
encoded by VACV, which replicates in the cytoplasm. Another example is the E3 protein 
(Yuwen et al., 1993) that binds dsRNA (Chang et al., 1992) and contributes to virulence 
(Brandt and Jacobs, 2001). In contrast, a group of other VACV proteins that affect 
transcription of NF-κB-responsive genes function from within the cytoplasm (Bartlett et al., 
2002; Bowie et al., 2000; Chen et al., 2006; Chen et al., 2008; Shisler and Jin, 2004). There 
are also reports of endogenous nuclear proteins being recruited to the cytoplasm during 
VACV infection (Oh and Broyles, 2005). Interestingly, pro-IL-1α possesses a NLS 
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(Wessendorf et al., 1993) and translocates into the nucleus in response to endotoxin 
stimulation and when overexpressed in mammalian cells (McMahon et al., 1997; Palmer et 
al., 2005; Werman et al., 2004). This protein can act as an intracrine proinflammatory 
transcriptional activator (Werman et al., 2004). SaOS-2 osteosarcoma cells stably transfected 
with pro-IL-1α showed reduced cell growth. In these cells, pro-IL-1α is localised to the 
nucleus and growth suppression was attributed to an intracellular effect of pro-IL-1α that 
could not be reversed by coexpression of icIL-1Ra (Werman et al., 2004) which was localised 
to the cytoplasm. In certain cases, icIL-1Ra localised at least partially to the nucleus, and this 
translocation was linked to inhibition of some biological effects of pro-IL-1α (Gabay et al., 
1997b). By contrast, inhibition of IL-1α-induced gene expression, by modification of mRNA 
stability or by inhibition of p38MAPK and NF-κB pathways, is mediated by icIL-1Ra acting 
in the cytoplasm (Watson et al., 1995).  This raises the possibility that nuclear translocation 
of icIL-1Ra is required to inhibit certain pro-IL-1α activities but not others. Hence, the 
presence of C16 in both the nuclear and cytoplasmic compartments indicates it could 
potentially mimic any of the distinct icIL-1Ra functions.  
 
The significance of a smaller approximately 25-kDa protein, that consistently cross-reacts 
with the anti-C16 Ab, remains unclear. The size was inconsistent with the protein being C4, 
the related VACV protein with a 64 % aa similarity to C16, and the absence of the band in 
v∆C16-infected cells implicates the C16L ORF as the coding region for this protein. The 
band was also present at slightly varying sizes in most different VACV and CPXV strains 
and was thus its expression was not confined to VACV WR infection. A protein of 
approximately the same size was found in E. coli-expressed C16 that was purified by nickel 
affinity chromatography and this reacted with an anti-His Ab. However, immunoblotting with 
anti-C16 Ab showed that this was a bacterial protein unrelated to C16 and was more likely to 
be the bacterial protein YodA, a histidine-rich E. coli protein often purified by bacterial 
lysates by nickel affinity chromatography (David et al., 2002). The smaller product of C16 
was not seen in transfected cells or in the presence of an inhibitor of late viral gene 
expression. This either implies that the 25-kDa protein is the product of differential late gene 
expression from somewhere within the C16L ORF (i.e. an internal initiation site) or that the 
post-translational processing of the 25-kDa protein is dependent on the expression of a late 
viral protein. The absence of this additional protein in VACV COP infections is relevant 
because comparison of the VACV WR and COP C16L genes reveals no difference in 
sequence that create a late internal initiation sequence in VACV WR gene and which was not 
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present in VACV COP. Most VACV late genes do not have a transcription termination 
sequences, and consequently are long and heterogenous in length, much longer than the gene 
of interest. For this reason the presence of a late transcription termination sequence WR but 
not COP is also unlikely.  Hence, the processing of the translated protein is a more promising 
explanation. While, there are three aa changes between WR and COP sequences of C16, none 
of these changes are at positions that would result in the generation of proteins of the 
approximate mass of 25 kDa, nor do they generate known protease cleavage sites. The 25-
kDa protein product needs to be investigated further by pulse-chase analysis to establish a 
precursor-product relationship, and by purification and mass-spectrophotometric analysis to 
identify the exact nature of this smaller protein. 
 
Recombinant C16 was produced in E. coli. Analysis of this protein by size exclusion 
chromatography and native PAGE indicated that recombinant C16 is an oligomeric protein 
that can form dimers and tetramers. The largest recombinant C16 complex eluted at 
approximately 140 kDa. In non-reducing conditions, recombinant C16 is oligomeric raising 
the possibility that C16 may engage in intramolecular disulphide bonds. Recombinant IL-1Ra 
also forms dimers that retain the proteins native-like structure and protein activity (Chang et 
al., 1996). Whether C16 or IL-1Ra could form homodimers and/or heterodimers was 
investigated further in yeast-two-hybrid system analysis. The dimerisation of C16 seen by gel 
filtration and by native PAGE was not confirmed by yeast-two hybrid analysis. Neither was 
an IL-1Ra dimerisation nor a C16:IL-1Ra interaction seen.  
 
The recombinant protein was used in an in vitro kinase assay to assess whether C16 was 
phosphorylated by either of the two kinases that showed the strongest consensus 
phosphorylation sites in the C16 protein sequence. PKA can phosphorylate C16 weakly in 
vitro whereas CKII has no effect. PKA is engaged in a number of diverse signalling 
pathways. For example, PKA kinase signalling activity counteracts apoptosis induced by 
IFN-α in human epidermoid cancer cells (Naviglio et al., 2007). Activation of the PKA 
increased IL-1-induced IL-6 expression synergistically (Bergamaschi et al., 2006; Szabo-
Fresnais et al., 2008). Furthermore, cAMP and PKA can modulate some of the effects of pro-
IL-1α as well as regulating its expression (Park et al., 2004). The effect of C16 on PKA 
phosphorylation of other targets should be analysed to assess whether the phosphorylation of 
C16 can antagonise the phosphorylation of other PKA targets. Equally, given the effect of 
C16 on the signalling cascades involved in ISRE activation and IL-6 production, the kinase 
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activities of the proteins involved in these cascades should be analysed in the presence and 
absence of recombinant C16 to establish whether C16 can inhibit kinase activity in vitro. 
 
 
 6.2.2  Role of C16 in virus infection 
Gel filtration of lysates from VACV-infected cells indicated C16 is present in a large 
complex (440 kDa – 669 kDa) during viral infection and the identification of these interaction 
partners will be an important step towards understanding the mechanism of C16 action. 
Given the similarity between C16 and icIL-1Ra, and that icIL-1Ra was reported to interact 
with CSN3, a protein of the COP9 signalosome complex, I investigated if C16 co-purified or 
interacted with proteins of this complex. Gel filtration analysis indicated that C16 did not 
copurify with CSN3, buy did co-elute with other CSN proteins (CSN1, CSN5 and CSN8). 
However, testing if C16 interacts with these proteins by immunoprecipitation has proved 
inconclusive at this point, and should remain a priority. The study analysing icIL-1Ra:CSN3 
interaction (Banda et al., 2005) demonstrated that this interaction downregulates IκB 
phosphorylation in response to overexpression of pro-IL-1α and in so doing inhibits NF-κB 
gene expression (Garat and Arend, 2003). It was shown in a yeast-two hybrid screen that C16 
can interact with K1 (McCraith et al., 2000), a protein affecting both host range and 
activation of the NF-κB pathway (Bradley and Terajima, 2005; Shisler and Jin, 2004) by 
preventing the degradation of the IκB protein. In view of this, the gel filtration analysis was 
expanded to determine if proteins of the IκB / NFκB pathway co-purified with C16. This 
confirmed that C16 and IκB co-purify and so might interact. Alternately, this co-purification 
may be entirely coincidental. In this vein, C16 was tested for its ability to modulate NF-κB 
gene expression stimulated by TNF-α and IL-1α but no modulation was detected. In this 
respect C16 activity differs from icIL-1Ra1 function.  
 
C16 was then tested in other reporter assays and it was found to downregulate IFNα-induced 
ISRE gene expression in a dose-dependent manner. To investigate how C16 might 
downregulate ISRE gene expression, the modulators which transduce the IFNα signal were 
analysed. Binding of IFNα to IFNAR, induces the catalytic activation of JAK that interacts 
with and phosphorylates the STAT1 protein, allowing interaction with STAT2 and IRF9, and 
the translocation of this ISGF3 complex into the nucleus, where it activates the transcription 
of genes containing an ISRE-promoter sequence.  C16 did not affect the phosphorylation of 
the overall level of STAT1 either in an infection or a transfection model. So although C16 
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and STAT1 co-purify by gel filtration, C16 did not affect the phosphorylation or stability of 
this protein. An additional experiment would be to test if C16 affects translocation of STAT1 
into the nucleus. STAT1 is entirely cytoplasmic in VACV-infected cells, but this may be 
because VACV protein H1 de-phosphorylates STAT1 and so prevents transport .Therefore, a 
role for C16 in STAT1 translocation should be investigated by ectopic expression of C16 by 
transfection.  At this point, STAT2 and IRF9 phosphorylation, multimerisation or 
translocation patterns have not been analysed and this analysis should be undertaken 
forthwith.  
 
p38 MAPK is also involved in the transduction of the IFN signal and is a defined target of 
icIL-1Ra (Garat and Arend, 2003). Like C16, this protein is present in both nucleus and 
cytoplasm. Therefore, the effect of the C16 on the p38 MAPK-induced ISRE reporter gene 
expression was analysed. Pharmacological inhibition of p38 MAPK reduced IFNα-stimulated 
ISRE-dependent gene expression, indicating that the extent of p38 MAPK involvement in the 
IFN-α signal transduction. In the presence of the p38 MAPK inhibitor, VACV protein K7 
could still inhibit ISRE-reporter gene expression, and the combination of K7 and the inhibitor 
of p38 MAPK inhibited IFNα-gene expression to baseline levels.  However, while C16 
inhibits ISRE-reporter gene expression in untreated cells, in the presence of the inhibitor of 
p38 MAPK, C16 can no longer show any inhibition of ISRE-reporter gene expression. This 
implies that C16 and K7 act on distinct elements of the ISRE-reporter pathway, and that C16 
may be involved not in the STAT1 pathway, but in the p38 MAPK pathway of IFN-α-
induced gene expression. However, while C16 eluted in the same fraction as STAT1, it did 
not elute with p38 MAPK. This implies that if C16 is involved in the downregulation of the 
p38 MAPK, it is involved downstream of MAPK and possibly within the nucleus, or 
alternatively that any interaction is transient and may not be seen by gel filtration analysis. 
Analysis of the phosphorylation state of p38 MAPK in vC16 or v∆C16-infected cells is 
inconclusive. 
 
Analysis of the role of C16 during virus infection utilised a set of recombinant viruses, 
namely vC16, v∆C16 and vC16Rev. These viruses were constructed through homologous 
recombination and with the use of selective drugs, and the virus genomes were then 
examined by PCR analysis. The PCR analysis confirmed the loss of the C16L gene and that 
the border between the ITR and the unique sequence had not undergone any other deletions. 
Restriction enzyme mapping confirmed these viruses had the predicted genome structures. 
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The isolation v∆C16 demonstrated that C16L is not essential for survival and replication of 
VACV in vitro, consistent with previous analysis of mutants with deletions in the ITR 
encompassing the C16L ORF (Perkus et al., 1991).  
 
The deletion mutant, v∆C16, formed a slightly smaller plaque when compared with wildtype 
and revertant controls, but replicated normally in the cell lines analysed. There was no defect 
in virus-induced actin tail formation, a pre-requisite for efficient cell-to-cell spread. Hence, 
the basis for this small plaque phenotype remains unexplained. This effect on plaque size did 
not appear to be cell-type specific, in contrast to the loss of the K1 protein that interacts with 
C16 (Bradley and Terajima, 2005). One possibility, consistent with the presence of C16 in 
both the nucleus and cytoplasm, is that C16 modulates intracellular signalling pathways and 
that over several cycles of infection, replication, release and re-infection this provides an 
advantage for the virus. Such a subtle difference might not be manifest during analysis of 
replication kinetics. Equally, given the effects of C16 on the ISRE and IL-6 pathway, it is 
likely that C16 may change the local concentration of inflammatory mediators, which would 
be a cause a localised increase in concentration in cytokines or IFNs and thereby change cell 
physiology around the site of infection and affect plaque size.  
 
v∆C16 had reduced virus virulence in a murine i.n. model (systemic infection) but not in an 
i.d. (local infection) model. The attenuation was characterised by significant reductions in 
virus-induced weight loss, signs of illness and virus titres. Although, v∆C16 virus titres in 
infected lungs was equivalent to control virus-infected lungs at 2 days p.i., at later times the 
virus titres were considerably reduced in v∆C16-infected tissues. This indicated that in the 
absence of C16, the virus can replicate as efficiently as the control viruses in vivo, but, in the 
absence of C16, virus clearance is accelerated.  
 
Investigation of this attenuated phenotype by analysis of lymphoid cells within infected tissue 
indicated a difference in the number and properties of the infiltrating cells and the kinetics of 
their recruitment. At 3 days p.i., the number of infiltrating cells was greater after infection 
with v∆C16, and more CD4+ and CD8+ T cells were activated (CD69+). By day 7 the 
numbers of cells present and the proportion that were activated were equivalent for all 
viruses. However, by day 10 the total number of infiltrating cells and the number of CD4+ 
and CD8+ T cells were reduced after infection with v∆C16, consistent with more rapid 
resolution of the infection. The accelerated recruitment and activation of T cells early after 
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infection fits with the diminished virus titres observed from day 4 p.i., and with the reduced 
weight loss and signs of illness.  
 
The recruitment of leukocytes to sites of inflammation is dependent on the expression of 
chemokines and cytokines. It follows that C16 is either directly or indirectly influencing the 
expression or function of such inflammatory mediators. The intracellular location of C16 
suggests that it might mediate such an effect by modulating intracellular signalling pathways. 
Given the role of icIL-1Ra in regulating pro-IL-1-induced IL-6 (Garat and Arend, 2003) and 
the similarity of C16 to icIL-1Ra, the potential of C16 to regulate IL-1-induced IL-6 
expression was tested in vitro and the levels of IL-6 were measured in vivo. In the absence of 
C16, the quantity of IL-6 in the infected BAL and lung was higher early after infection. In 
particular, in a multiplex analysis screen, IL-6 was markedly increased in v∆C16-infected 
lungs at days 1 through to 4 p.i. This suggests that C16 may be involved in the 
downregulation of IL-6 production, early after VACV infection.  
 
This in vivo observation correlated with the ability of C16 to down-regulate pro-IL-1α-
induced IL-6 production in vitro. While one method of IL-1-mediated upregulation of IL-6 
production is exerted at an extracellular level, when IL-1α/β binds to the IL-1R to induce a 
stream of signalling cascades which culminate in the induction of IL-6 gene expression 
(among other acute phase proteins and inflammatory cytokines and chemokines), intracellular 
pro-IL-1α can also induce IL-6 expression (Garat and Arend, 2003; Palmer et al., 2005; 
Werman et al., 2004). Furthermore, icIL-1Ra downregulates this intracellular inflammatory 
response (Garat and Arend, 2003; Palmer et al., 2005). The in vitro analysis presented here 
reproduced these effects for pro-IL-1α and icIL-1Ra, and it was shown that C16 inhibited this 
pro-IL-1α-mediated induction of IL-6.  
 
IL-6 is a potent, inflammatory cytokine that mediates a plethora of physiological functions, 
including the developmental differentiation of lymphocytes, cell proliferation, and cell 
survival and amelioration of apoptotic signals (Heinrich et al., 1998; Kamimura et al., 2003). 
IL-6 is secreted by T cells and macrophages and is traditionally considered an activator of 
acute phase responses and a lymphocyte stimulatory factor (Kishimoto et al., 1995). IL-6 was 
identified as a B-cell differentiation factor that induced maturation of B cells into Ab-
producing cells (Hirano et al., 1985). Analysis of the role of IL-6 in the context of a poxviral 
infection, showed that IL-6 expression either from VACV or from non-replicating fowlpox 
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vectors, enhanced numbers of specific antiviral IgG plasma cells, and serum IgG levels many 
fold (Leong et al., 1994; Ramsay et al., 1994a; Ramsay et al., 1994b). In light of this, an 
investigation of the effect of C16 on the recruitment and proliferation of IgG plasma cells at 
the site of infection would be interesting. If there was an effect on B cell maturation, it would 
also be expected that the Ab responses to infection would be different in the absence of C16. 
Despite the reduction of virulence of v∆C16 in the i.n. model and the difference in T cell 
recruitment and activation, v∆C16 was as effective as wild type and revertant controls in 
inducing protective immunity against subsequent virus challenge with an otherwise lethal 
dose of VACV strain WR. This suggested that the acquisition of humoral immunity, known 
to be important for protection against VACV, might be unaltered in the absence of C16. If 
there was an effect on B cell maturation, it would also be expected that the Ab responses to 
infection would be different in the absence of C16. Ab responses to EEV antigens, IMV 
antigens and whole VACV were therefore analysed at several times p.i. The only notable 
difference was that there were marginally higher Ab titres to every antigen in v∆C16-infected 
animals, at day 21 p.i. However, none of these changes were statistically significant. As the 
response to every antigen was increased in the absence of C16, it may mean that other times 
between day 14 and day 21 should be investigated to see if C16 influences the speed of 
acquisition of the VACV-specific Ab response. 
 
IL-6 has a positive effect on haematopoiesis (Ikebuchi et al., 1987). This may offer an 
explanation for the generalised upregulation on infiltrating cells in v∆C16-infected BAL, and 
for the increased proliferation and activation of T cells in v∆C16-infected lungs. IL-6 is also 
involved in the activation of T cells (Lotz et al., 1988). IL-6 receptors are expressed on 
resting T cells, and IL-6-induced IL-2 receptor activation and IL-2 production in T cells 
(Noma et al., 1987). IL-6 also induces T cell growth (Ceuppens et al., 1988; Takai et al., 
1988), proliferation and activation (Ceuppens et al., 1988; Lotz et al., 1988). In the latter 
function, IL-6, in concert with IL-1, controls the initial steps of the T-cell activation, with 
CD8+ being the target cells. IL-6 enhances IL-2 responsiveness, and IL-6 and IL-1 act in 
synergy to stimulate T-cell production of IL-2 (Ford et al., 1991; Renauld et al., 1989). The 
subsequent interaction of IL-2 with its high-affinity receptor promotes the rapid clonal 
expansion of the T-cell population (Smith, 1992). Activation of T cells is initiated by T cell 
receptor (TCR) cross-linking but also requires co-stimulatory signals (Mueller et al., 1989). 
These include molecules such as B7.1 and B7.2 but can also involve inflammatory cytokines 
(Renauld et al., 1989). Early work indicated that both IL-1 and IL-6 could both provide co-
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stimulatory signals for activation of primary CD8+ and CD4+ T cells (Stein and Singer, 1992) 
and in the presence of either of these molecules and TCR-crosslinking, there is activation of 
CD3-induced proliferation and IL-2 secretion by both CD4+ and CD8+ T cells. These data 
may indicate that the upregulation of IL-6 seen in the absence of C16, may be one of the 
reasons behind the upregulation of T cell activation in the v∆C16-infected lungs.  
 
C16 had a marginal effect on apoptosis in transfected cells. After staurosporine treatment, 
C16 induced more apoptosis than cells transfected with an empty vector. This may be due to 
any number of reasons. Structural predictions (www.expasy.cdtk.edu) shows that the C16 is 
likely to be predominantly β-sheet, rather than the alpha-helical structures of the Bcl-2 
proteins involved in pro- and anti-apoptotic signals (Graham et al., 2008). Proteins outside of 
the Bcl-2 family of cell survival and apoptosis also modulate apoptosis. In particular, IL-6 
acts as a potent survival signal and can prevent T-cell apoptosis by binding to its soluble 
receptor and activating a signalling cascade which causes Bcl-2 and Bcl-xL activation and 
enhanced survival (Atreya et al., 2000; Catlett-Falcone et al., 1999). IL-6 plays a crucial role 
in cell survival in many cell lines including fibroblasts, osteoclasts and endothelial cells 
(Giraudo et al., 1996; Kudo et al., 2003; Mihara et al., 1995). The inhibition of endogenous 
IL-6 production by C16 may be responsible for the slight increase in apoptosis seen in C16-
transfected cells. IL-6 and Insulin-like growth factor-1 (IGF-1) afford protection against Dex-
induced apoptosis by up-regulation of Bcl-xL, and Mcl-1 (through STAT1 and STAT3 
proteins) and by activation of the MAPK and PI3K/Akt pathways, which contribute to 
inactivation of caspase 9 (reviewed in (Oancea et al., 2004)). Data discussed above shows 
that C16 can downregulate IL-6 production, and the slightly pro-apoptotic activity of C16 
may be due to inhibition of the production of the IL-6 survival signal.  
 
IL-4 and IL-12 also show marginal increases in both the lungs and BAL of v∆C16-infected 
mice at day 1 and day 2 p.i. MHC II-restricted T cells are classified into two groups, 
designated Th1 and Th2, based on their production of characteristic cytokines. Th1 cells are 
predominantly involved in CD8+ T cell priming and dominate immune responses targeted at 
viral and bacterial infections, resulting in a polarisation towards cell-mediated (CTL) effector 
functions. Th2 cells are involved in B-cell priming and are prominent in the control of 
parasitic infections (Mosmann et al., 1986), and result in a skew towards humoral immunity. 
For example, IL-12 secreted by APCs such as macrophages and DCs plays a pivotal role in 
differentiation of Th1 cells. IL-12 is a heterodimeric cytokine that promotes the 
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differentiation of naïve CD4+ T cells to the Th1 phenotype and suppresses expression of Th2 
cytokines. It is a critical regulator of Th-1 driven immune responses. In contrast, IL-4 is 
known to be the most potent cytokine to initiate Th2 cell differentiation. IL-4 produced by 
naïve CD4+ T cells themselves promotes differentiation into Th2 cells (Agnello et al., 2003; 
Murphy and Reiner, 2002).  
 
The CTL response to poxviruses is dependent on the production of IFNγ and Th1 cytokines, 
which contribute as effector molecules in the successful clearance of infection (Ramsay et al., 
1993). In VACV, the expression of IL-4 by a recombinant virus can significantly impair the 
ability of the host to clear this pathogen, tipping the balance significantly in favour of the 
virus (Andrew and Coupar, 1992). Mice deficient in IL-6 or IL-12 are generally more 
susceptible to viral infection (Ramshaw et al., 1997). The early production of Th2 cytokines 
and IL-4 inhibits the development of CTLs from precursor cells and can even promote the 
development of CD8+ T cells that lose their cytotoxicity (Erard et al., 1993). IL-6 itself has 
been implicated in regulating the production of IL-4 (Heijink et al., 2002). It was 
demonstrated that IL-6 induced initial IL-4 production in naïve CD4+ cells thereby polarising 
these cells into Th2 cells (Rincon et al., 1997). In fact, the presence of IL-6 upregulates the 
production of all Th2-like cytokines and this upregulation is blocked by inhibition of the p38 
MAPK pathway (Heijink et al., 2002), while inhibition of either ERK or PI3K have no such 
effect. This study also showed that the priming effect of IL-6 on IL-4 gradually disappears 
after longer incubations, which may explain why the upregulation of IL-6 seen up to day 4 
p.i. is only reflected in upregulation in IL-4 at earlier timepoints.  
 
IL-4 production can itself differentially regulate IL-12 production hence their coincident 
upregulation is not unprecedented. IL-12 augments the Th1 response by inducing T cell 
proliferation and activation (Gately et al., 1998; Trinchieri, 1993). In fact, while both IL-6 
and IL-4 can suppress TLR-dependent production of IL-12 (Koch et al., 1996), whereas there 
are also some more recent studies demonstrating that IL-4 can enhance IL-12 production 
(Ebner et al., 2001; Hochrein et al., 2000). It is the balance between the levels of IL-4 and IL-
12 early during an immune response that may be response to bias the generation of Th2 and 
Th1 cells respectively, and the other cytokines, as well as the APCs present at the site of 
infection may synergistically determine the response to infection (Robinson et al., 1997). 
Thus it is possible that while many cytokines are upregulated on initial infection, selection 
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then occurs over the initial 48 hpi, which determines the pathway that the antiviral immune 
response engages. 
 
The C16-directed inhibition of IL-6 production may be explained in several ways by data 
presented here. Reporter assays analysing the NF-κB-induced gene expression in the presence 
of transfected C16, showed that C16 had no effect on this pathway, so this pathway of IL-6 
upregulation does not, at this juncture, seem plausible. More recent work has shown that 
LPS-induced IL-6 production is regulated by a JAK/STAT pathway (Kimura et al., 2005). 
Yasuda has shown that IFN-α production by murine DCs is required for IL-6 production 
implying a relevant role for the ISRE reporter downregulation shown by C16 (Yasuda et al., 
2007). That study concluded that IL-6 production induced by TLR3 and TLR7/8 ligands was 
almost entirely dependent on stimulation of the ISRE pathway, through IFNAR.  
 
Induction of IL-12 can also be brought about by diverse TLR stimuli. In particular, TLR3, 
TLR4 and TLR8 induce the production of this inflammatory cytokine (Bekeredjian-Ding et 
al., 2006; Gautier et al., 2005; Re and Strominger, 2001). Again, while NF-κB-dependent 
gene expression was considered the prime instigator of this, recently it was shown that a type 
I IFN loop is also involved in TLR-induced IL-12 secretion (Gautier et al., 2005; Goriely et 
al., 2006). IL-12 is partially induced by ISREs in its promoter region (Masumi et al., 2002; 
Musikacharoen et al., 2005) and an ISRE was also identified in the IL-4 promoter (Li-Weber 
et al., 1994). Complementary to this, further analysis indicated that the p38MAPK pathway 
was involved in a cooperative manner to enhance antigen-induced IL-4 production in mast 
cells (Hirasawa et al., 2000). CD28 initiates phosphorylation of p38MAPK and this 
phosphorylation plays an important role in the expression of IL-4, (Tamma et al., 2006). 
There is a dose-dependent inhibition of IL-4 secretion and cell proliferation in the presence of 
inhibitors of p38 MAPK (Tamma et al., 2006). The novel upregulation of both of these 
cytokines early after v∆C16 infection, may be as a result of the absence of the C16-directed 
inhibition of ISRE activity as demonstrated by C16 in vitro. 
 
6.3  Future work  
An important element of the continuing investigation of the function of C16 is the 
identification of interaction partners of C16.  In line with this, I have constructed a TAP-
tagged C16, and it will be used to identify the proteins that bind to C16. It is hoped that this 
will define where C16 acts in the above pathways. Direct immunoprecipitations will be 
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attempted to assess interactions between C16 and molecules involved in icIL-1Ra function, 
the transduction of the ISRE signal, or in the induction of IL-6 production. Proteins such as 
the CSNs, the STATs, p38 MAPK, and other transducers of the relevant signalling cascades 
will be investigated in direct immunoprecipitation analysis. Other proteins co-precipitated or 
pulled-down with tap-tagged C16 will be purified by 2D-SDS PAGE and analysed by mass 
spectrometry to identify novel interaction partners.  
 
The localisation of these interaction partners in the presence of C16 should also be 
considered. At this juncture, we have shown that C16 does not affect phosphorylation of the 
downstream modulators of the signalling cascades investigated. However, the presence of 
C16 in the cytoplasm and nucleus may affect the localisation of these key signalling proteins 
and prevent them from translocating to the nucleus to exert their role in antiviral immunity. 
Thus the translocation of these proteins into the nucleus in the presence of the C16 protein 
should be investigated. Furthermore, the binding of the relevant transcription factors, such as 
ISGF3, to their target DNA sequences should be investigated by EMSA to determine whether 
the presence of C16 in the nucleus may inhibit binding and upregulation of the target 
sequences.  
 
Site-directed mutagenesis will be used to identify important residues in the function and 
interactions of C16. Initially, this will involve mutation of individual residues such as the 
VTRFYF sequence, thought to overlap with icIL-1Ra function, to assess whether this highly 
conserved sequence is important for C16 function. As C16 is a 37-kDa protein, large by the 
standards of icIL-1Ra (17 kDa), it is possible that C16 has multiple functions, hence mutants 
of C16 lacking sections of the protein will be analysed within the in vitro and in vivo systems 
to assess whether these truncated proteins remain functional, and which functions can be 
attributed to which portions of the protein. 
 
The elucidation of the structure of C16 will also form an important element of understanding 
the role of C16 in VACV infection. Sequence analysis predicts that the structure will be 
largely β-sheet in composition, this overlaps with the known structure of IL-1Ra. 
Furthermore, modelling has threaded the C terminus of C16 onto the known structure of IL-
1Ra and resulted in the generation of a thermodynamically favourable model for the structure 
of this half of C16. Production of C16 protein to enable crystallisation analysis is essential to 
assess whether that predicted model is seen in the structure of recombinant C16. At present, 
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scale-up of C16 protein production in E.coli has been unsuccessful, however the production 
of enough pure protein to garner a crystal structure must remain a priority. This structure will 
lend further help to the identification of individual residues involved in putative interactions, 
and to allow reconciliation of how the structure of the protein may contribute to its function 
in the infected cell. 
 
Future work on C16 will also focus on establishing whether C4, the VACV protein related to 
C16, has a function that overlaps that of the C16 protein. Both of these proteins contain the 6 
aa sequence thought to be important for the immunosuppressive activity of IL-1Ra. However, 
they cannot exercise completely redundant functions, or else the deletion of C16 would have 
had no phenotype in vivo. While C16 is an intracellular protein and may mimic the 
intracellular roles of IL-1Ra including the downregulation of IL-6, it is possible (despite the 
absence of a secretion signal) that C4 is a secreted protein that complements C16 function by 
acting as an sIL-1Ra. Alternatively, while some sequences have been conserved between C4 
and C16, their functions may be entirely divergent.   
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6.4 Summary 
The VACV strain WR C16 protein has been characterised and its effects on virus replication 
and virulence have been determined. The C16L gene is present in ITR and so is one of the 
few VACV genes that are diploid. The C16 protein is highly conserved between different 
VACV strains, and also in the OPVs VARV, ECTV, HSPV and CPXV. C16 is a 37 kDa 
protein, which is expressed early during infection and localises to the cell nucleus and 
cytoplasm of infected and transfected cells.  
 
The loss of the C16L gene had no effect on virus growth kinetics but did reduce plaque size 
slightly. Furthermore, the virulence of a virus lacking C16L (v∆C16) was reduced in a 
murine i.n. model compared to control viruses and there were reduced virus titres from 4 days 
p.i. In the absence of C16, the recruitment of inflammatory cells in the lung and 
bronchoalveolar lavage was increased early after infection (day 3) and more CD4+ and CD8+ 
T cells expressed the CD69+ activation marker. Conversely, late after infection with v∆C16 
(day 10) there were fewer T cells remaining, indicating more rapid clearance of infection.  
 
C16 downregulates ISRE-dependent gene expression in vitro in a manner independent of 
STAT1 phosphorylation. C16 also inhibits pro-IL-1α-induced production of IL-6 in vitro and 
this mimics the function of icIL-1Ra. This downregulation of IL-6 production by C16 is also 
seen in vivo where in the absence of C16, the levels of IL-6 are significantly higher in the 
first four days of infection. At these early times, C16 also downregulates IL-4 and IL-12 
production, and it is possible that this downregulation is accomplished either indirectly 
through an effect on IL-6, or through a downregulation of the activity of the ISREs in the 
promoter sequences of these early cytokines. While the presence of C16 does not alter the 
ability of v∆C16 to induce protective immunity to challenge with a lethal dose of VACV, 
there are higher levels of Abs to all VACV antigens analysed at 21 days p.i., although these 
are not significant, indicating that C16 may have a marginal effect on the speed of the 
acquisition of humoral immunity. Collectively, these data indicate that C16 diminishes the 
immune response and is an intracellular immunomodulator.  
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Appendix 1 
 
Characterisation of v∆C16/EcogptGFP in the intranasal model 
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Groups of five mice were infected intranasally with 1 x 104 pfu of virus in 20µl PBS, and 
their weights were monitored over the course of the infection. Weights are plotted as a 
percentage of starting weight. 
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